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ABSTRACT 
Haemophilus influenzae is a pathogenic Gram-negative bacterium that colonizes 
the upper respiratory tract of humans and can cause otitis media, upper and lower 
respiratory infections, and meningitis. Factors important for H. influenzae to colonize 
humans and cause disease are not fully understood. Different bacterial pathogens are 
armed with virulence mechanisms unique to their specific strategies for interacting with 
their hosts. Many of the proteins mediating these interactions are secreted and contain 
disulfide bonds required for function or stability. I postulated that identifying the set of 
secreted proteins in H. influenzae that require periplasmic disulfide bonds would 
provide better understanding of this bacterium's pathogenic mechanisms. 
In this thesis, the periplasmic disulfide bond oxidoreductase protein, DsbA, was 
found to be essential for colonization and virulence of H. influenzae. Mutants of dsbA 
were also found to be sensitive to the bactericidal effects of serum. However, the DsbA-
dependent proteins important for pathogenesis of this organism have not been previously 
identified. To find them, putative targets of the periplasmic disulfide bond pathway were 
identified and examined for factors which might be important for mediating critical 
virulence aspects. By doing so, novel virulence factors were discovered including those 
important for heme and zinc acquisition, as well as resistance to complement. Overall, the 
work presented here provides insight into requirements for H. influenzae to survive 
within various host environments. 
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CHAPTER I 
Introduction and literature review 
Haemophilus influenzae 
Haemophilus influenzae is a non-motile Gram-negative coccobacillus which 
belongs to phylum gammaproteobacteria and family Pasteurellacae. This exclusive 
human pathogen normally colonizes the respiratory tract asymptomatically; however, it 
can cause disease by invading sites such as the inner ear, lungs, or blood. H. influenzae 
has an absolute requirement for supplementation with exogenous heme and NAD to grow 
aerobically in vitro (72), but does not require heme supplementation for growth as a 
facultative anaerobe. With proper supplementation of heme and NAD, it can be readily 
cultured in vitro on Brain Heart Infusion (BHI), chocolate agar, or complex defined 
media (15, 37). H. influenzae grows normally at 35 to 37°C, however, is highly sensitive 
to greater temperatures. Additionally, it is naturally competent, a quality that allows it to 
uptake double stranded DNA from its environment and integrate it into its chromosome 
(15). In the laboratory, this quality makes H. influenzae a genetically tractable model 
organism allowing for examination of aspects of its pathogenesis. 
Encapsulated strains 
H. influenzae strains are classified into two categories, encapsulated and non-
encapsulated strains (225). Encapsulated strains are “typed” based on the antigenicity of 
their protective outer surface polysaccharide capsule, which comes in six forms: types a 
through f (225). The most virulent of these, H. influenzae type b (Hib) was a major cause 
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of invasive infections, including septicemia and meningitis until wide spread use of a 
vaccine in 1990 (33, 271). Although the incidence of meningitis caused by Hib has 
declined rapidly in vaccinated populations, it remains a major cause of disease in 
developing countries where the vaccine is not readily available (33). 
Nontypeable strains 
 Non-encapsulated or nontypeable Haemophilus influenzae (NTHi) lack an outer 
surface capsule and are common commensals of the upper respiratory tract. Unlike 
encapsulated varieties, NTHi are aclonal in population and highly variable in their 
surface antigens (195). They are currently important causes of sinusitis, conjunctivitis, 
and pneumonia (201, 203) and are the second most common cause of otitis media, or 
middle ear infection, behind Streptococcus pneumoniae (203). NTHi are also one of the 
most prevalent organisms found in the lungs of patients with exacerbations of chronic 
obstructive pulmonary disease (COPD) and may persist in the lungs of these patients for 
months or even years causing considerable morbidity and mortality (168, 202, 205, 251). 
Moreover, NTHi strains are commonly isolated from the lungs of patients with cystic 
fibrosis (CF) (86, 187, 245), where pulmonary infections result in 90% of the deaths due 
to CF (10, 51, 242).  
NTHi strains are not often associated with invasive disease and most instances of 
bacteremia occur in children with underlying medical issues (203, 215). However, recent 
studies suggest that healthy individuals are also at risk (31, 34, 47, 129, 211). The Hib 
vaccine, based on the type b polyribosylribitol phosphate capsule, is not effective against 
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NTHi strains (226) and currently a vaccine remains elusive, likely due to high variability 
within surface antigens between strains (251). Therefore, the threat of disease from NTHi 
remains of importance even in regions where the Hib vaccine is universally available. 
Virulence determinants of H. influenzae 
 To cause disease, bacterial pathogens must possess specific virulence mechanisms 
for mediating interactions with their hosts. These mechanisms are often important for 
resistance to host defenses, invasion of host tissues, and production of toxins for host cell 
manipulation. H. influenzae is not known to produce protein toxins, and its ability to 
colonize the human respiratory tract and opportunistically invade privileged host 
environments, such as the blood, lungs, and middle ear, is thought to be its most 
important pathogenesis feature. However, our understanding of factors important for H. 
influenzae to survive within its host is limited. Current knowledge suggests that these 
factors are likely to mediate processes such as adherence to human cells, nutrient 
acquisition, and defense against host immune functions such as complement, 
opsonophagocytosis, and oxidative radicals produced by phagocytes. Additionally, gene 
regulation is thought to be an important feature for transition of the bacteria between sites 
of infection. Below is a review of known and potential virulence mechanisms of H. 
influenzae: 
Polysaccharide capsule 
The polysaccharide capsule is an important virulence feature of encapsulated H. 
influenzae strains. It is known to be required for bacteremia and meningitis caused by Hib 
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(196). Although the mechanism by which the capsule promotes invasive disease is not 
well understood, the capsule has been shown to protect Hib from host immune functions. 
This is exemplified by the fact that increases in surface polysaccharide and copy number 
of the Cap b locus, which encodes genes required for capsule expression, result in 
increased serum resistance of Hib strains (212, 264). Hib strains containing four copies of 
Cap b also exhibited reduced C3 deposition on their surface and reduced binding to 
murine or human macrophages compared with strains containing two copies (212). 
Furthermore, strains expressing the type-b capsule were protected from complement 
mediated opsonophagocytosis by macrophages, whereas capsule deficient strains were 
susceptible to engulfment (213).  
Lipooligosaccharide 
Lipopolysaccharide (LPS), a major component of the outer leaflet of the Gram-
negative bacterial outer membrane, mediates interactions between the bacterium and the 
host immune system (195). In H. influenzae and many other respiratory pathogens, LPS 
typically lacks long polysaccharide repeats and is referred to as lipooligosaccharide 
(LOS) (197). In NTHi stains, LOS is a critical factor for defense against host 
complement, which is encountered in the blood (46, 214) and at mucosal surfaces (9, 169, 
208, 209, 278). The LOS consists of lipid A attached via phosphorylated Kdo to an inner 
core of three L-glycero-D-manno-heptose residues and outer core of short hexose chains 
of glucose and galactose attached to each heptose residue (175, 224, 248). Several of the 
enzymes which synthesize LOS have been shown to be important for serum resistance of 
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NTHi. For example, the galactosyltransferase encoded by lgtC was shown to be 
important for serum resistance of an invasive NTHi isolate (117, 122). Expression of lgtC 
resulted in delayed deposition of C4b on the surface of the strain, thereby inhibiting 
complement mediated killing (117). Additionally, the glucosyltransferases encoded by 
the genes losA, lex2A, and lic2B have been shown to add important sugars to the LOS 
which are necessary for enhancing serum resistance (69, 96, 303). Thus, LOS plays an 
important role in defense against host immunity. 
H. influenzae strains also incorporate sialic acid into the LOS outer core, and the 
presence of this amino sugar helps avoid immune clearance. However, H. influenzae 
cannot synthesize sialic acid and must acquire it from the host. Sialic acid is transported 
by a tripartite ATP-independent periplasmic transporter encoded by siaPQM (27, 281). It 
is then activated by CMP-sialic acid synthetase, encoded by siaB (123), and added to 
certain hexose residues of the LOS outer core by the sialyltransferase, encoded by lic3A 
(120). Genes involved in sialic acid uptake and attachment are required for serum 
resistance of H. influenzae (27, 123). Additionally, strains with disruptions in lic3A or 
siaB are defective for survival in a chinchilla model of otitis media (27, 120, 136). 
Depletion of complement restored the ability of a siaB mutant to colonize the chinchilla 
ear (75), demonstrating that sialylation of the LOS is a critical strategy for complement 
defense of H. influenzae during infection. 
Adhesion and invasion 
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To prevent clearance of the bacterium by the host mucociliary escalator, H. 
influenzae expresses several adhesion proteins and surface fibrils for attachment to host 
mucosal structures. Many of these have been shown to promote binding of H. influenzae 
to epithelial cells in vitro, including several auto transporter proteins such as the High-
molecular-weight proteins 1 and 2 (HMW1 and HMW2) of nontypeable strains (259), 
Haemophilus influenzae adhesin (Hia) of encapsulated strains (260), and Hap which is 
broadly distributed (76, 261). Additionally, outer membrane proteins play a role in 
adherence such as P2 which binds respiratory mucin, P5 which binds mucin as well as 
CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule 1) and ICAM1 
(intercellular adhesion molecule 1) receptors (26, 115, 132, 186, 236) and OapA whose 
target molecule is unknown (228). Furthermore, Haemophilus surface fibril (Hsf), 
expressed by Hib, or protein E (PE), expressed by both NTHi and Hib strains, bind host 
cell extracellular matrix protein, vitronectin (102, 106). Lastly, some H. influenzae strains 
contain pili, encoded by hifA-hifE or pilA, and these structures have been shown to 
promote adherence of NTHi to epithelial cells in tissue culture (74, 137, 165, 235, 261, 
274). PilA was also shown to be important for NTHi to form biofilms and colonize the 
chinchilla middle ear (137) suggesting that adherence is an important virulence property 
for survival of H. influenzae during infection. 
Binding of H. influenzae to host cells is thought to promote invasion of host 
tissues allowing for the bacteria to access the basolateral surface and enter the 
bloodstream. For example, when NTHi are incubated with host cell monolayers, they 
enter cells or disrupt tight junctions (146, 277). Moreover, addition of phosphorylcholine 
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(ChoP) to the LOS promoted binding to host cell PAF (platelet activating factor) 
receptors and invasion of human bronchial epithelial cells in vitro (266). Expression of 
protein D, a glycerophosphodiester phosphodiesterase important for addition of ChoP to 
the LOS (73, 198), was also shown to promote invasion of human monocytic cells (2), 
further demonstrating that ChoP addition promotes adhesion and invasion. 
H. influenzae IgA protease has also been implicated in invasiveness of NTHi. IgA 
protease cleaves immunoglobulin A at the hinge region and its activity is thought to 
prevent agglutination at the mucosal surface and subsequent mechanical clearance of the 
pathogen (147, 282). Increased levels of IgA protease activity correlated with increased 
invasiveness of NTHi strains in humans, similar to data produced for IgA protease 
produced by Neisseria meningitidis (282, 283). Likely increased survival of NTHi at the 
mucosal surface allows for increased pathogenesis and invasion (282). 
Phase variation 
Phase variation is thought to be an important immune evasion strategy during 
infection where the outer surface is modified to adapt to changes in the host environment 
(195). For example, many phase variable loci encode factors important for production of 
the outer core of LOS (69, 96, 122, 289, 293, 294). Phase variation allows genes to be 
turned on or off through the action of slipped strand base mispairing, usually at 
tetranucleotide repeats within the 5’ end of their coding regions (122, 160, 200, 294). By 
modulating expression of these structures, H. influenzae can likely avoid antibody 
binding and complement-mediated lysis. For instance, LOS decoration via addition of 
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ChoP is important for H. influenzae colonization of the respiratory tract and middle ear 
(119, 219, 295). However, expression of ChoP has also been shown to reduce the 
virulence of Hib in an infant rat model of infection (125). Additionally, ChoP is a target 
for the classical complement pathway activator, CRP (78, 286, 295), and its expression 
results in sensitivity of Hib to complement-mediated lysis (125). The lic1 locus, which 
encodes the machinery for adding ChoP, is phase variable (293). Therefore, ChoP is 
thought to be modulated allowing for efficient colonization of the respiratory tract and 
infection of the bloodstream (291). This example highlights the importance of phase 
variation in protection of H. influenzae against host defenses. 
Several genes encoding outer surface proteins have also been shown to undergo 
phase variation. Examples include the hemoglobin or hemoglobin-haptoglobin-binding 
proteins, HgbA, HgbB, and HgbC (38) and adhesins, such as, OapA, HMW1, HMW2, 
and outer surface fibrils (56, 276, 290). Additionally, heterogeneity within protein 
sequences may also contribute to serum and resistance and inhibition of host antibody 
binding. During the course of persistent infections such as chronic bronchitis, the outer 
membrane proteins P2 and P5 were found to vary significantly in molecular weight and 
sequence between isolates (62, 63, 97, 284, 288). Subsequently, variation in outer loops 
of P2 was shown to contribute to differential antibody binding between strains (217, 
273). Variation was proposed to be driven by selective pressure imposed by host antibody 
and complement encountered by the bacteria during infection (62). Together, variation of 
surface proteins is thought to prevent recognition of H. influenzae by host antibody and 
therefore reduce complement mediated killing and opsonophagocytosis. 
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Binding of host complement regulatory factors 
Binding of complement regulators is thought to be an important survival strategy 
for H. influenzae during colonization and infection (105). Normally, complement 
regulators benefit the host by protecting tissues from unnecessary damage during 
complement activation. However, these regulators can also be hijacked by bacterial 
pathogens and used to subvert host defenses. H. influenzae utilizes several different 
complement regulatory factors to block activity at various steps throughout the 
complement pathway, including the classical pathway inhibitor C4b binding protein 
(C4BP), the alternative pathway inhibitors factor H (FH) and factor H-like protein-1 
(FHL-1), as well the membrane attack complex inhibitor, vitronectin (105). Binding of 
C4BP appears to be exclusive to NTHi strains (103), whereas FH, FHL-1 (107), and 
vitronectin are bound by both Hib and NTHi (102, 106). As mentioned above, the 
adhesins Hsf and PE bind vitronectin (102, 106); however, the outer surface structures 
important for binding of C4BP and FH and FHL-1 remain undiscovered.  
Several reports have demonstrated that binding of regulatory factors protects H. 
influenzae from the bactericidal effects of serum complement (102, 103, 107). 
Additionally, NTHi stains isolated from patients with upper respiratory-tract infections or 
sepsis exhibited in vitro binding to C4BP, FH, or vitronectin (104). Together, binding of 
complement regulatory factors is a likely an important mechanism for H. influenzae to 
subvert complement activation and cause disease. 
Heme utilization 
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Because H. influenzae lacks the biosynthetic pathways required for producing 
heme, it must procure this essential molecule from its host (91). Heme is an important 
prosthetic group for proteins related to H. influenzae pathogenesis, including those 
involved in oxygen sensing, electron transport, detoxification, and responding to 
oxidative stress (218). For example, catalase, a heme containing protein encoded by hktE, 
was shown to be necessary for Hib to colonize the rat nasopharynx and resist hydrogen 
peroxide (24). Although H. influenzae cannot synthesize heme de novo from 5-
aminolevulinic acid (218), it has the capability of producing heme from its immediate 
precursor, protoporphyrin IX (PPIX). This process is achieved by a ferrochelatase 
encoded by hemH, which joins Fe2+ to PPIX to produce heme (91, 247). However, heme 
is likely to be the only source of porphyrin available to H. influenzae during infection. 
Most heme sources in vivo are sequestered in host cells (157). Additionally, heme 
released from necrotic host cells is rapidly bound by host-carrier proteins such as albumin 
or hemopexin, which bind it avidly (39). To overcome these limitations, H. influenzae 
has evolved outer membrane heme binding proteins to scavenge heme from host 
molecules including heme-hemopexin, hemoglobin, hemoglobin-haptoglobin, and heme-
albumin (42, 193). Many of these outer surface proteins are required for pathogenesis of 
H. influenzae such as the hemoglobin/hemoglobin-haptoglobin binding proteins, 
HgpABC, which were shown to be required for virulence of NTHi in a chinchilla middle 
ear infection model (133, 188, 238) and the heme-hemopexin binding proteins, HxuCBA, 
which are required for Hib infection of infant rats (40-42, 191). Moreover, tehB and hel, 
which encode factors important for growth of H. influenzae on multiple heme sources, 
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were also required for pathogenesis of Hib in the infant rat (194, 237, 296). The multitude 
of outer membrane heme binding proteins highlights the importance of heme acquisition 
in colonization and virulence of H. influenzae. 
Oxygen responsive gene regulation 
Virulence factors of H. influenzae have been shown to be modulated in response 
to environmental oxygen concentrations. One way genes can be regulated in response to 
oxygen is through the ArcA/ArcB two-component system (98). In this signal transduction 
pathway, the membrane associated sensor kinase, ArcB, detects low oxygen and 
phosphorylates the soluble response regulator ArcA, which can then bind to DNA and 
regulate genes (98). Mutants of arcA are defective for serum resistance and survival in a 
mouse bacteremia model (57, 302). It was discovered that lic2B, which encodes a 
glycosyltransferase that adds a galactose to the LOS outer core, is positively regulated by 
ArcA during low oxygen conditions (303). NTHi lic2B mutants are defective for serum 
resistance and survival during blood stream infection (303). Likely, serum resistance 
defects of an arcA mutant after growth in low oxygen can be attributed to lack of 
expression of lic2B.  
A second response regulator, FNR, has been implicated in pathogenesis of H. 
influenzae. FNR directly senses low oxygen environments via reduction of its iron-sulfur 
center allowing for it to maintain an active dimer form that can bind to DNA to either 
repress genes required for aerobic growth or activate those needed for growth in low 
oxygen (156). When oxygen is present the iron-sulfur center is oxidized and FNR 
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assumes an inactive monomeric form (45, 61). During low oxygen conditions FNR 
positively regulated the nrfA and ytfE genes, which encode factors critical for resistance 
to nitric oxide (110). Furthermore, in low oxygen, ytfE was shown to be essential for 
NTHi resistance to nitric oxide produced by IFN-γ stimulated macrophages (110). These 
results suggested that nitric oxide is likely to be encountered at cites of infection that 
contain low oxygen, such as high bacterial density on mucosal surfaces or during 
invasion of submucosal layers (110). 
Modification of the LOS with ChoP has also been shown to be regulated by 
oxygen. Addition of ChoP is increased during in vitro culture with high aeration 
conditions and inhibited during low oxygen conditions (300). However, the mechanism 
behind this regulation is not known (300). Taken together, regulation of genes in 
response to oxygen may serve as an important strategy for modulating factors important 
for evading host immune functions at various sites of infection. 
Bacterial virulence factors and disulfide bonds 
 Little is known about factors important for H. influenzae to survive within its 
host. However, many of these factors such as the adhesins and heme uptake factors 
described above are secreted into the extracytoplasmic spaces including the periplasm, 
outer membrane, and extracellular space. Unlike the cytoplasm, which is a reducing 
environment, the extracytoplasmic spaces expose secreted proteins to oxidizing 
conditions (230). Thus, many secreted proteins contain disulfide bonds that likely 
enhance stability and provide proper folding allowing for function. This process has been 
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extensively studied in E. coli and shown to be catalyzed by the periplasmic Dsb proteins 
(Figure 1.1). The following sections will review the mechanism of disulfide bond 
formation and discuss the known roles for disulfide-dependent proteins in virulence of 
Gram-negative bacteria and the potential role for disulfide formation in pathogenesis of 
H. influenzae. 
Disulfide bond formation 
 DsbA, the major disulfide forming protein of E. coli, catalyzes disulfide bond 
formation by donating a disulfide from its active site cysteines to pairs of reduced 
cysteines on newly secreted proteins (17, 93, 143, 312). DsbA’s active site, Cys30-Pro31-
His32-Cys33, possesses a high oxidizing potential of -122 mV due to the extremely low 
pKa of its N-terminal cysteine (Cys30) (124, 306). At physiological pH, the oxidized form 
of DsbA is less stable than its reduced form, thus DsbA is likely to donate its disulfide to 
achieve a lower energy state (312). Disulfide exchange occurs when Cys30 is attacked by 
a deprotonated cysteine on a newly secreted protein, resulting in formation of an 
intermolecular disulfide between DsbA and the protein (Figure 1.2) (52, 140, 252, 312). 
A second deprotonated cysteine on the secreted protein can then attack the mixed-
disulfide resulting in disulfide formation between cysteines on the substrate. The end 
products of this reaction are an oxidized substrate and reduced DsbA. 
After disulfide exchange with a substrate, DsbA is recycled by reoxidation of its 
active site cysteines by DsbB (Figure 1.1). DsbB is an inner membrane protein with four 
trans-membrane helices and two periplasimc loops which contain essential pairs of  
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Figure 1.1. Models for disulfide-bond formation in the periplasm of E. coli. The solid 
black rightward arrow indicates the oxidative folding reaction catalyzed by DsbA. In the 
instance in which the first folding reaction resulted in a misoxidized protein, DsbC may 
repair it by acting as a reductase (dotted arrow) or an isomerase (not shown in this figure) 
of the incorrect disulfide bond. The thinner arrows indicate the flow of reducing 
equivalents. Q, quinones (ubiquinone or menaquinone). For simplicity, DsbC, a dimeric 
molecule, is depicted as a monomer. This figure was reproduced from (139) with 
permission from Mary Ann Liebert Publishers. 
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Figure 1.2. Disulfide-bond formation by DsbA. Substrate oxidation by DsbA likely 
proceeds through two steps. First, a deprotonated cysteine of a substrate attacks the sulfur 
atom of Cys30 of the oxidized DsbA, leading to the formation of a disulfide-linked 
complex between DsbA and the substrate. In the next step, one of the remaining cysteines 
of the substrate is deprotonated and attacks the sulfur atom of the substrate cysteine that 
is disulfide bonded with Cys30 of DsbA. This reaction results in the formation of a 
disulfide bond in the substrate and reduction of DsbA. This figure was reproduced from 
(139) with permission from Mary Ann Liebert Publishers. 
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cysteines for catalyzing disulfide formation (127, 138). Reoxidation of DsbA begins 
when deprotonated Cys30 on DsbA attacks Cys104 in the second periplasmic loop of DsbB 
(99, 128, 151). Subsequently, the mixed disulfide between DsbA and DsbB is resolved by 
attack of the disulfide by DsbA Cys33, resulting in reoxidized DsbA and reduced Cys104 
and Cys130 of DsbB (150). Cys104 and Cys130 are then reoxidized by the disulfide on first 
loop of DsbB (92, 150). The first loop Cys are maintained in an oxidized state by 
quinones that shuttle electrons from DsbB to the electron transport chain, thus driving the 
oxidizing potential of the system (13, 92, 154). Additionally, DsbB is highly specific for 
DsbA as a substrate and cannot exchange disulfides with other periplasmic substrates 
(126).  
Occasionally, incorrect disulfide bonds are formed and these errors can be 
repaired by the periplasmic disulfide isomerase DsbC (Figure 1.1), an enzyme which 
possess both isomerization and chaperone activities (20, 35, 116, 239, 254, 314). DsbC 
contains an active site CXXC motif similar to DsbA, but is maintained in a reduced form 
allowing it to bind to misfolded proteins and to catalyze isomerization or reduction of 
misoxidized disulfides (139). It exists as a V-shaped homodimer with its active sites 
facing a hydrophobic cleft which is necessary for substrate specificity (139, 176). This 
configuration is also thought to inhibit interaction with DsbB and therefore prevent 
oxidation of the active site (11).  
A second protein, DsbG, is similar in structure and amino acid sequence to DsbC 
and also forms V-shaped homodimers (112). Similar to DsbC, DsbG possesses in vitro 
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isomerase and chaperone activity (23, 253); however, its primary role appears to be 
interaction with the reduced forms of three enzymes of the peptidoglycan cross-linking 
pathway, YbiS, ErfK, and YnhG (58). These enzymes all contain single cysteine residues 
which are essential for their functions (167). By interacting with DsbG, these cysteines 
are effectively protected from the oxidizing environment of the periplasm. 
Both DsbC and DsbG are maintained in a reduced form by the inner membrane 
protein DsbD (23, 185, 239). DsbD is reduced by cytoplasmic thioredoxin, which in turn 
is reduced by thioredoxin reductase, which is reduced by NADPH (239) (Figure 1.1). In 
this way, DsbD utilizes an electron transfer cascade to generate the reducing potential of 
the system. 
DsbA-dependent proteins and their role in virulence 
Mutation of dsb genes results in loss of stability and function of secreted 
enzymes. For example, mutation of E.coli dsbC causes instability within proteins that 
contain disulfides on non-consecutive cysteines such as periplasmic endoribonuclease 
(RNase I), penicillin-insensitive murine endopeptidase (MepA), acid phosphatase 
(AppA), and endonuclease-1 (End1) (20, 116, 178, 280). However, DsbA affects a much 
wider range of proteins, which according to informatics-based estimates may number 
~300 in E. coli (64, 206). These include periplasmic alkaline phosphatase (PhoA), the P-
ring of flagella (FlgI) and outer membrane protein A (OmpA) of E. coli (49, 141, 158). 
More importantly, mutation of dsbA results in defects in maturation or export of major 
secreted virulence factors in a variety of bacterial pathogens, including biogenesis and 
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stability of pili in Vibrio cholerae, Proteus mirabilus, Neisseria meningitidis, 
enteropathogenic E. coli, and uropathogenic E. coli (30, 131, 222, 268, 315), toxin 
production in V. cholerae, E. coli, and Bordetella pertussis (216, 222, 263, 308, 311), and 
type III secretion in Yersinia pestis, Shigella flexneri, Pseudomonas spp., and Salmonella 
enterica (101, 130, 181, 287) (Table 1.1). Consequently, dsbA mutants exhibit defects for 
virulence properties such as the ability to adhere and invade host cells (29, 101, 268, 287) 
and cause disease in animal models (30, 89, 181).  
Due to the large number of virulence-related defects of dsbA mutants, 
identification of DsbA substrates may lead to discovery of additional bacterial virulence 
factors. The full range of DsbA-dependent proteins has not been elucidated in any 
organism; however, attempts at identifying DsbA-substrates of E. coli using biochemical 
techniques have been described. These studies utilized 2-D gel based analyses in which 
substrates were identified by comparing wild-type E.coli with dsbA mutants for either 
decrease in substrate concentration on the gel or change in binding of thiol reactive 
probes (differential thiol trapping) (116, 158). Additionally, Kadokura and co-workers 
identified substrates using a DsbA P151T mutant, which accumulates DsbA-substrate 
complexes in its periplasm allowing them to be affinity purified and sequenced (141). 
Combined, biochemical techniques identified only 25 substrates, with little overlap 
between studies (Table 1.2). This suggests that a large number of DsbA-dependent 
proteins have yet to be found and other techniques will have to be employed to identify 
them. 
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Table 1.1. Virulence defects of dsbA mutants 
Organism Affected 
proteins 
Defective virulence properties in dsbA 
mutants 
E. coli STI, STII 
Secretion of heat stable and heat labile 
enterotoxin, systemic infection in infant rats 
(89, 216, 308) 
Adherent-invasive unknown Survival in macrophages (29) 
Enteropathogenic EscC, BfpA Type III secretion, bundle forming pilus, (182, 315) 
Uropathogenic PapD P. fimbriae (131) 
Salmonella enterica SpiA, Pef Spi-2 type III secretion, virulence in mice (181) 
Shigella flexneri Spa32 Type III secretion, invasion of epithelial 
cells (287) 
Proteus mirabilus unknown MR/P fimbriae, virulence in mice (30) 
Bordetella pertussis S1, S2 Stability of pertussis toxin (263) 
Vibro cholerae unknown Pili, cholera toxin, heat-labile enterotoxin (222, 311) 
Neisseria meningitidis unknown Type IV pili, adhesion to cells (268) 
Pseudomonas aruginosa PilA Type III secretion, intracellular survival (101) 
Yersinia pestis YscC Type III secretion of Yops (130) 
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Table 1.2. List of E. coli DsbA substrates discovered by biochemical techniques 
Substrate Function Reference 
ArtJ Arginine ABC transporter periplasmic-binding protein (158) 
DppA Dipeptide binding lipoprotein (141, 158) 
Imp Organic solvent tolerance protein precursor (141, 158) 
MepA Penicillin-insensitive murein endopeptidase (116) 
OmpA  Outer membrane protein A (141, 158) 
OppA Oligopeptide transporter periplasmic-binding protein (141, 158) 
ZnuA Zinc transporter subunit: periplasmic-binding component of 
ABC superfamily 
(141) 
DegP Periplasmic serine protease (116) 
HisJ Amino acid ABC transporter periplasmic-binding protein (141, 158) 
RcsF Dat1 predicted outer membrane protein (135) 
GltX Glutamyl-tRNA synthetase (158) 
SspA Stringent starvation protein A (158) 
FlgI Flagellar hook-filament junction protein  (116) 
GltI Glutamate and aspartate transporter subunit  (116, 141) 
LivJ Leucine/isoleucine/valine transporter subunit  (116, 141) 
LivK Leucine transporter subunit (141) 
Rna RNAse I (116) 
PhoA Alkaline phosphatase (116) 
UgpB Glycerol-3-phosphate transporter subunit (158) 
YbjP Predicted lipoprotein (141) 
YcdO Conserved protein (141) 
YedD Predicted protein (141) 
YggN Predicted protein (116) 
YodA Conserved metal-binding protein (141) 
YibQ Predicted polysaccharide de-acetylase (141) 
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DsbA substrates may be virulence factors of H. influenzae 
The components of the E. coli disulfide bond pathway are conserved in H. 
influenzae (270). However, the role of the Dsb pathway in pathogenesis of this organism 
has not been previously investigated. Evidence from high-throughput screening 
techniques indicated that DsbB is required for Hib infection in infant rats (114) and is 
induced in a chinchilla model of NTHi otitis media (173), suggesting that periplasmic 
disulfide bond formation may be required for virulence of H. influenzae. Additionally, 
some H. influenzae virulence-associated proteins have DsbA-dependent homologs in E. 
coli. Examples include the cytochrome C-type nitrite reductase NrfA, which is important 
for H. influenzae defense against nitric oxide (110, 179), and outer membrane protein P5, 
which has been shown to be important for virulence of H. influenzae (256). Together, this 
suggests that DsbA-dependent factors are virulence determinants of H. influenzae.  
Thesis overview 
Many virulence factors of H. influenzae are not known but are likely to be 
secreted and contain disulfide bonds for function and stability. Therefore, I hypothesized 
that the periplasmic disulfide oxidoreductase, DsbA is important for pathogenesis in H. 
influenzae and furthermore, identification of the substrates of the disulfide pathway will 
lead to discovery of virulence determinants of this organism. 
In Chapter II, the role of DsbA in pathogenesis of H. influenzae was investigated; 
dsbA mutants were generated and evaluated for growth in vitro and virulence in several 
infection models. A comparison of known DsbA substrates in other species to predicted 
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secreted proteins in H. influenzae revealed several proteins that could contribute to 
virulence of this organism. One of these proteins, the heme utilization factor, HbpA, was 
examined due to the importance of exogenous heme for aerobic growth of H. influenzae. 
In Chapter III, informatics-based techniques were used to identify H. influenzae 
proteins that may require DsbA-dependent disulfide bonds for function and stability. This 
list was cross-referenced with data from a whole genome transposon mutagenesis screen 
that identified factors important for H. influenzae to colonize the lung. Through this 
method, a system important for zinc utilization during infection was discovered and 
characterized. 
In Chapter IV, I investigated the role of DsbA-substrates in serum resistance. This 
project was based on the observation that a dsbA mutant was sensitive to serum 
complement. The list of potential DsbA substrates was examined for proteins that have 
been implicated in serum resistance of other organisms. By doing so, the outer membrane 
protein P5 was identified and its role in serum resistance was investigated. 
Chapter V provides a summary of this thesis, conclusions, and future research 
directions. 
 
 
  
23 
 
PREFACE TO CHAPTER II 
This Chapter has been published 
Charles V. Rosadini, Sandy M.S. Wong, and Brain J. Akerley. The periplasmic disulfide 
oxidoreductase DsbA participates in Haemophilus influenzae pathogenesis. Infection 
and Immunity. 76(4): 1498-508. 2008 
 
Charles V. Rosadini performed all experiments. 
Sandy M.S. Wong assisted with animal experiments and RNA purification. 
Brain J. Akerley and Charles V. Rosadini designed the experiments and wrote the 
manuscript. 
  
24 
 
CHAPTER II 
The periplasmic disulfide oxidoreductase DsbA contributes to Haemophilus 
influenzae pathogenesis 
ABSTRACT 
H. influenzae is an obligate human pathogen that persistently colonizes the 
nasopharynx and causes disease when it invades the bloodstream, lungs, or middle ear. 
Proteins that mediate critical interactions with the host during invasive disease are likely 
to be secreted. Many secreted proteins require addition of disulfide bonds by the DsbA 
disulfide oxidoreductase for their activity or stability. In this study, we evaluated the role 
in H. influenzae pathogenesis of DsbA as well as HbpA, a substrate of DsbA. Mutants of 
H. influenzae Rd and type b (Hib) Eagan containing nonpolar deletions of dsbA were 
attenuated for bacteremia in animal models, and complemented strains exhibited 
equivalent virulence to that of the parental strains. Comparison of predicted secreted 
proteins in H. influenzae to known DsbA substrates in other species revealed several 
proteins that could contribute to the role of dsbA in virulence. One candidate, the heme 
transport protein, HbpA, was examined because of the importance of exogenous heme for 
aerobic growth of H. influenzae. The presence of a dsbA-dependent disulfide bond in 
HbpA was verified in an alkylation protection assay, and HbpA was less abundant in a 
dsbA mutant. The hbpA mutant exhibited reduced bacteremia in the mouse model, and 
complementation restored its in vivo phenotype to that of the parental strain. These results 
indicate that dsbA is required in vivo, and that HbpA and additional DsbA-dependent 
factors are likely to participate in H. influenzae pathogenesis. 
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INTRODUCTION 
Haemophilus influenzae efficiently colonizes the human nasopharyngeal mucosa 
in a primarily asymptomatic manner with a carriage frequency of ~80% in healthy adults 
(197). However, it can disseminate to other anatomical sites and cause otitis media, upper 
and lower respiratory tract infections, septicemia, and meningitis in children (86, 152, 
187, 197, 202, 205, 251). The incidence of H. influenzae meningitis has dramatically 
declined in populations immunized with a vaccine against the type b capsular 
polysaccharide (33). The vaccine has not affected the incidence of infection with 
nontypeable strains (NTHi), which lack the capsule. NTHi predominantly cause 
respiratory tract infections and otitis media, but in rare cases can invade the bloodstream 
leading to meningitis. This disease profile raises the possibility that genes promoting 
intravascular invasion could be present among NTHi strains (47, 71, 211, 215). However, 
the molecular basis for the invasive properties of H. influenzae that promote transmission 
from the nasopharynx to the bloodstream or middle ear are not fully understood. 
 Secreted bacterial proteins mediate critical aspects of pathogenesis including 
attachment, nutrient utilization, and subversion of host defenses. Many secreted proteins 
of Gram-negative bacteria acquire disulfide bonds in the periplasm that stabilize their 
mature, folded structures (17). Formation of such linkages has been most extensively 
studied in E. coli, in which a series of disulfide oxidoreductases (Dsb) creates and 
exchanges disulfide bonds in periplasmic proteins (reviewed in (140, 206)). The soluble 
periplasmic disulfide oxidoreductase, DsbA, directly catalyzes this process by 
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exchanging its disulfide bond with free thiol groups of cysteine residues in target proteins 
(79, 313). DsbA is efficiently re-oxidized by DsbB, a membrane protein that transfers 
electrons to quinones for subsequent transfer to electron acceptors of the respiratory chain 
(16, 206). The soluble periplasmic DsbC and DsbG proteins mediate rearrangement of 
mispaired disulfides using electrons transferred via the membrane bound DsbD protein 
from cytoplasmic thioredoxin (6, 23, 154, 155, 239, 314). Mutants defective in 
periplasmic disulfide bond formation are viable under standard culture conditions, but 
exhibit a range of phenotypes as a result of defective maturation of secreted proteins. 
These effects vary depending on the repertoire of periplasmic and secreted substrates of 
DsbA among different bacteria. These deficiencies can involve single enzymes that 
require a disulfide bond for activity, such as the periplasmic alkaline phosphatase, PhoA, 
of E. coli as well as defects in components of transporters, resulting in inappropriate 
localization of substrates.  
DsbA homologs contribute to the pathogenesis of multiple bacterial species in 
which they are required for maturation or export of major secreted virulence factors. 
DsbA activity is required for production of functional type IV pili (also called fimbriae) 
that mediate adherence to host surfaces in Vibrio cholerae, Neisseria meningitidis, 
enteropathogenic E. coli, and uropathogenic E. coli (131, 222, 268, 315). Toxin 
production or secretion is defective in many dsbA mutants including cholera toxin in 
Vibrio cholerae, heat-labile and heat-stable E. coli enterotoxins, and pertussis toxin in 
Bordetella pertussis (222, 263, 311). Type III secretion systems consist of multisubunit 
protein conduits that inject effector proteins directly from the bacterial cytoplasm into 
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host cells to subvert diverse host cell functions. Components of the type III secretion 
apparatus are defective in dsbA mutants of Y. pestis, S. flexneri, Pseudomonas spp., and 
Salmonella enterica sv. typhimurium (101, 130, 181, 287). Furthermore, DsbA has been 
implicated in systemic infection by E. coli K1, and prolonged survival of adherent-
invasive E. coli within macrophages (29, 89).  
The dsbA gene of H. influenzae (HI0846, also called por) transcomplements a 
dsbA mutant of E. coli (270). Disruption of dsbA with a transposon insertion resulted in 
changes in secreted protein localization in a cellular fractionation experiment and 
dramatically reduced natural transformation efficiency (270). The role of DsbA in H. 
influenzae pathogenesis has not been examined. However, a transposon-based ‘signature-
tagged mutagenesis’ screen detected the putative dsbB homolog as a virulence gene 
candidate in an infant rat model of bacteremia, suggesting a potential role for periplasmic 
disulfide bond formation in H. influenzae pathogenesis (114). In H. influenzae, the 
protein targets of DsbA and virulence factors dependent on its activity have not been 
identified. In this study, we demonstrate that dsbA is required for H. influenzae 
bacteremia with both unencapsulated strain Rd and a virulent encapsulated type b strain. 
Heme uptake is required for aerobic growth of H. influenzae, which cannot synthesize the 
porphyrin ring (91, 297), and several heme utilization pathways have been implicated in 
bloodstream infection by H. influenzae (194, 249). We demonstrate that the heme 
transport protein, HbpA, contains a DsbA-dependent disulfide bond. A nonpolar hbpA 
deletion mutant exhibited a reduced magnitude of bacteremia in mice, yet this defect was 
not as pronounced as that of the dsbA mutant. Based on these results, it is likely that dsbA 
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is required in vivo for production of optimal levels of hbpA, and that additional virulence 
factors that remain to be identified also participate in the critical role of DsbA in H. 
influenzae pathogenesis.  
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MATERIALS AND METHODS 
Strains and culture conditions. H. influenzae Rd, a capsule deficient serotype d 
derivative (301), and a virulent streptomycin resistant derivative of H. influenzae type b 
strain Eagan (Hib) (8) were grown in Brain Heart Infusion broth supplemented with 10 
µg/ml hemin and 10 µg/ml β-nicotinamide adenine dinucleotide (sBHI) or on sBHI agar 
plates at 35°C. Competence development for transformation of H. influenzae was as 
previously described (15). For the selection of Rd and Hib derived strains, antibiotics 
were used at concentrations of 8 µg/ml tetracycline (Tet), 20 µg/ml kanamycin (Km), 10 
µg/ml gentamicin (Gm), or 100 µg/ml streptomycin (Sm).  
DsbA strain construction. Plasmids and PCR products were constructed using standard 
molecular biology techniques (12). For complementation of mutants, DNA fragments 
were amplified by PCR and cloned between adjacent SapI restriction sites of the 
chromosomal delivery vector pXT10, which does not replicate in H. influenzae (301). 
The pXT10-based plasmids contain upstream (xylF) and downstream (xylB) homologous 
regions flanking the SapI cloning sites that allow precise fusions of genes of interest to 
the xylose inducible xylA promoter as previously described (301). Recombination at the 
xylose catabolic locus replaces the endogenous xylA gene with the cloned fragment and 
the tetAR tetracycline resistance cassette. Plasmids were linearized by digestion with PciI 
and SacI and tetracycline resistant (TetR) recombinants were selected on sBHI agar 
plates. Double crossovers within xylF and xylB were confirmed by PCR with primers 
specific to sequences outside of the inserted recombinant region.  
30 
 
To generate a dsbA mutant and a complemented strain in H. influenzae, which requires 
DsbA for natural transformation, we first generated a strain containing an inducible copy 
of dsbA and sequentially introduced the dsbA deletion and the complementation construct 
or the ‘empty vector’ construct into this background. Initially, an additional copy of dsbA 
under the control of the xylose-inducible promoter of xylA was introduced into H. 
influenzae Rd to create strain RX. The coding sequence of DsbA lacking the translational 
termination codon was amplified by PCR with primers F-NTdsb (5’-
AAAGATCTGCTCTTCAATGAAAAAAGTATTACTTGC-3’) and 3dsbAHA (5’-
AAAGATCTGCTCTTCGTAATGCATAATCTGGCACATCATATGGATATTTTTGC
AATAAACCTTTTACGGTT-3’), which introduce SapI sites in the termini of the 
fragment. The resulting fragment was cloned into pXT10 that was digested previously 
with SapI. The resulting plasmid pXyldsbA1.1 was linearized and used to transform H. 
influenzae to tetracycline resistance to create strain RX. 
Next, the native copy of dsbA was deleted from RX by replacement with the 
aacC1 gentamicin resistance gene to create strain RdsbAX by PCR “stitching” as 
follows. Overlapping PCR fragments generated with the indicated primers representing 
the 951 bp region immediately 5’ of the dsbA translational start codon (primers 5844H 
5’-TTTAAGCTTTTAGATGACTGTTTTCTTTAAATC-3’ and 3Dsbout 5’-
TTCTTTCCTCTTATTTAATGATACCGCGAG-3’), the 569 bp aacC1 gene encoding 
gentamicin resistance (primers 5GentD 5’-
TAAATAAGAGGAAAGAAATGTTACGCAGCAGCAACGATGTT-3’ and 3GentD 
5’-CATTAAACCAATTTTTCGTTAGGTGGCGGTACTTGGGTCGAT-3’), and the 
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1641 bp 3’ region starting at the dsbA termination codon (primers 5Dsbout 5’-
CGAAAAATTGGTTTAATGCCAGCCC-3’and 3848H 5’-
TTTAAGCTTCTACTTGCGAATGAGCCATAGGC-3’) were combined by overlap 
extension PCR with primers 5844H and 3848H to precisely replace the dsbA coding 
sequence with that of aacC1. The resulting 3126 bp DNA fragment was used to 
transform strain RX and GmR recombinants isolated to create strain RdsbAX, which 
contains a single copy of dsbA under the control of the xylose-inducible xylA promoter. 
 To complement the dsbA knockout with a wild type copy of dsbA under its own 
promoter, overlap extension PCR was performed as follows: primers pXT10thyA-F (5’-
AGGGCTTGAATCGCACCTCCA-3’) and 3dsbkan1 (5’-
CATCAGAGATTTTGAGACACGGGCCTCTTATTTTTGCAATAAACCTTTTACGG
T-3’) were used in PCR to amplify a 1983 bp fragment containing dsbA from a pXT10-
based plasmid carrying dsbA coding sequences. A 2716 bp PCR product was amplified 
from a kanamycin-marked derivative of pXT10 with primers 5pkan1 (5’-
GAGGCCCGTGTCTCAAAATCTCTGATG-3’) and 3revRfaD1 (5’-
AACAGGCTACGATAAACCATTCAAAACAGT-3’). The 1983 bp and 2716 bp 
fragments were joined via their 27-bp of overlapping sequence by PCR with primers 
pXT10thyA-F and 3revRfaD1, and the resultant 4672 bp PCR product was transformed 
into strain RdsbAX (grown in 1mM D-xylose to induce expression of dsbA) and KmR 
transformants isolated to create strain RdsbAC. 
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To control for effects of the insertion at the xyl locus, a dsbA mutant containing 
the integrated ‘empty vector’ sequences was generated by transforming RdsbAX grown 
in the presence of 1 mM D-xylose with a 4334 bp PCR product containing a precise 
deletion of the dsbA coding sequences of the 4672 bp construct described above in 
RdsbAX except that primers 3xylF1 (5’-ACGTTTATCAACAGCGATAGGATCAAGT-
3’) and 3pDsbAsapKan (5’-
CATCAGAGATTTTGAGACACGGGCCTCTTACGAAGAGCGGCGCGCCGCTCTT
CCCATTTCTTTCCTCTTATTTAATGATACCGCGA-3’) were used in place of primers 
pXT10thyA-F and 3dsbAkan. Selection for KmR transformants resulted in isolation of 
strain RdsbAV. To construct a strain that contains the ‘empty vector’ in a wild type 
background, the same 4334 bp PCR product was transformed into H. influenzae Rd, and 
KmR transformants were isolated to create strain RXV. 
 Similarly, the same set of constructs was used to generate the dsbA mutant 
(HdsbAV), vector only strain (HXV), and a complemented strain (HdsbAC) in the Hib 
strain Eagan background. All strains were verified for wild type and dsbA mutant 
phenotypes in the DTT sensitivity assay and evaluated by sequence analysis to contain 
the desired recombinant loci as described for the corresponding Rd derivatives above. 
HbpA strain construction. The hbpA mutant strain RhbpA was constructed by 
replacement of the coding sequence of hbpA with the kanamycin resistance gene, aphI. 
The exchange fragment was synthesized by overlap extension PCR between three 
regions: a 1083 bp PCR product containing the 5’ flanking region of hbpA generated 
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using primers 5hbp1 (5’-AGTCATTCACGCCAGTTGGCACTGGAT-3’) and 3hbp1 (5’-
TTCCCGTTGAATATGGCTCATACCTCAATGTTAGGCAGGGAATGCCCTA-3’), 
an 816 bp PCR product containing the coding region for the kanamycin resistance gene 
generated with primers 5kan1.1 (5’-ATGAGCCATATTCAACGGGAA-3’) and 3kan1.1 
(5’-TTAGAAAAACTCATCGAGCATCAAATG-3’), and a 1020 bp PCR product 
containing the 3’ flanking region of hbpA generated with primers 5hbp3 (5’-
CATTTGATGCTCGATGAGTTTTTCTAATTCATATTGATTTACTTATTTTAAGCC
CT-3’) and 3hbp3 (5’-CAAAAGGGGTGAGTATAAATTTACACTCAA-3’). The 1083 
bp, 1020 bp, and 816 bp fragments were joined in a PCR reaction via their 
complementary ends in combination with primers 5hbp1 and 3hbp3. The resulting 2871 
bp fragment was introduced into H. influenzae Rd and KmR transformants selected on 
sBHI containing Km to create strain RhbpA. To construct an hbpA knockout carrying the 
integrated empty exchange vector, strain RhbpA was transformed with linearized vector 
pXT10, and TetR transformants were isolated to create strain RhbpAV.  
To complement the hbpA mutation with a copy of hbpA expressed from the hbpA 
promoter, a 1842 bp fragment containing the hbpA coding region and including 142 bp 
upstream of hbpA was amplified from Rd using primers 5hbpha (5’-
AAAGCTCTTCAATGATTAATTTGTTATAATCCATAGA-3’) and 3hbpha (5’-
TTTGCTCTTCTTTATGCATAATCTGGCACATCATATGGATATTTACCATCAACA
CTCACACCATA-3’). This set of primers also adds a C-terminal HA epitope tag to 
hbpA. This PCR product was cloned between the two SapI sites of pXT10 to generate the 
plasmid pXhbp1.5, which was then introduced into strain RhbpA with selection for TetR, 
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to create strain RhbpAC. To introduce a non-polar, in-frame deletion of dsbA into strain 
RhbpAC, this strain was transformed with the 3126 bp dsbA replacement fragment 
described above and GmR transformants selected to create strain RhbpAC∆dsbA.  
Other strains. Strain RdV carrying pXT10 ‘empty vector’ sequences in the xyl locus and 
strain RdlacZ (H. influenzae Rd carrying lacZ at the xyl locus) were constructed as 
previously described (302). Strain RdgalU was constructed by replacement of galU with 
the aphI KmR cassette. For all mutant strains, replacement of endogenous loci by double-
crossover homologous recombination with mutant constructs was confirmed by PCR with 
primers specific to sequences flanking the inserted recombinant region. 
DTT sensitivity assay. To determine the sensitivity of dsbA knockouts to dithiothreitol 
(DTT), strains were inoculated in triplicate from overnight cultures into 25 ml of sBHI in 
a 50-ml Erlenmeyer flask at an optical density at 600 nm (OD600) of 0.01 and incubated at 
35°C with shaking at 250 RPM. When cultures reached log phase, they were diluted in 
sBHI to an OD600 of 0.02 and 100 µl was transferred to a 96 well flat bottom dish. Each 
well in the dish was then treated with 100 µl of sBHI containing 10 mM DTT to a final 
concentration of 5 mM, or with sBHI alone in control wells. The plate was then incubated 
at 35°C for 16 hours in a Versamax microplate reader (Molecular Devices, Sunnyvale, CA) 
set to read absorbance at 600 nm every 10 min. Sensitivity was scored as a relative 
growth yield as assessed by OD600 at the end of the incubation period. 
Hydrogen peroxide sensitivity. To determine the sensitivity of the dsbA deletion mutant 
to H2O2, strains Rd, RXV, RdsbAV, and RdsbAC were inoculated from overnight 
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cultures in triplicate into 25 mls of sBHI in 50-ml Erlenmeyer flasks or 5 mls in culture 
tubes at an OD600 of 0.01. The resulting cultures were incubated aerobically at 35°C, 
shaking at 250 RPM (flasks) or in an anaerobic chamber (culture tubes) with BBL 
GASPAK Plus generators (Becton, Dickinson and Company, Sparks, MD). When 
cultures reached log phase, they were diluted in sBHI to an OD600 of 0.02 and 100 µl of 
each culture was seeded into a 96 well flat bottom dish. Hydrogen peroxide (Sigma-
Aldrich, St. Louis, MO) diluted in 100 µl of sBHI was then added to cultures grown in 25 
ml flasks at final concentrations of 0 µM, 62.5 µM, 125 µM and 250 µM in sBHI and for 
anaerobically grown cultures, 0 µM, 62.5 µM, 125 µM and 500 µM. The plate was then 
incubated at 35°C for 16 hours in the microplate reader and absorbance read at 600 nm 
every 10 min for evaluation of growth rates and final culture densities. 
Growth of dsbA strains. To determine growth rates in rich media and in defined media, 
strains were inoculated in triplicate at 0.01 OD600 from standing overnight cultures into 
25-ml Erlenmeyer flasks containing 15 ml of sBHI or MIc, a low nutrient media capable 
of supporting growth of H. influenzae (15). The resulting cultures were incubated at 
35°C, shaking at 250 RPM and aliquots removed for absorbance measurements at 600 
nm every 30 min for 6.5 hours. Growth rates were calculated by nonlinear regression 
analysis.  
To evaluate growth of the dsbA mutant in comparison to the hbpA mutant under 
heme limiting conditions, strains (RXV, RdsbAV, RhbpAV, and RhbpAC) were grown 
as standing overnight cultures, washed once in sterile Hanks’ Balanced Salt Solution 
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(HBSS) (Invitrogen, Carlsbad, CA), and diluted to an OD600 of 0.01 in BHI broth 
supplemented with NAD and different concentrations (5 µg/ml, 0.5 µg/ml, 0.25 µg/ml, 
and 0.025 µg/ml) of heme (Sigma-Aldrich, St. Louis, MO) or hemoglobin (Becton, 
Dickinson and Company) in a 96-well microplate at a final volume of 200 µl. Cultures 
were then incubated at 35°C in the
 
microplate reader, and absorbance at 600 nm 
measured every 10 min for 16 hours. 
Growth of hbpA strains. To compare the generation times at different heme 
concentrations under anaerobic and aerobic conditions, overnight cultures of strains Rd, 
RdV, RhbpAV, and RhbpAC (pelleted and resuspended in HBSS) were used to inoculate 
10 mls of BHI containing different concentrations of free heme (10 µg/ml, 0.5 µg/ml, 
0.05 µg/ml, and 0 µg/ml). These cultures were then aliquoted into the wells of eleven 96 
well flat bottom dishes. One dish was incubated at 35° for 14 hours in the microplate 
reader and absorbance read at 600 nm every 10 min (no aerobic growth was detected in 
wells not supplemented with heme). The other ten dishes were sealed in individual BD 
GasPak EZ Anaerobe Gas Generating Pouches (Becton, Dickinson and Company) and 
incubated at 35° C. Plates were removed from bags at appropriate intervals and 
absorbance at 600 nm was recorded. Growth rates were determined as described above. 
Competence assay. Cultures were grown in triplicate as described for DTT sensitivity 
assays above, and competent cells were prepared from these cultures as previously 
described (15). Competence in mutant and parental strains was measured by assessing 
transformation frequencies with chromosomal DNA from a streptomycin resistant H. 
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influenzae strain (1 µg) and selection on sBHI agar plates containing 100 µg/ml 
streptomycin. Transformation efficiencies were calculated as the number of streptomycin 
resistant colonies divided by the number of colonies on sBHI agar plates without 
antibiotic. Transformation frequencies were normalized by Log10 transformation and 
analyzed with Prism 4.0c (GraphPad Software, San Diego, CA) using ANOVA with 
Bonferroni’s multiple comparison test to evaluate frequency differences between 
RdsbAV and all other strains. 
Murine bacteremia model. Strains were inoculated from standing overnight cultures at 
an OD600 of 0.01 into 10 mls of sBHI in a culture tube. The resulting cultures were 
incubated in an anaerobic chamber shaking at 120 RPM and 35°C for 5 hours, a 
condition that was permissive for growth of the hbpA mutant (Table 3.2). For co-
infections, strain RdlacZ (reference strain) was mixed with each experimental strain at a 
1:1 ratio. For inoculation, bacteria were washed and diluted in HBSS to a final 
concentration of 2 x 109 bacteria per ml. Female 6.5 week old C57BL/6J mice (4 or 5 per 
strain) (The Jackson Laboratory, Bar Harbor, ME) were inoculated by intraperitoneal (IP) 
injection of 200 µl of bacterial suspension. Twenty-four hours after inoculation, 5 µl of 
blood was recovered aseptically from each mouse via tail bleeds. The blood was diluted 
into BHI broth, plated on sBHI agar plates (for single strain infections) or sBHI agar 
plates containing S-Gal (Sigma-Aldrich) (for co-infections), and incubated overnight in 
an anaerobic chamber at 35°C for CFU determination. For statistical analysis, CFU/ml 
for single strain infections were normalized by Log10 transformation for ANOVA using 
Prism 4.0c. CFU for co-infection data were Log10 transformed and the ratio of 
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experimental strains to RdlacZ was calculated and analyzed using Prism 4.0c. 
Comparisons of two data sets utilized the t-test and comparisons of greater than two data 
sets were performed using ANOVA with Bonferroni’s multiple comparison test. All 
procedures were conducted in accordance with NIH Guidelines and with prior approval 
by the University of Massachusetts Medical School Institutional Animal Care and Use 
Committee. 
Infant rat infections. H. influenzae type b derived strains were inoculated from standing 
overnight cultures at an OD600 of 0.01 into 50 mls of sBHI in a 50-ml Erlenmeyer flask. 
Cultures were incubated with shaking at 120 RPM at 35°C until they achieved a density 
of 0.4 OD600. Cells were washed once and diluted in sterile HBSS to a final concentration 
of 2 x 103 bacteria per ml. Five-day-old Sprague-Dawley rat pups (Charles River 
Laboratories, Boston, MA) were inoculated IP with 100 µl of strains HXV (n = 11) and 
HdsbAV (n = 11), or HdsbAC (n = 12). Infants inoculated with each strain were returned 
to mothers and each group was housed separately. Blood (5 µl) was collected aseptically 
via tail bleeds at 12, 36, and 120 hours post inoculation, diluted into BHI, and plated on 
sBHI agar plates for enumeration of CFU’s as described above. For statistical analysis, 
ANOVA with Bonferroni’s multiple comparison test was used as described above. 
HbpA western blot. For analysis of HbpA, strains were inoculated from standing 
overnight cultures into duplicate 50 ml sBHI cultures in 50-ml flasks at a starting density 
of 0.01 OD600 and incubated at 35°C with shaking at 250 RPM. When cultures achieved 
log phase, 1 ml was removed and pelleted by centrifugation (18000 x G for 5 min) for 
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immunoblot analysis and the remaining culture was used for RNA isolation as described 
below. After removal of the supernatant, the pellets were normalized by resuspension in 
an appropriate volume of HBSS. Cells (0.3 OD600 equivalents per lane) were then boiled 
in SDS-PAGE sample buffer and proteins separated on 8% SDS-PAGE followed by 
electrotransfer to Immobilon-P (Millipore, Billerica, MA). HbpA-HA was visualized via 
Western blot using primary antibody anti-HA1.1, 1:1000 (Covance, Berkeley, CA) and 
secondary antibody goat anti-mouse IgG HRP conjugate, 1:5000 (Upstate, Lake Placid, 
NY). Equal sample concentration was verified by Coommassie Blue staining. HbpA-HA 
was quantified by generating a 10% dilution series of each protein sample and separating 
them on 8% SDS-PAGE. HbpA-HA was then visualized by Western blot as described 
above. HbpA levels were quantified by densitometry using ImageJ (National Institutes of 
Health, Bethesda, MD). 
qRT-PCR. To quantify hbpA mRNA, we isolated total RNA in parallel from the same 50 
ml cultures used for the HbpA western blot using TRIzol Reagent (Invitrogen, Carlsbad, 
CA). RNA was then treated with DNaseI (Ambion, Austin, TX), extracted with acid 
phenol, chloroform extracted, and concentrated by ethanol precipitation. The RNA (5µg 
total) samples served as a template for cDNA synthesis with random primers (New 
England Biolabs, Beverley, MA) and Super Script II reverse transcriptase (Invitrogen, 
Carlsbad, CA). The qRT-PCR was performed with iQ SYBR Green Supermix (Bio-Rad 
Laboratories, Hercules, CA) and fluorescence measured using the DNA Engine Opticon 
II system (MJ Research, Waltham, MA). One tenth of each cDNA reaction was used as a 
template for qRT-PCR with primers 5’hbpART (5’-
40 
 
ATGATTAATTTGTTATAATCCATAGA-3’) and 3’hbpART (5’-
CAAGCTGCCAAAACAAGAGT-3’) that amplify the first 200 bp of hbpA. Primers 
RpoA5’ (5’-GTAGAAATTGATGGCGTATTG-3’) and RpoA3’ (5’-
TCACCATCATAGGTAATGTCC-3’) were used to amplify the RNA polymerase alpha 
subunit gene, rpoA as an internal reference. Real time cycler conditions were as described 
previously (302).  
Complement binding. Western blotting for assessment of binding of complement C3 
and C4 activation products was performed as previously described (75, 231). Briefly, 
cultures of strains RXV, RdsbAV, and RdsbAC were grown as described for HbpA 
westerns above, then washed and suspended in HBSS containing 0.15 mM CaCl2 and 1 
mM MgCl2 in a final reaction volume of 0.5 ml. Normal human serum (NHS) pooled 
from 12 healthy individuals was added to a final concentration of 2% and incubated for 
30 min at 37oC followed by differential treatment with 1M methylamine (pH 11), which 
dissociates complement ester-linkages but not amide linked complement from target 
structures (75, 231). Bacteria were lysed in 1X SDS-PAGE sample buffer and analyzed 
by immunoblotting using primary antibodies to human C3 (Sigma-Aldrich, St. Louis, 
MO) and C4 (Biodesign, Saco, ME) and alkaline phosphatase conjugated secondary anti-
human antibodies as described previously (75). No differences were observed in binding 
profiles of these strains to C3 or C4 subunits with or without methylamine treatment. 
Serum bactericidal assay. Sensitivity of dsbA mutants to serum was determined as 
previously described (233). Briefly, triplicate cultures of strains RXV, RdsbAV, 
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RdsbAC, and RdgalU were grown as described for DTT sensitivity assays above. At log 
phase, 2,000 CFU from each culture were diluted in HBSS and incubated at 37oC for 30 
min with or without a final concentration of 2% NHS in a 150 µl reaction volume. For 
CFU determination, 15µl was plated on sBHI agar. Bacteria were also incubated in 
parallel with serum that had been previously inactivated by incubation at 56oC for 30 
min. 
Thiol modification. 10 OD units of cells grown as described above for the anti-HA 
immunblot were harvested at log phase, by centrifugation at 5000 x G for 5 min. Before 
thiol modification of periplasmic proteins, the outer membrane was disrupted using the 
methods provided in the PeriPreps periplasting kit (Epicentre, Madison, Wisconsin). 
Briefly, the cell pellets were resuspended in 2 mls of 200 mM Tris (pH7.4), 1mM EDTA, 
20% sucrose and 30 units of lysozyme (Sigma-Aldrich, St. Louis, MO) and incubated at 
room temperature for 5 min. After incubation, 3 ml of cold water was added followed by 
10 min of incubation on ice. Each 5 ml preparation was then divided in half, with one 
half receiving treatment with 5 mM EZ-Link Maleimide-PEO2 Biotin (which adds 525.23 
daltons per bond) (Pierce, Rockford, IL) and the other half receiving no treatment. After 
incubation for 50 min at room temperature the resulting spheroplasts and associated 
membranes were collected by centrifugation at 4000 x g for 15 min and resuspended in 
375 µl Peripreps lysis buffer (10mM Tris-HCl pH 7.5, 50 mM KCl, 1mM EDTA and 
0.1% deoxycholate). After lysis, 0.30 OD600 equivalents of each sample were boiled for 5 
min in SDS loading buffer, and proteins were separated by non-reducing 8% SDS-PAGE. 
HbpA-HA was then visualized by Western blot as described above. Apparent levels of 
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HbpA-HA in the spheroplasts were similar to those in whole-cell lysates of the same 
number of cells (data not shown), suggesting that HbpA-HA is localized primarily in this 
fraction, consistent with membrane localization of the predicted HbpA lipoprotein. 
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RESULTS 
Phenotypic properties of a nonpolar dsbA deletion mutant. A series of strains were 
constructed to evaluate the potential role of DsbA in H. influenzae pathogenesis (Table 
2.1). To verify that the dsbA mutant exhibits the DTT sensitivity phenotype seen with 
dsbA mutants of other species (184), and to determine its growth properties, wild type 
parent (Rd), Rd carrying the ‘empty vector’ (RXV), dsbA deletion mutant carrying the 
‘empty vector’ (RdsbAV), and the complemented strain (RdsbAC) were evaluated for 
growth phenotypes under a range of conditions and for defects in DTT resistance and 
transformation. Generation times under aerobic conditions in rich medium (sBHI) for 
RXV, RdsbAV, and RdsbAC were 32 ± 2 min, 32 ± 3 min, and 36 ± 4, and in defined 
medium (MIc) 48 ± 4 min, 41 ± 2 min, and 38 ± 3 min, respectively. Similarly, growth 
yields of these strains after 6.5 hours of anaerobic culture in sBHI were indistinguishable. 
All DsbA+ strains (Rd, RXV, and RdsbAC) exhibited equivalent growth yields after 16 
hrs in the presence of 5 mM DTT, reaching final average densities of ~0.5 OD600, 
whereas growth of the DsbA- strain, RdsbAV, was dramatically attenuated under this 
condition and did not exceed a density of 0.1 OD600 similar to results with dsbA mutants 
in E. coli (184). Strain RdsbAX, which contains a D-xylose inducible copy of dsbA and 
was used to construct strains RdsbAV and RdsbAC, was resistant to DTT in the presence 
of 1mM D-xylose, and sensitive to DTT in the absence of D-xylose.  
H. influenzae dsbA (por) was previously implicated in natural transformation. 
Therefore, we evaluated transformation efficiencies of our strains using H. influenzae 
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Table 2.1. Strains and plasmids used in this chapter 
Strains and 
Plasmids Relevant features Source 
Plasmids    
pXT10 
Delivery vector for chromosomal expression at the 
xylose locus of H. influenzae, containing xylF, xylB, 
xylA∆4-804 and tetracycline resistance cassette, tetAR   
(301) 
pXylHA1.1 
pXT10 carrying a 614 bp fragment immediately 3’ of 
PxylA containing ATG to 1 codon before TAA of dsbA 
from RdAW with a C- terminal HA epitope tag  
This study 
pDsbAHA1.2 
pXT10 carrying a 1060 bp fragment immediately 3’ of 
PxylA containing PdsbA to 1 codon before TAA of 
dsbA from RdAW with a C- terminal HA epitope tag 
This study 
pXhbp1.5 
pXT10 carrying a 1842 bp fragment immediately 3’ of 
PxylA containing pHbpA to 1 codon before TAA of 
hbpA from RdAW with a C-terminal HA epitope tag  
This study 
Strains Genotype Phenotype  
RdAW H. influenzae capsule deficient type D WT 
(302) 
RXT10 xylA::pXT10,  tetR tetracycline resistant (301) 
RX xylA::dsbA, tetR dsbA
+
, xylose 
inducible dsbA 
This study 
RdsbAX RdxyD2, dsbA::gentR  dsbA
-
, xylose 
inducible dsbA 
This study 
RXV xylA::kanR kanamycin resistant This study 
RdsbAV RdxyG2.1, xylA::kanR dsbA- This study 
RdsbAC RdxyG2.1, xylA::dsbA, kanR dsbA+, complemented This study 
RhbpA hbpA:: kanR hbpA- This study 
RhbpAV RdhbpA6, xylA::pXT10, tetR hbpA- This study 
RhbpAC RdhbpV2.1, xylA::hbpA, tetR hbpA+, complemented This study 
RhbpACD RdhbpX6.2, dsbA::gentR dsbA-, hbpA+ This study 
RdlacZ xylA::lacZ, tetR lacZ+ (302) 
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DNA carrying a streptomycin resistance allele (Materials and Methods). Transformation 
efficiencies relative to the wild type parental Rd strain for strains RXV, RdsbAV, and 
RdsbAC, were 1.12, 1.33 x 10-6, and 1.04, respectively, and this 6-log decrease in the 
transformation frequency of the dsbA mutant (RdsbAV) relative to the other strains was 
statistically significant (p < 0.0001). Therefore, previously reported phenotypes 
associated with dsbA mutants are observed with our in-frame H. influenzae dsbA deletion 
mutants and complemented strains exhibit the wild type phenotypes. 
DsbA is required during H. influenzae infection in mice. The strains generated above 
provided a well-defined set of mutants for investigation of the role of dsbA during 
infection. Though not a recent clinical isolate, Rd has virulence properties similar to 
those of clinically important NTHi strains in several models of infection and has provided 
a useful system for studies of H. influenzae biology and pathogenesis (50, 159). The 
mouse model was used to evaluate bloodstream survival of the dsbA mutant, RdsbAV, 
versus the vector only control strain, RXV. At 24 hours post-inoculation, 48-fold fewer 
bacterial CFU were recovered from mice inoculated with the dsbA mutant compared to 
the control strain (Figure 2.1A). Recovery of bacteria from most of the mice inoculated 
with RdsbAV was close to the limit of detection. An additional experiment was 
conducted to confirm this result with a complemented strain, RdsbAC. To more 
accurately assess the level of attenuation, this experiment was performed as a competition 
between each strain in mixed infections with strain RdlacZ, which expresses E. coli lacZ 
at the xyl locus. Consistent with results from single strain inoculations, the competitive 
index of RdsbAV was 100 to 170-fold less than that of Rd, RXV, or RdsbAC (Figure  
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Figure. 2.1. Effect of dsbA mutation on survival of H. influenzae in the mouse model. 
Strains were inoculated IP into mice and bacteremia assessed after 24 hrs. Individual 
animals are represented by symbols and the dashed line represents the average. (A) 
Single strain infection. Asterisk indicates p = 0.039 (t-test). (B) Co-infections with the 
experimental strains indicated and reference strain (RdlacZ). Competitive indices are the 
ratios of LacZ- (experimental strain) to LacZ+ (reference strain, RdlacZ). Asterisk 
indicates p < 0.001 (ANOVA with Bonferroni’s multiple comparison test). Lower limit 
of detection (LLD) was 500 CFU/ml. Data points below the LLD indicate bacteremia was 
not detected. 
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2.1B). Therefore, infection with a mutant containing a nonpolar dsbA deletion resulted in 
reduced levels of bacteremia in mice, and complementation verified that this effect was 
specific to the dsbA mutation. 
Pathogenesis associated phenotypes in the dsbA mutant. H. influenzae lacks 
previously implicated dsbA-dependent virulence factors found in other species including 
exotoxins and type III secretion structures. Production of the type IV pilus found in some 
NTHi is likely to require dsbA, however the pilus gene cluster is absent in Rd (77). 
Therefore, we examined several major virulence-associated phenotypes in H. influenzae 
to determine whether a defect in a known pathogenic mechanism could account for the 
survival defect of the dsbA mutant in vivo.  
Resistance to oxidative stress generated by hydrogen peroxide exposure has been 
correlated with H. influenzae pathogenesis in several studies (48, 302). Therefore we 
addressed the possibility that loss of DsbA confers sensitivity to this oxidant. After either 
anaerobic or aerobic pre-growth conditions, the mutant and wild type exhibited equal 
levels of growth inhibition during exposure to hydrogen peroxide at a range of doses 
(data not shown).  
Multiple structures of the lipooligosaccharide outer core have been implicated in 
animal models of H. influenzae bacteremia (95, 121, 243), and resistance to complement 
has emerged as an important virulence mechanism mediated by these structures (75, 117). 
Therefore, we investigated whether the dsbA mutant exhibits major LOS structural 
alterations or increased susceptibility to killing by serum complement. We detected no 
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apparent changes in LOS mobility on SDS-PAGE for the dsbA mutant versus wild type. 
Wild-type, dsbA mutant, and complemented strains were compared in a serum 
bactericidal assay with 2% pooled NHS. Percent survival for strains RdV, RdsbAV, and 
RdsbAC was 12%, 2.9%, and 11.6%, respectively (p < 0.05). For comparison, a galU 
mutant deficient in synthesis of the LOS outer-core, a structure predicted to be essential 
for complement resistance, was tested in parallel and exhibited 0% survival. No killing of 
H. influenzae was observed with heat-inactivated serum consistent with an essential role 
of complement in this assay. Differences were not detected in levels of complement 
binding to strains RdV, RdsbAV, and RdsbAC as assessed on anti-C3 and anti-C4 
immunoblots containing lysates of cells that had been incubated with 2% pooled NHS 
(data not shown), though it is possible that a small difference in C3 or C4 binding not 
detected by immunoblotting could mediate the moderate increase in serum sensitivity 
observed in the mutant.  
We conclude that the dsbA mutant is not markedly impaired under the conditions 
tested for hydrogen peroxide resistance or LOS production. An effect on serum resistance 
was observed that could play a role. However, this effect was moderate and it seems 
likely that DsbA influences additional factors required for virulence. To address this 
hypothesis, we sought the identities of potential DsbA substrates in H. influenzae. 
Proteins containing DsbA-dependent disulfide bonds have been identified in E. coli (116, 
141, 158). These proteins were compared by BLASTP (4)(http://www.ncbi.nlm.nih.gov) 
to the predicted proteins in the H. influenzae genome to derive a list of potential DsbA 
targets in H. influenzae (Table 2.2). H. influenzae proteins identified by this search  
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Table 2.2  Potential DsbA Targets 
Putative DsbA 
targets in 
E.coli 
Proposed function in E. coli 
Potential 
H. 
influenzae 
homologue 
Blast 
identities (%) 
Expect 
value 
ArtJ Arginine ABC transporter periplasmic-binding protein 
ArtI 
(HI1179) 115/244 (47) 7e-57 
DppA Dipeptide/heme binding protein 
HbpA 
(HI0853) 282/517 (54) 3e-168 
Imp/OstA Organic solvent tolerance protein 
OstA 
(HI0730) 372/791 (47) 0 
MepA Penicillin-insensitive murein 
endopeptidase 
MepA 
(HI0197) 113/271 (49) 2e-75 
OmpA Outer membrane porin P5 (HI1164) 169/371 (45) 2e-67 
OppA Oligopeptide transporter periplasmic-binding protein 
OppA 
(HI0213) 281/531 (52) 5e-157 
ZnuA Zinc uptake system periplasmic binding protein 
ZnuA 
(HI0119) 140/341 (41) 6e-70 
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include a predicted periplasmic lipoprotein, HbpA, which is required for utilization of 
multiple heme sources (108, 189). Multiple systems participate in scavenging heme from 
sources in the host that include heme-hemopexin, hemoglobin, hemoglobin-haptoglobin, 
heme-albumin, and free heme (42, 193). HbpA appears to be required for scavenging low 
levels of heme regardless of the source or carrier protein suggesting that it could be 
critical for growth in vivo. The link between DsbA and HbpA suggested a potential 
mechanism of attenuation of the dsbA mutant in the mouse model. 
The heme uptake protein, HbpA, is a target of disulfide oxidoreductase. Based on 
comparison to the crystal structure of the highly related E. coli DppA protein, which has 
an intramolecular disulfide bond (210), HbpA has a predicted disulfide bond between 
cysteine residues cys27 and cys255 of the mature protein. A third cysteine located at the 
N-terminus constitutes the predicted lipoprotein acylation site. Many proteins containing 
DsbA-dependent disulfide bonds are less stable in DsbA deficient cells. Therefore, we 
examined the effect of the dsbA deletion mutation on levels of HbpA. To address this 
question, we developed a functional derivative of HbpA fused to an epitope tag from the 
Influenza virus hemagglutinin (HbpA-HA). We first constructed a nonpolar hbpA 
deletion mutant (RhbpAV) in H. influenzae. The mutant was defective for aerobic growth 
on medium containing low levels of heme as previously reported for an independently 
derived hbpA insertional mutant (189). Furthermore, the hbpA mutant exhibited 
equivalent anaerobic growth to that of wild type Rd and the isogenic ‘vector only’ strain 
(RdV), regardless of heme availability (Table 2.3). When expressed in the hbpA mutant 
background, HbpA-HA fully complemented the mutant for aerobic growth at all heme  
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Table 2.3. Growth phenotype of hbpA mutant
 
 Generation time in minutes 
Strain 
Aerobic conditions with free 
heme supplement at a concn 
ofa 
  
Anaerobic  conditions with free heme 
supplement at a concn ofb 
c10 
µg/ml  
0.5 
µg/ml 
0.05 
µg/ml   
10 
µg/ml 
0.5 
µg/ml 
0.05 
µg/ml 0 µg/ml 
Rd 46 ± 3 47 ± 3 57 ± 4   57 ± 8 56 ± 1 61 ± 2 64 ± 3 
RdV 45 ± 1 45 ± 2 50 ± 3   65 ± 13 62 ± 7 65 ± 6 73 ± 3 
RhbpAV 41 ± 3 55 ± 7 NGc   49 ± 4 54 ± 2 55 ± 4 56 ± 5 
RhbpAC 46 ± 3 48 ± 2 53 ± 1   61 ± 4 60 ± 2 66 ± 1 66 ± 2 
          
aGrowth in microplate reader 
bGrowth in anaerobic bag system 
cNo growth 
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concentrations tested (strain RhbpAC) suggesting that the epitope tag does not impair its 
function (Table 2.3).  
The resulting strains were used to assess the effect of a dsbA mutation on levels of 
HbpA-HA on western blots and transcript levels were assessed in parallel by QRT-PCR. 
Levels of HbpA-HA in the dsbA deletion mutant RhbpACDdsbA were approximately 
50% of the amount detected in the DsbA+ control strain, RhbpAC as determined by 
densitometry (Figure 2.2A). QRT-PCR detected no differences in levels of hbpA specific 
transcripts in these cultures (data not shown). Together these results suggest that the 
effect of DsbA on HbpA abundance is mediated at a post-transcriptional level consistent 
with its role as a disulfide oxidoreductase. 
To more directly assess the role of DsbA in formation of disulfide bonds in 
HbpA, the HbpA-HA protein was analyzed by non-reducing SDS-PAGE after isolation 
from the DsbA- and DsbA+ H. influenzae strains (Figure 2.2B). Whereas HbpA-HA from 
DsbA+ cells appeared as a single band, samples from DsbA- cells yielded an additional 
HbpA-HA band of slower electrophoretic mobility. Treatment of cells prior to protein 
isolation with a thiol reactive ligand, maleimide PEO2 biotin (MPB), resulted in no 
change in HbpA-HA in the parental strain (Figure 2.2B, lanes 1 and 2) as expected if the 
two non-acylated cysteine residues are in the oxidized state as a disulfide bond. In 
contrast, the slower migrating species in the dsbA mutant (Figure 2.2B, lane 3) exhibited 
an additional decrease in mobility in samples from MPB treated cells (Figure 2.2B, lane 
4), consistent with addition of MPB to free thiols on cysteine residues of this protein.  
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Figure. 2.2. Effects of dsbA mutation on HbpA protein levels and thiol redox state. 
(A) Detection of HbpA levels in DsbA+ versus DsbA- strains. Whole-cell lysates of 
duplicate cultures of RhbpAC (complemented hbpA deletion mutant carrying hbpA-HA 
in the xyl locus)(lanes 1 and 2) and RhbpAC∆dsbA (RhbpAC with dsbA deletion)(lanes 3 
and 4) were resolved by 8% SDS-PAGE under reducing conditions and detected via anti-
HA Western blot (left panel). Equal sample concentration was verified by Coomassie 
Blue stain (right panel). (B) Differential modification of thiols on HbpA in dsbA mutant 
compared to wild-type. Spheroplasts were prepared from log phase cultures, resolved by 
8% SDS-PAGE under non-reducing conditions, and detected via anti-HA Western blot. 
Strains were the same as in panel A, and treated (+) or untreated (-) with 5 mM MPB 
where indicated. Arrows indicate the oxidized (ox) form of HbpA, the reduced (red) form 
of HbpA, and the reduced form with thiols modified with MPB (red + MPB). 
54 
 
Relatively low levels of the reduced form of HbpA were detected, consistent with 
decreased stability of the reduced form relative to the oxidized form in the dsbA mutant, a 
characteristic property of many DsbA-dependent proteins (17). Therefore, a longer 
exposure time was used to clearly visualize the reduced form in Figure 2B, masking the 
decrease in total HbpA levels that was detected in the dsbA mutant in the quantitative 
studies above (Figure 2.2A).  
HbpA in the oxidized form was detected in the dsbA mutant, and it is likely that 
some HbpA activity is retained in this mutant. Consistent with this observation, we could 
not detect a growth defect of the dsbA mutant on low heme media. The growth rates of 
DsbA+ and DsbA- strains (RXV and RdsbAV) were compared to those of the hbpA 
mutant and complemented strains (RhbpAV and RhbpAC) at 5 µg/ml, 0.5 µg/ml, 0.25 
µg/ml, and 0.025 µg/ml of either heme or heme-hemoglobin (data not shown). RhbpAV 
exhibited progressively reduced growth rates as heme or hemoglobin concentrations were 
lowered, and RhbpAC grew at the same rates as wild type, similar to results in Table 3. 
Conversely, no differences were observed between RXV and RdsbAV, suggesting that 
the residual levels of active HbpA in the dsbA mutant are sufficient for acquisition of 
these heme sources in vitro. Together these data indicate that the DsbA disulfide 
oxidoreductase is required to maintain the complete oxidation of free thiols on HbpA and 
for wild type levels of this protein in H. influenzae.  
HbpA is required during bloodstream infection. Heme is required for aerobic growth 
and is obtained by H. influenzae from sources within the host. The decreased levels of 
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HbpA observed in the dsbA mutant could contribute to its decreased survival in the 
bloodstream by interfering with heme acquisition in vivo where heme is efficiently 
sequestered by multiple systems of the host. To evaluate this hypothesis we assessed the 
role of hbpA in the mouse model using the hbpA mutant (RhbpAV), isogenic HpbA+ 
parent (RdV), and the complemented strain (RhbpAC). Inocula were prepared from 
cultures grown anaerobically, a condition permissive for growth of the hbpA mutant 
(Table 2.3), and mice were inoculated by the IP route (Figure 2.3). Single strain 
infections indicated a decrease in recovery of bacterial CFU from mice inoculated with 
the RhbpAV compared to RdV (17-fold) or RhbpAC, (~60-fold); however, this trend did 
not achieve statistical significance (Figure 2.3A). To control for variation between 
animals, we repeated the experiment in the competition format. Each strain was co-
inoculated with an equal number of cells of strain RdlacZ and competitive indices 
evaluated. The mutant exhibited a ~27-fold defect in competition relative to the ‘vector 
only’ and complemented strains, and these differences were statistically significant 
(Figure 2.3B). We conclude that survival of the hbpA mutant is attenuated in the 
bacteremia model, but to a lesser extent than is the dsbA mutant. Therefore, a decreased 
level of HbpA could contribute to the defect of dsbA mutants during infection, yet 
additional factors such as serum sensitivity and other mechanisms that remain to be 
identified are likely involved. 
DsbA is required for growth and persistence of virulent H. influenzae type b in the 
bloodstream. We next addressed whether dsbA is required during infection by the highly 
virulent H. influenzae type b strain Eagan. The infant rat bacteremia model provides a  
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Figure. 2.3. Effect of hbpA mutation on survival of H. influenzae in the mouse 
model. Strains were inoculated IP into mice and bacteremia assessed after 24 hrs. 
Individual animals are represented by symbols and the dashed line represents the average. 
(A) Single strain infection. (B) Co-infections with the experimental strains indicated and 
reference strain (RdlacZ). Competitive indices are calculated as the ratio of LacZ- 
(experimental strain) to LacZ+ (reference strain, RdlacZ). Asterisk indicates p < 0.001. 
Lower limit of detection (LLD) was 500 CFU/ml. Data points below the LLD indicate 
bacteremia was not detected.
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well-characterized system for examining factors required for H. influenzae type b 
pathogenesis. Therefore, the mutations used to evaluate the role of dsbA in Rd were 
moved into the Hib background. Infant rats at five days of age were inoculated IP with 
wild-type ‘vector only’ (HXV), dsbA mutant (HdsbAV), and the complemented strain 
(HdsbAC) and monitored for bloodstream infection at 12, 36, and 120 hours post-
inoculation (Figure 2.4). At all times of sampling, recovery of H. influenzae CFU’s from 
animals inoculated with the dsbA mutant was reduced by at least 100-fold compared with 
the parental or complemented strains, and this level of attenuation was statistically 
significant in all cases. Furthermore, by 120 hours post-inoculation only two of eleven 
animals inoculated with the dsbA mutant had detectable bacteremia, whereas most of the 
animals infected with wild type (9/11) or the complemented strain (11/11) remained 
infected with mean bacterial levels of 9.5 x 104 and 5.6 x 104 CFU/ml, respectively. 
These results indicate that dsbA is required for efficient production and persistence of a 
high magnitude of bacteremia in the infant rat model by a virulent clinical isolate of H. 
influenzae type b. 
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Figure. 2.4. Effect of dsbA mutation on virulence of H. influenzae type b in infant 
rats. Strains were inoculated IP into 5-day-old infant rats. Individual animals are 
represented by symbols and the dashed line represents the average. Asterisks indicate p < 
0.001. The lower limit of detection (LLD) was 500 CFU/ml. Data points below the LLD 
indicate bacteremia was not detected. 
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DISCUSSION 
We report a role for the H. influenzae disulfide oxidoreductase, DsbA, in 
bloodstream infection. Nonpolar dsbA deletion mutations in either the Rd or Hib Eagan 
strain backgrounds resulted in equal levels of attenuation in animal models, and virulence 
of complemented strains was equivalent to that of the parental strains. Because the in vivo 
defect was observed with dsbA mutants of both nonencapsulated Rd and encapsulated 
type b strains of H. influenzae, an effect on production of capsule would be unlikely to 
account for these observations. Therefore, we investigated several other potential 
mechanisms. The primary set of factors implicated in pathogenesis of nonencapsulated H. 
influenzae in animal models includes genes of LOS synthesis, evasion of complement 
deposition, and oxidative stress resistance. We detected no apparent role for dsbA in LOS 
synthesis or hydrogen peroxide resistance though we cannot exclude the possibility that 
these phenotypes are influenced in a subtle way that our assays were not sufficiently 
sensitive to detect. A decrease in serum resistance was observed in the dsbA mutant, and 
it will be of interest to establish the mechanism by which DsbA contributes to this 
virulence related trait. However, the effect on serum resistance was only moderate, and 
does not seem sufficient to account for the full defect of the dsbA mutant in pathogenesis. 
The results suggest that unrecognized factor(s) may account for the observed virulence 
defect of the dsbA mutants. 
To expand our search to other factors that could participate in the defect of the 
dsbA mutant in vivo, we considered a set of potential secreted substrates of H. influenzae 
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DsbA identified by amino acid sequence comparison to reported DsbA targets in other 
species. The resulting list of potential DsbA substrates in H. influenzae includes a number 
of known or suspected nutrient transport proteins. Therefore, a nutritional deficiency 
could contribute to the defect of the dsbA mutant in the blood. We examined growth of 
the H. influenzae dsbA mutant under a range of in vitro conditions. The H. influenzae 
dsbA mutant grew normally under aerobic and anaerobic conditions, and in a low nutrient 
medium. The only in vitro condition under which we could detect a growth defect for the 
dsbA mutant was in the presence of high concentrations (5 mM) of dithiothreitol, a 
condition that H. influenzae is unlikely to encounter in vivo. Reducing agents are present 
in plasma, such as glutathione which is found as a mixture of reduced and oxidized forms 
at a total concentration estimated to be ~5-30 mM (7). Growth in the presence of 
glutathione was tested at concentrations ranging from 0.005-1 mM, and growth of the 
dsbA mutant and parental strain was equivalent under each of these conditions (data not 
shown). A general growth defect or sensitivity to physiological levels of reducing agents 
does not appear to account for the decreased virulence of our dsbA deletion mutants. If 
the effect of dsbA on pathogenesis involves a defect in nutrient uptake or utilization, then 
it is likely to involve a nutrient that is selectively limiting in H. influenzae’s environment 
within the host.  
One essential factor that H. influenzae cannot synthesize and must obtain from the 
host is the porphyrin ring of heme. Results of amino acid sequence comparison of H. 
influenzae proteins with known or probable DsbA substrates in other species identified 
the H. influenzae heme binding protein, HbpA, as a potential substrate of DsbA. Deletion 
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of hbpA results in an aerobic growth defect on media containing low levels of exogenous 
heme sources (108, 189) and normal growth under anaerobic conditions (Table 2.3). We 
identified the presence of a DsbA-dependent disulfide bond in HbpA and decreased 
abundance of HbpA in the dsbA mutant. Therefore, we evaluated the phenotype of an 
hbpA mutant during infection. The hbpA mutant exhibits a defect in the murine 
bacteremia model, though not as pronounced as the defect of the dsbA mutant, and 
complementation restores its ability to promote bacteremia to that of the parental strain. 
These results suggest that decreased levels of HbpA could contribute to the in vivo defect 
of the dsbA mutants. 
The decreased level of HbpA in the dsbA mutant would be expected to influence 
growth under conditions of heme limitation, however, we were unable to detect such an 
effect in vitro. It is likely that residual HbpA activity in the dsbA mutant is capable of 
supporting in vitro growth on low heme. Nevertheless, both DsbA and HbpA participate 
in bloodstream infection. Survival in vivo, where diverse host factors efficiently sequester 
free heme, may exert a more stringent requirement for wild type levels of HbpA than the 
in vitro conditions tested here. Alternatively, it is possible that the in vivo growth defect 
of the dsbA mutant results from effects on a DsbA-dependent protein whose role in 
virulence remains to be identified. The partial attenuation of the hbpA mutant relative to 
the more dramatic virulence defect of the dsbA mutant supports the hypothesis that other 
factors are involved. In this regard, two potential DsbA targets in H. influenzae, Pzp1 
(ZnuA) and outer-membrane protein P5 (Table 2.2), are required for growth under zinc 
limiting conditions in vitro (166) and adhesion to mucosal epithelium during colonization 
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of the chinchilla nasopharynx (26), respectively. In addition, homologs of Pzp1 and P5 in 
several other bacterial species have been implicated in pathogenesis (5, 148, 240, 250, 
292, 309). We did not observe a requirement for zinc supplementation for in vitro growth 
of the dsbA mutant (data not shown), potentially due to residual activity of Pzp1, yet is 
possible that zinc levels available to bacteria within the mammalian host are lower than 
those in vitro. A defect in levels or activity of Pzp1 in the H. influenzae dsbA mutant 
could contribute to its virulence defect and additional studies will be required to evaluate 
this hypothesis. In addition, a role for P5 during H. influenzae bacteremia has not been 
reported, and it will be of interest to investigate this possibility. Related outer-membrane 
proteins in other pathogens have been implicated in diverse aspects of pathogenesis, 
including complement resistance (240, 250, 292), and changes in the outer-membrane 
protein profile of the dsbA mutant could account for similar effects in H. influenzae. The 
roles of the other potential DsbA substrates (Table 2.2) are not defined in H. influenzae, 
and their putative homologs in E. coli do not appear to mediate virulence related 
functions. Furthermore, the complete set of H. influenzae DsbA substrates remains to be 
determined experimentally. Investigation of the virulence properties conferred by 
proteins that contain DsbA-dependent disulfide bonds in H. influenzae will likely uncover 
important aspects of pathogenesis by this bacterium, and may lead to novel approaches to 
treatment or prevention of invasive disease. 
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CHAPTER III 
A novel zinc binding system, ZevAB, is critical for survival of nontypeable 
Haemophilus influenzae in a murine lung infection model. 
ABSTRACT 
 Nontypeable Haemophilus influenzae (NTHi) is a gram-negative bacterial 
pathogen that causes upper and lower respiratory infections. Factors required for 
pulmonary infection by NTHi are not well understood. Previously, using High-
throughput Insertion Tracking by deep-Sequencing (HITS), putative lung colonization 
factors were identified. Also, previous research indicates that secreted disulfide-
dependent factors are important for virulence of H. influenzae. In the present study, HITS 
data were compared with an informatics-based list of putative substrates of the 
periplasmic oxidoreductase, DsbA, to find and characterize secreted virulence factors. 
This analysis resulted in identification of the “zinc binding essential for virulence” (zev) 
locus consisting of zevA (HI1249) and zevB (HI1248). NTHi mutants of zevA and zevB 
grew normally in rich media, but were defective for colonization in a mouse lung model. 
Mutants also exhibited severe growth defects in media containing EDTA and were 
rescued by supplementation with zinc. Additionally, purified recombinant ZevA was 
found to bind to zinc with high affinity. Together, these data demonstrate that zevAB is a 
novel virulence factor important for zinc utilization of H. influenzae during conditions 
when zinc is limiting. Furthermore, evidence presented here suggests zinc limitation is 
likely an important mechanism for host defense against pathogens during lung infection. 
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INTRODUCTION 
Nontypeable Haemophilus influenzae (NTHi) is a Gram-negative bacterial 
pathogen uniquely adapted to colonize the nasopharynx of healthy humans with a 
carriage frequency of approximately 20-80% (197). An opportunistic pathogen, NTHi 
resides asymptomatically in the upper airways of humans, but can disseminate into 
privileged anatomical locations causing infections such as otitis media, sinusitis, and 
pneumonia (201). NTHi is also one of the most prevalent microorganisms found in the 
lungs of patients with exacerbations of chronic obstructive pulmonary disease (202, 205, 
251) and cystic fibrosis (86, 187, 245). An effective vaccine against NTHi strains has not 
yet been discovered, likely due to high variability of surface antigens between strains 
(251). 
Little is known regarding factors required for survival of H. influenzae in the 
lung. To address this, we recently examined a transposon mutant library of H. influenzae 
Rd in a mouse lung infection model using a novel technique termed High-throughput 
Insertion Tracking by deep-Sequencing (HITS) (84). HITS analysis revealed a total of 
136 genes required for survival in this site, including previously identified virulence 
determinants such as those involved in lipooligosaccharide synthesis (219) as well as 
several genes previously unrecognized to play a role in pathogenesis, some of which are 
implicated in diverse processes including DNA repair, membrane remodeling, and 
nutrient acquisition. However, many genes identified by HITS have unknown functions 
and are yet to be characterized.  
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Previously, the periplasmic disulfide-bond pathway was investigated to find 
virulence determinates of H. influenzae (241). Disulfide formation is mediated by the 
periplasmic oxidoreductase protein, DsbA, which directly catalyzes disulfide bond 
formation by transfer of a disulfide bond to free thiol groups of cysteine residues in 
secreted target proteins (79, 313). This system is important for providing structural 
stability and function to secreted virulence factors in a range of bacterial pathogens (113). 
DsbA was demonstrated to be required for pathogenesis of H. influenzae in a mouse 
model of bacteremia (241). Additionally, the heme-binding lipoprotein, HbpA, an 
important factor required for growth of H. influenzae on several heme sources (108, 189), 
was found to be a substrate of DsbA and was required for pathogenesis. However, the 
defect of an hbpA mutant was not as severe as that of a dsbA mutant suggesting that 
other, unidentified DsbA-dependent factors must be required for pathogenesis.  
Since a DsbA-dependent protein was found to have a role in virulence of H. 
influenzae, we hypothesized that by examining genes required in the lung additional 
DsbA-dependent factors involved in infection could be found. We were particularly 
interested in investigating this set of proteins because their extracytoplasmic location and 
accessibility makes them attractive targets for development of therapeutics or vaccines 
for combatting NTHi infections. In this study, potential DsbA-substrates were identified 
based on predicted extracytoplasmic localization and putative disulfide bond formation. 
The whole-genome fitness data generated via the HITS procedure was used to identify 
candidate DsbA substrates required for survival of H. influenzae in the lung. This 
approach led us to characterize a locus important for zinc utilization, herein referred to as 
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“zinc binding essential for virulence” (zev). This locus contains an operon consisting of 
two genes: the potential DsbA-substrate zevA and a gene encoding a putative membrane 
protein called zevB. In contrast to the previously characterized ZnuABC zinc transport 
system which is required for optimal growth in rich culture medium in vitro (166), the 
zevAB system is specifically required for growth under severe zinc limitation. Results of 
this study suggest that the lung represents a niche that exposes infecting pathogens to 
severe zinc limitation and that the zevAB system is required for zinc homeostasis of H. 
influenzae during pathogenesis.  
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MATERIALS AND METHODS 
Strains and culture conditions. H. influenzae RdAW (NZ_ACSM00000000), a capsule-
deficient serotype d derivative (301), and pathogenic nontypable H. influenzae strain 
NT127 (NZ_ACSL01000014.1) were grown in brain heart infusion broth (BHI) 
supplemented with 10 µg/ml hemin and 10 µg/ml NAD (sBHI), or on sBHI agar plates at 
35°C. To generate an anaerobic environment, strains were grown in anaerobic chambers 
with BBL GasPak Plus generators (Becton Dickenson and Company, Sparks, MD). 
Development of competence for transformation of H. influenzae was accomplished as 
previously described (15). For selection of Rd- and NTHi-derived strains, antibiotics were 
used at the following concentrations: 8 µg/ml tetracycline (Tc), 20 µg/ml kanamycin 
(Km), and 10 µg/ml gentamicin (Gm). For strain generation, plasmids and PCR products 
were constructed using standard molecular biology techniques (12). For complementation 
of mutants, DNA fragments were amplified by PCR and cloned between adjacent SapI 
restriction sites of the chromosomal delivery vector pXT10, linearized and used to 
transform H. influenzae strains as previously described (301). 
zevA strain construction. The NTHi zevA mutant strain NT1249G was constructed by 
replacement of the coding sequence of zevA (NT127 Locus_Tag HIAG_01363) with the 
Gm resistance cassette, aacC1. To do this, a 707-bp PCR product containing the 5' 
flanking region of ZevA-generated using primers 1249for and 1249B (Table 3.1), a 762-
bp PCR product containing the coding region for the Gm resistance cassette generated 
with primers 5pGent1 and 3Gent2, and a 1,661-bp PCR product containing the 3' flanking  
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TABLE 3.1. Oligonucleotides used in this chapter 
Primer Sequence 
1249for CTTGTAGAATTTCACCAACAGAGGTGGGT 
1249B AGGCTTATGTCAATTCGAGAATTGAAAAAATCCTATTATTTT
GAACGCTAGAATTTGA 
5pGent1 CAATTCTCGAATTGACATAAGCCT 
3Gent2 TTAGGTGGCGGTACTTGGGTCGAT 
1249A ACCCAAGTACCGCCACCTAAAAATGAAAAAATATAAAACT
GGGCTCGT 
1248rev ACGAAAGTCGGAATGCAGAATGAATGGT  
51249HA AAAGCTCTTCAATGCTATAAAGATAATCATCTCTAAAATGC
TCACGCT 
31249R TTTGCTCTTCTTTACTCACATTGAATTATTATTTTTTGCGCGA 
1248BJBpArc
A 
TCTTTGTGATAGAATTTCGAGAATCTTCTACTCACATTGAAT
TATTACTTTTTGTGCGA 
5parca GATTCTCGAAATTCTATCACAAAGA 
1248Ahib ACCCAAGTACCGCCACCTAAAGTTAAAAATAAAGCCCATCA
ACATGA 
1247revJB AGGATAGATCGTAAAACGTGGGACAGCA 
31248R TTTGCTCTTCTTTAAAATAGGATTTTGCTTCCGCCAGTTGA 
5ZnuA1 TGGCTAGAATAGATAATTACGAACAACGCT 
3ZnuA1 AAGCATTGGTGCACCGTGCAGTCGATTTATGTTTCCTTACTT
GTTGGTAGTAATTCT 
IFTrcF CGACTGCACGGTGCACCAATGCTT 
3kan1.1 TTAGAAAAACTCATCGAGCATCAAATG 
5ZnuA3 CATTTGATGCTCGATGAGTTTTTCTAAATCTTTCTAAAAACA
ATGACCGCATATAAAAGT 
3ZnuA3 CTATTTTGGCGACTTTAACTGCATTG 
5znuB1 CTAAGGTTTTAACATTTTTTCAGCTTCACGA 
3ZnuB1 AAGCATTGGTGCACCGTGCAGTCGAAAATCGCCGTGTTTTC
AACAATGGTTGG 
5znuB3 CATTTGATGCTCGATGAGTTTTTCTAAGCTTGCCCAACCAGT
GAAAACCAT 
3znuB3 TTAGCAATAACCGTAAGACATTAAACGTTCATAGCGT 
1249BL AAAAAATCCTATTATTTTGAACGCTAGAATTTGA 
LacFor2 TCTAGCGTTCAAAATAATAGGATTTTTTATGATTACGGATTC
ACTGGCCGTCGT 
tetB TGACGAAATAACTAAGCACTTGTCTCCTGTTTACT 
1248AL AGACAAGTGCTTAGTTATTTCGTCAAGTTAAAAATAAAGCC
CATCAACTGGAT 
31248gent AGGCTTATGTCAATTCGAGAATTGTTATCAAAATAGGATTT
TGCTTCCGCCAGTTGA 
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PXT10thyAF AGGGCTTGAATCGCACCTCCA 
3Revrfad1 AACAGGCTACGATAAACCATTCAAAACAGT 
5'FNRcloning CGGAATGTTGCATCAAGCACAC 
3'FNR cloning GGCTGCCACCAAATGGACATTAC 
3FNRgent AGGCTTATGTCAATTCGAGAATTGTTATTTAACTAATGTAAT
TTTTGTTTTATTCGTACCA 
5xylBgent ACCCAAGTACCGCCACCTAATCAGAATTGGTTAATTGGTTG
TAACACTGGCA 
51249test TCCCTAAATTAAATAGACACTTTAGGGCT 
31249test TCATCATTTCAATATCAAATTGGGTTCGT 
5znuAtest TGATAATAATGGAAACTGGCTTGGCA 
3znuAtest ACATAATATGCATAATGCTTTAATGGCGA 
5znuBtest CTTGCTCAACAAGCAAATGAAGTGGA 
3znuBtest TGATTTGCTCTAAAGCAAAAAGAATTTGA 
51249JTOPO GTGAAAACGTATTCATTATTACTCGCTCTA 
31249JTOPO GGACTGAAAATACAGGTTTTCGCCGCTGCTCTCACATTGAA
TTATTACTTTTTGTGCGA 
51249RT AAACGTATTCATTATTACTCGGT 
31249RT TCCGCTTTAGTTCTAGCTTGT 
51248RT AAAAAATATAAAACTGGGCTCGT  
31248RT TGGTGCCTGCCTTGATGCT 
RpoA5' GTAGAAATTGATGGCGTATTG 
RpoA3' TCACCATCATAGGTAATGTCC 
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zevA generated with primers 1249A and 1248rev were joined by overlap extension PCR, 
via complementary ends, using primers 1249for and 1248rev. The resulting 3,086-bp 
fragment was introduced into competent cells of strain NTX, a derivative of NT127 in 
which the xylose locus was modified for efficient recombination with plasmid pXT10 
and its derivatives (110). Gm resistant (GmR) transformants were selected on sBHI 
containing Gm creating strain NTzevAG. NTzevAG was transformed with linearized 
“empty vector” pXT10, and TcR transformants were isolated to create strain NTzevAV. 
Double crossovers into the zevA locus were verified using primers 51249test and 
31249test, which bind outside the recombination junctions. 
 To complement the zevA deletion, zevA and upstream promoter elements were 
amplified by PCR with primers 51249HA and 31249R, which introduce SapI restriction 
sites at the termini of the fragment. The resulting 1,017-bp fragment was digested with 
SapI and cloned into SapI digested vector, pXT10, creating plasmid pX1249J. Plasmid 
pX1249J was linearized with ApaLI and introduced into competent cells of strain 
NT1249G. TcR recombinants were selected on sBHI containing Tc, resulting in strain 
NTzevAX. 
zevB strain construction. Deletion of zevB in NTHi was also performed by replacement 
of the coding region of zevB (HIAG_01364) with the Gm resistance gene. To increase 
efficiency of mutant selection, the aacC1 promoter was replaced with the H. influenzae 
arcA promoter. First, a 1,332-bp fragment containing the 5' flanking region of zevB was 
amplified by PCR using NT127 genomic DNA as a template with primers 1249for and 
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1248JBpArcA, a 762-bp fragment amplified from a pXT10 plasmid carrying the arcA 
promoter fused to the coding region of the Gm resistance gene from aacC1 using primers 
5pArcA and 3Gent2, and a 1326 bp fragment containing the 3' flanking region of zevB, 
amplified from NT127 genomic DNA using primers 1248AHib and 1247RevJB were 
joined by overlap extension PCR using primers 1249for and 1247RevJB. The resulting 
3,638-bp fragment was used to transform competent cells of strain NTX. GmR 
transformants were selected on sBHI-Gm plates resulting in strain NTzevBG. NTzevBG 
was then transformed with linearized vector pXT10, and Tcr transformants were isolated 
to create strain NTzevBV. Double cross-overs into the zevB locus were verified using 
primers 51249test and 31249test, which bind outside the recombination junctions. 
To complement the zevB mutant, the region consisting of zevA, zevB and upstream 
promoter elements were amplified by PCR with primers 51249HA and 31248R, which 
introduce SapI restriction sites at the termini of the fragment. The resulting 1,988-bp 
fragment was digested with SapI and cloned into SapI digested vector, pXT10, creating 
plasmid pX1248J. Plasmid pX1248J was linearized with ApaLI and introduced into 
competent cells of strain NT1248G. TcR recombinants were selected on sBHI containing 
Tc, resulting in strain NTzevBX. 
For performing mixed infections with zevA and zevB mutant strains, a reference 
strain featuring a xylose inducible lacZ gene was generated by transforming NT127 with 
ApaLI digested plasmid pXELacZ2, which contains lacZ in place of xylA. TcR 
recombinants were selected on sBHI containing Tc, resulting in strain NTlacZ. 
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znuA and znuBC strain construction. To generate an NTHi znuA (HIAG_01677) 
mutant, a 971-bp fragment, containing the 5' flanking region of znuA was amplified from 
NT127 genomic DNA with primers 5ZnuA1 and 3ZnuA1. A 1,065-bp fragment 
containing the trc promoter fused to the Km resistance gene (aphI) was amplified from 
plasmid pENTtrcK (containing the mini-mariner transposon, mmTrcK, previously 
described (84)) with primers IFTrcF and 3kan1, and a 1,065 bp fragment, containing the 
3’ flanking region of znuA, amplified from NT127 genomic DNA with primers 5ZnuA3 
and 3ZnuA3 were joined using overlap extension PCR by virtue for their complementary 
ends, with primers 5ZnuA1 and 3ZnuA3. The resulting 3,033-bp fragment was 
introduced into competent cells of strains NTV, NTzevAV and NTzevBV and Km 
resistant (KmR) colonies were selected on sBHI Km, resulting in strains NTznuA, 
NTzevAznuA and NTzevBznuA, respectively. Double crossovers into the znuA locus 
were verified using primers 5znuAtest and 3znuAtest, which bind outside the 
recombination junctions. 
To generate an NTHi znuBC (HIAG_00759 and HIAG_00758) mutant, a 1,592-
bp fragment, containing the 5' flanking region of the znuBC operon was amplified from 
NT127 genomic DNA with primers 5ZnuB1 and 3ZnuB1, the 1,065-bp fragment 
described above, containing the trc promoter fused to the Km resistance gene, and a 
1,027 bp fragment, containing the 3’ flanking region of znuBC, amplified from NT127 
genomic DNA with primers 5ZnuA3 and 3ZnuA3, were joined using overlap extension 
PCR by virtue for their complementary ends using primers 5ZnuB1 and 3ZnuB3. The 
resulting 3,700-bp fragment was introduced into competent cells of strains NTV, 
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NTzevAV and NTzevBV and KmR colonies were selected on sBHI Km, resulting in 
strains NTznuBC, NTzevAznuBC and NTzevBznuBC, respectively. Double crossovers 
into the znuBC locus were verified using primers 5znuBCtest and 3znuBCtest, which 
bind outside the recombination junctions.  
zevA reporter strain construction. To generate the reporter strain, R5, we replaced the 
coding region of zevAB (HI1249 and HI1248) in Rd, with a reporter construct containing 
the lacZ gene, designed to fuse the zevA promoter to the translational start of lacZ , and 
the tetAR Tc resistance operon as a selectable marker. To do this, a 683-bp fragment 
containing the 5’ flanking region from zevA amplified by PCR from Rd genomic DNA 
with primers 1249for and 1249BL, a 6,869-bp fragment containing the lacZ gene and 
tetAR amplified from plasmid pXELacZ2 with primers LacFor2 and tetB, and a 689-bp 
fragment containing the 3’ flanking region of zevB amplified from Rd genomic DNA 
with primers 1248AL and 1248rev, were joined using overlap extension PCR with 
primers 1249for and 1248rev. The resulting 8,188-bp fragment was used to transform Rd 
competent cells. TcR transformants were selected on media containing Tc resulting in 
strain R5. 
 To complement mutation of zevAB in R5, a 1,988-bp fragment containing the 
zevAB coding regions as well as upstream promoter elements was amplified by PCR from 
Rd genomic DNA with primers 51249HA and 31248R, which introduce SapI restriction 
sites at the termini. The resulting fragment was digested with SapI and cloned into SapI 
digested vector, pXT10, creating plasmid pX1248R. Next a 2,891-bp fragment containing 
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the xylF gene as well as the 5’flanking and coding regions of zevAB amplified from 
plasmid pX1248R with primers pXT10thyAF and 31248gent, the 762-bp Gm resistance 
cassette fragment described above, and a 1,794-bp fragment containing the xylB gene 
amplified from pXT10 with primers 5xylBgent and 3revrfad1, were joined using overlap 
extension PCR with primers pXT10thyAF and 3revrfad1. The resulting 5,447-bp 
fragment was used to transform competent cells of strain R5 resulting in R5X. 
fnr mutant construction. For mutation of fnr (HI1425), a 4,230-bp fragment containing 
the fnr gene with a magellan1 transposon insertion 170-bp from the 5' end of the FNR 
translational start was amplified by PCR from previously described strain Rfnr (110) with 
primers 5FNRcloning and 3FNRcloning and used to transform competent R5 cells. KmR 
transformants were selected on sBHI Km, and the mutation was verified by PCR 
resulting in strain R5fnr.  
To complement the fnr mutation, a 2,201-bp fragment containing xylF, the fnr 
promoter and fnr (amplified by PCR from strain RfnrC with primers pxt10thyAF and 
3FNRgent), the 762-bp Gm resistance cassette fragment described above, and a 1,794-bp 
fragment containing the xylB gene (amplified from pXT10 with primers 5xylBgent and 
3revrfad1) were joined using overlap extension PCR with primers pXT10thyAF and 
3revrfad1. The resulting 4,733-bp fragment was used to transform competent cells of 
strain R5fnr and the mutation was verified by PCR resulting in strain R5fnrX. 
His-tagged ZevA construction. To generate the ZevA-His fusion, a 618-bp fragment 
containing the zevA gene was amplified from NT127 genomic DNA template with 
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primers 51249JTOPO and 31249JTOPO. Primer 31249TOPO adds a tobacco etch virus 
(TEV) protease cleavage site to the 3’ end of the zevA gene (275). The 618-bp fragment 
was then TA cloned into the pBAD-TOPO-TA cloning vector (Invitrogen, Carlsbad, 
CA), which adds a C-terminal 6X his tag (immediately after the TEV cleavage site), and 
transformed into Oneshot® TOP10 E. coli (Invitrogen, Carlsbad, CA) creating strain 
ECZevAHIS, harboring plasmid pZevAHIS. Plasmid pZevAHIS was verified by 
sequencing. 
Genetic footprinting. H. influenzae Rd genomic DNA from input and output libraries 
was used as a template for genetic footprinting analysis as previously described (3, 255). 
PCR reactions were performed using the transposon-specific primer, marout, and gene-
specific primer 3129rev that binds 661-bp downstream of the zevB gene and visualized 
on a 0.9% agarose gel stained with ethidium bromide. Migration distances and gene 
positions were determined as described previously (84, 246). 
Murine lung infection model. Standing overnight cultures were used to inoculate 25 ml 
of sBHI in a 50 ml flask to a final optical density at 600 nm (OD600) of 0.01. The 
resulting cultures were incubated shaking at 250 rpm and 35°C until mid-log phase. 
Experimental strains were either mixed (mixed infections) with the NTlacZ reference 
strain at a 1:1 ratio or not mixed (single strain infections), washed, and diluted in HBSS 
to obtain a final concentration of 5 x 108 bacteria per ml. Forty microliters (2 x 107 CFU 
total) were inoculated into the nares of female 6.5-week-old C57BL/6 mice (Charles 
River Laboratories, Boston, MA) anesthetized with ketamine (65 mg/kg) and xylazine 
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(6.5 mg/kg) by i.p. injection. At 40 h of infection, lungs were harvested and homogenized 
using a Fisher Tissuemiser. Dilutions of the lung homogenate were plated on sBHI agar 
plates with or without 1 mM D-xylose and X-gal (5-bromo-4-chloro-3-indolyl β-D-
galactopyranoside; Sigma-Aldrich, St. Louis, MO) for CFU enumeration. For statistical 
analysis of mixed infections, the ratio of each experimental strain to NTlacZ was 
calculated, multiplied by 100, log10 transformed, and analyzed using one-way ANOVA 
with Tukey’s multiple-comparison test (Prism 5.03; GraphPad Software, La Jolla, CA). 
For single strain infections, numbers of CFU/lung were calculated and analyzed by t-test. 
All animal procedures were conducted in accordance with NIH guidelines and with prior 
approval by the University of Massachusetts Medical School Institutional Animal Care 
and Use Committee. 
EDTA sensitivity and growth curve analysis. Strains were inoculated from standing 
overnight cultures at an OD600 of 0.01 into 25 ml of sBHI in a 50 ml flask and incubated 
shaking at 250 rpm and 35°C until mid-log phase. These cultures were used to inoculate 
sBHI media containing EDTA (at the final concentrations specified) at an OD600 of 0.02 
and 100 µl was dispensed into the wells of a 96-well microtiter plate (Corning) prefilled 
with 100 ul sBHI broth containing EDTA (final concentrations specified in results). 
When necessary, media was supplemented with MgCl2, CaCl2, MnCl2, FeCl3, CoCl2, 
NiCl2, CuSO4, ZnSO4, or Na2MoO4 to final concentrations of 30 or 60 µM. As a control, 
strains were also grown in sBHI media without additions. For double mutant analysis, 
strains were grown in media containing various concentrations of EDTA (final 
concentration of 0.0025 mM, 0.005 mM, or 0.01 mM), or media containing various 
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concentrations of ZnSO4 (final concentration of 0.001 mM, 0.003 mM, or 0.05 mM). 
Microtiter plates were incubated at 35°C for 10 h in a Versamax microplate reader 
(Molecular Devices, Sunnyvale, CA) set to read the absorbance at 600 nm every 10 min. 
Effects of EDTA concentration and metal supplementation on strains were assessed by 
relative growth yields and generation times (Prism 5.03; GraphPad Software, La Jolla, 
CA).  
Purification of ZevA-His. To purify the ZevA-His fusion protein, 1 liter cultures of 
strain ECZevAHis were inoculated from 10 ml overnight cultures and grown in Luria-
Bertani broth containing 100 µg/ml ampicillin with shaking at 200 rpm and 37°C. When 
cultures achieved an OD600 between 0.6 and 0.8, L-arabinose was added to a final 
concentration of 0.02%, and cultures were incubated for an additional 3 hrs. After 
incubation, cells were pelleted by centrifugation at 5,000 x g for 10 min, resuspended in 
25 mM Tris-ClH (pH 8.0), 500 mM NaCl and lysed using a French pressure cell. Lysates 
were cleared by ultracentrifugation at 30,000 x g and protein was purified by affinity 
chromatography using a Ni2+-nitrilotriacetic acid (Ni-NTA) column (Qiagen, Valencia, 
CA). Protein was eluted using buffer containing 150 mM imidazole and concentrated by 
centrifugation in an Amicon Ultra, 10 kDa cutoff filter (Millipore, Billerica, MA). To 
remove the His-tag, ZevA-His fusion protein was incubated with purified 6X His-tagged 
TEV protease (1:1 molar ratio) for 1 hr at 22°C in buffer containing 50 mM Hepes-NaOH 
(pH 7.5), 200 mM NaCl, 3 mM reduced glutathione, and 0.3 mM oxidized glutathione. 
After incubation, TEV-His was removed by affinity purification with Ni-NTA resin 
(Figure 3.1). Protein concentration was determined using the Bradford reagent (Sigma- 
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Figure 3.1. Removal of the tag from recombinant ZevA-His fusion. Equivalents of 
each sample were loaded in lanes of Coomassie Brilliant Blue stained gel (top panel) and 
corresponding lanes of western blot (bottom panel). Lane 1 represents TEV-His fusion 
alone, Lane 2 represents ZevA-His fusion alone, Lane 3 and 4 represent the cutting 
reaction after a 1 hr incubation, and Lane 5 and 6 represent ZevA recovered after 
incubation with Ni-NTA resin to remove TEV-His. Lane 6 represents purified untagged-
ZevA protein used in Zn2+ binding experiments. Purified untagged-ZevA was determined 
by densitometry to be at least 99% pure of ZevA-His (Lane 2 versus Lane 6) and 98% 
pure of TEV-His (Lane 4 versus Lane 6).
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Aldrich, St. Louis, MO). Purity was assessed by Coomassie Brilliant Blue staining of 
overloaded SDS-PAGE and by immunostaining western blots with rabbit anti-His 
polyclonal primary antibody (GenScript, Piscataway,NJ, USA) and, goat anti-rabbit IgG 
secondary antibody (horseradish peroxidase conjugate; GenScript, Piscataway,NJ, USA) 
(Figure 3.1). For Zn2+ binding assays, reaction buffer was exchanged with 50 mM Hepes-
NaOH (pH 7.5), 200 mM NaCl, and 10% glycerol by centrifugation in an Amicon Ultra, 
10 Kd cutoff filters (Millipore, Billerica, MA). 
Zn2+ binding stoichiometry determination. Stoichiometry assays were performed as 
described previously (68). ZevA protein (0.8 µM) was incubated for 1 min at room 
temperature in presence or absence of 50 µM ZnSO4. Buffer (50 mM Hepes-NaOH pH 
7.5, 200 mM NaCl, and 10% glycerol) containing 50 µM ZnSO4 was incubated in 
parallel as a control. After incubation, excess Zn2+ was removed by size exclusion with 
Sephadex G-25 columns. Eluted protein was acid digested with concentrated nitric acid 
overnight at room temperature. Following digestion, samples were treated with H2O2 to a 
final concentration of 1.5%. The concentration of Zn2+ in each sample was measured 
using atomic absorption spectroscopy (AAS) (AAnalyst 300; PekinElmer, Waltham, 
MA). Average background Zn2+ levels detected for control samples were <2% of levels 
determined for ZevA+Zn2+ samples. 
Determination of ZevA affinity for Zn2+. Binding affinity of ZevA for Zn2+ was 
determined using the Zn binding chromophore, mag-fura-2 (Invitrogen, Carlsbad, CA) as 
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previously described (68, 163, 279). Briefly, 10 µM ZevA protein and 20 µM mag-fura-2 
were mixed and titrated with 1 mM Zn2+. Free mag-fura-2 was determined by monitoring  
OD366, using ε366 = 29,900 M-1cm-1 (285). Free Zn2+ concentrations were calculated using 
the equation KI = [I·Zn2+]/[Ifree][Zn2+], where I is the concentration of mag-fura-2 and KI 
is the association constant of magfura-2 for Zn2+ (KI = 5 x 107 M-1) (163, 285). The Zn2+-
protein association constant (Ka) and the apparent stoichiometry (n) of ZevA, were 
calculated by fitting the data to v = nKa[Metal]f/(1 + Ka[Metal]f), where v is the ratio of 
moles of metal bound to total protein and n is the number of binding sites (100). 
qRT-PCR. RNA was prepared from liquid cultures of Rd using the RNeasy mini kit and 
on column DNase I kit (Qiagen, Valencia, CA). The RNA samples (5 µg) were used as 
templates for cDNA synthesis with Random Primer 9 (New England Biolabs, Beverley, 
MA) and SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA). Quantitative 
reverse transcription PCR (qRT-PCR) was performed with iQ SYBR green Supermix 
(Bio-Rad Laboratories, Hercules, CA), and fluorescence was measured over time using 
the DNA Engine Opticon II system (MJ Research, Waltham, MA). For transcript analysis 
of zevA and zevB, qRT-PCR performed with primers 51249RT and 31249RT or 51248RT 
and 31248RT, respectively. Primers RpoA5' and RpoA3' were used to amplify the RNA 
polymerase alpha subunit gene, rpoA, as an internal reference. The real-time cycler 
conditions used have been described previously (302). Results of mock reverse 
transcription reactions, containing RNA and all reagents except reverse transcriptase, 
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confirmed, that results obtained were not due to contaminating genomic DNAs (data not 
shown). 
Reporter expression analysis. Strains were plated at a density of 2 x 105 CFU per plate 
on sBHI agar with or without 100 mM ZnSO4, addition and incubated at 35°C overnight 
in either an open air incubator or an anaerobic chamber. Cells were swabbed from plates 
and diluted into Z-buffer (183) to a concentration of 1 x 109 bacteria per ml (OD600 of 
0.333). Alternatively, cells were cultured in sBHI broth containing 0.5 mM EDTA 
shaking at 250 rpm and 35°C until mid-log phase before being diluted into Z-Buffer. The 
β-galactosidase assay was then performed as described (183). The optical density at 420 
nm (OD420) was recorded using a Versamax microplate reader (Molecular Devices, 
Sunnyvale, CA), and converted to Miller units with the equation: Miller Units = (1000 x 
OD420) / (T x V x OD600) where T is time in minutes and V is volume of the reaction. 
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RESULTS 
Identification of secreted factors involved in H. influenzae pathogenesis. An 
informatics-based approach was utilized to compile a database of the exported proteins in 
H. influenzae that are likely to require DsbA for oxidative folding. First, web-based 
prediction servers, signalP (19) and LipoP (135) were used to identify polypeptides with 
predicted cleavage sites for signal peptidase I (soluble exported proteins) or signal 
peptidase II (lipoproteins), respectively. Next, the list was refined to include only mature 
proteins (excluding leader peptides) with two or more cysteine residues, as these are 
expected to be DsbA substrates (206). The β-barrel Outer Membrane Protein predictor 
(BOMP) (22) and membrane topology prediction servers TMHMM (258) and phobius 
(142) were used to predict the locations of cysteines in the loops of membrane proteins 
thereby excluding proteins with cysteines that are predicted to be cytoplasmic and 
inaccessible to DsbA. The final database includes secreted proteins involved in a variety 
of functional processes, which are cataloged based on Clusters of Orthologous Groups 
(COG) categories in Table 3.2. 
Next, to identify the putative substrates of DsbA that are required for 
pathogenesis of H. influenzae, we cross-referenced the list of genes in Table 3.2 with the 
set of genes previously implicated in survival of H. influenzae Rd in the lung as identified 
by the HITS technique (84). In that study, tranposon mutant libraries were acquired 
before and after selection for survival in the mouse lung model, and 
transposon/chromosomal junctions were amplified from genomic DNA, captured,  
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TABLE 3.2. Potential H. influenzae DsbA-substrates identified using informatics 
techniques 
Category Gene 
ID 
Nam
e 
Predicted function / description 
Translation, ribosomal structure     
 HI0526 - * Hypothetical protein HI0526  
    
Cell wall/membrane/envelope 
biogenesis 
   
 
HI0197 mepA Penicillin-insensitive murein endopeptidase  
 HI0275 - Hypothetical protein HI0275  
 HI0364 - Penicillin-binding protein 7  
 HI0366 - Fimbrial biogenesis and twitching motility 
protein  
 HI0383 tolA Cell envelope integrity inner membrane 
protein 
 HI0389 - Outer membrane protein  
 HI0706 nlpD Lipoprotein 
 HI0730 - Organic solvent tolerance protein  
 HI0990 iga1 Immunoglobin A1 protease  
 HI1138 murG N-acetylglucosaminyl transferase  
 HI1164 ompA Outer membrane protein P5  
 HI1330 dacB D-alanyl-D-alanine 
carboxypeptidase/endopeptidase  
    
Posttranslational modification, 
chaperones 
   
 HI0271 djlA DNA-J like membrane chaperone protein  
 HI0428 dsbB Disulfide bond formation protein B  
 HI0846 dsbA Periplasmic oxidoreductase  
 HI0885 dipZ Thiol:disulfide interchange protein precursor  
 HI0934 nrfF Cytochrome C-type biogenesis protein  
 HI0935 dsbE Thiol-disulfide interchange protein  
 HI1213 dsbC Thiol-disulfide interchange protein  
 HI1453 purL Phosphoribosylformylglycinamidine 
synthase  
 HI1455 msrA Bifunctional methionine sulfoxide reductase 
 HI1541 sppA Protease IV  
    
Signal transduction mechanisms    
 HI0267 narQ Nitrate/nitrite sensor protein NarQ  
 HI1378 phoR Phosphate regulon sensor protein PhoR  
    
Intracellular trafficking and secretion    
 HI0015 lepB Signal peptidase I  
 HI0264 hxuA Heme-hemopexin utilization protein A  
    
Energy production and conversion    
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HI0345 napG Quinol dehydrogenase periplasmic 
component  
 HI0347 napB Periplasmic nitrate reductase  
 HI0348 napC Cytochrome C-type protein  
 HI0643 bisC Biotin sulfoxide reductase  
 HI0644 yecK Cytochrome C-like protein  
 HI1047 dmsA Anaerobic dimethyl sulfoxide reductase 
chain A  
 HI1067 nrfC Nitrite reductase Fe-S protein  
 HI1586 - Isoleucyl-tRNA synthetas  
 HI1684 - Electron transport complex protein RnfB  
    
Amino acid transport and metabolism    
 HI0213 oppA Oligopeptide transporter periplasmic-binding 
protein  
 HI0745 ansB L-asparaginase II  
 HI0853 hbpA Heme-binding lipoprotein  
 HI1048 - Hypothetical protein HI1048  
 HI1179 artI Arginine ABC transporter periplasmic-
binding protein  
 HI1638 sapA Anti-peptide resistance ABC transporter 
periplasmic protein  
    
Nucleotide transport and metabolism    
 HI0583 cpdB Bifunctional 2',3'-cyclic nucleotide 2'-
phosphodiesterase/3'-nucleotidase 
periplasmic precursor protein  
    
Coenzyme transport and metabolism    
 HI0118 - Hypothetical protein HI0118  
 HI1019 tbpA Thiamin ABC transporter periplasmic-
binding protein  
 HI0113 hemR Hemin receptor  
 HI0119 znuA High-affinity zinc transporter periplasmic 
component  
 HI0131 afuA Ferric ABC transporter protein  
 HI0712 - Hemoglobin-binding protein  
 HI0994 tbp1 Transferrin-binding protein 1 precursor  
 HI0995 tbp2 Transferrin-binding protein 2 precursor  
 HI1050 merP Mercuric ion scavenger protein  
 HI1068 nrfB Cytochrome c-type protein NrfB  
 HI1069 nrfA Cytochrome c nitrite reductase  
 HI1217 - Transferrin-binding protein  
 HI1427 - Hypothetical protein HI1427  
 
   
2° metabolites biosynthesis and 
transport  
  
 HI0733 - Truncated suppressor of ftsI protein  
 
   
Function unknown    
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 HI0120 - Hypothetical protein HI0120  
 HI0178 - Hypothetical protein HI0178  
 HI0246 - Hypothetical protein HI0246  
 HI0310 - Hypothetical protein HI0310  
 HI0449 - Hypothetical protein HI0449  
 HI0696 - Hypothetical protein HI0696  
 HI0930 - Hypothetical protein HI0930  
 HI0941 - Hypothetical protein HI0941  
 HI0966 - Hypothetical protein HI0966  
 HI0973 - Hypothetical protein HI0973  
 HI0983 - Hypothetical protein HI0983  
 HI1236 - Hypothetical protein HI1236  
 HI1262 sanA SanA  
 HI1413 - Hypothetical protein HI1413  
 HI1452 - Hypothetical protein HI1452  
    
General function prediction only    
 
HI0036 - ABC transporter ATP-binding protein  
 HI0331 oapB Opacity associated protein OapB  
 HI0436 com
D 
Competence protein D  
 HI0495
m 
aphA Acid phosphatase/phosphotransferase  
 HI0933 - Hypothetical protein HI0933  
 HI1005 - Hypothetical protein HI1005  
 HI1064 - Hypothetical protein HI1064  
 HI1249 zevA Hypothetical protein HI1249  
 HI1655 yraM Antigen  
* Gene name unavailable 
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sequenced and aligned with the H. influenzae genome sequence. Results of the analysis 
were reported as a survival index (s.i.), which denotes the number of mutations detected 
in a given gene in the lung-selected output library divided by mutations detected in the in 
vitro grown input library. Genes required during lung infection were identified on the 
basis of two parameters: having s.i. of 0.3 or lower and sustaining insertions in >40% of 
the potential TA dinucleotide insertion sites, specific to the himar1-derived transposon 
used in the study (84). Comparison of our list of potential DsbA substrates to results of 
HITS revealed three genes that fit these criteria: znuA (s.i. 0.101), encoding the 
periplasmic component of a high affinity zinc uptake transporter (166, 221), nlpD (s.i. 
0.000), encoding a lipoprotein suggested to be involved in daughter cell separation (267, 
272), and HI1249 (s.i. 0.106), encoding a putative protein herein referred to as ZevA. The 
role of znuA in virulence has been studied by several groups (5, 32, 55, 83, 161, 244, 309) 
and nlpD has been implicated in virulence of Yersinia pestis and Yersinia enterocolitica 
(53, 267). However, zevA has not been previously investigated and its role in virulence 
was unknown. Additionally, the putative gene 2-bp downstream of the 3’ end of the zevA 
coding sequence, HI1248, herein referred to as zevB, was also found to be required for 
lung survival (s.i. 0.103).  
Results of HITS were verified using genetic footprinting on our mutant libraries. 
In this technique, transposon insertions in a given region are physically mapped using 
PCR with a chromosomal-specific primer paired with a transposon-specific primer (3, 
255). Sizes of amplified products correspond to the distance between the chromosome-
specific primer and the transposon insertion within that gene. In agreement with HITS, 
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footprinting of the library recovered from lung infection reveals a reduction in transposon 
insertions within the zevAB locus compared with footprints of the input library (Figure 
3.2). These data indicate that zevA and zevB are essential for lung colonization by H. 
influenzae Rd.  
zevAB is required for efficient NTHi infection of the mouse lung. Mutants of zevA and 
zevB were generated in an NTHI clinical isolate, NT127 (110) to evaluate roles of these 
genes during in vitro growth and lung infection. Mutants were constructed by 
replacement of coding regions with a drug resistance marker to generate non-polar 
deletions and complementation was conducted using an exchange vector for delivery and 
expression at the xylose locus (301). The complete strain set consisted of the parent strain 
carrying the “empty vector” (NTV), zevA mutant carrying the empty vector (NTzevAV), 
zevB mutant carrying the empty vector (NTzevBV), and complemented zevA and zevB 
mutants (NTzevAX and NTzevBX, respectively) (Table 3.3). When grown aerobically in 
sBHI media, all strains had equivalent growth yields and generation times (NTV: 45.4 ± 
1.7 min, NTzevAV: 44.1 ±1.3 NTzevBV: 41.6±0.6, NTzevAC: 43.0 ± 0.5, and 
NTzevBC: 44.2±1.9). Ratios of CFU to optical density at 600 nm were indistinguishable 
between these strains.  
Next, these strains were evaluated for their ability to infect the lungs of C57Bl/6 
mice. This experiment was performed using mixed infections in which a competition was 
performed between each strain and strain NTlacZ, which expresses E. coli lacZ at the xyl 
locus. At 40 hrs after inoculation, average competitive indices (c.i.) were ~3 fold lower  
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Figure 3.2. Analysis of transposon insertions within the zevAB locus. In vitro selected 
(Input) and in vivo selected (Output) libraries were compared using HITS and genetic 
footprinting data. Bars represent the number of sequencing reads at each individual 
insertion site within the zevAB region. MW standards are displayed to the right and apply 
to both HITS plots and footprints. Positions of the zevA and zevB genes are indicated. 
Genetic footprinting was performed by PCR with transposon-specific primer marout and 
chromosomal-specific primer 31248rev (represented by the arrow) which binds 661-bp 
downstream of zevB. 
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TABLE 3.3. Strains and plasmids used in this chapter 
Strains or plasmids Genotypes, description, and/or relevant features Reference or 
source 
Strains   
NT127 Nontypeable H. influenzae clinical isolate (110) 
NTV NT127 xylA∆4-804::tetAR; tetAR sequence from pXT10 
replaces xylA (110) 
NTzevAV NT127 ∆zevA::aacCI, xylA∆4-804::tetAR; zevA deletion mutant 
with tetAR tetR cassette replacing xylA This study 
NTzevAX 
NT127 ∆zevA::aacCI; xylA∆4-804::zevA; zevA deletion mutant 
complemented with zevA expressed via the zevA promoter in 
place of xylA 
This study 
NTzevBV NT127 ∆zevB::aacCI; xylA∆4-804::tetAR; zevA mutant 
replacing xylA This study 
NTzevBX 
NT127 ∆zevB::aacCI; xylA∆4-804::zevAB; zevB deletion 
mutant complemented with zevAB expressed via the zevA 
promoter in place of xylA 
This study 
NTlacZ NT127 xylA∆4-804::lacZ; lacZ coding sequence expressed via the xylA promoter replacing xylA This study 
NTznuA NT127 ∆znuA::aphI, xylA∆4-804::tetAR; znuA deletion mutant 
with tetAR tetR cassette replacing xylA This study 
NTzevAznuA NTzevAV ∆znuA::aphI; zevA and znuA double mutant This study 
NTzevBznuA NTzevBV ∆znuA::aphI; zevB and znuA double mutant This study 
NTZnuB NT127 ∆znuBC::aphI, xylA∆4-804::tetAR; znuBC deletion 
mutant with tetAR tetR cassette replacing xylA This study 
NTzevAznuBC NTzevAV ∆znuBC::aphI; zevA and znuBC double mutant This study 
NTzevBznuBC NTzevBV ∆znuBC::aphI; zevB and znuBC double mutant This study 
Rd AW Wild type; H. influenzae capsule-deficient type d (301) 
R5 Rd ∆zevAB::lacZ; zevAB deletion mutant with lacZ expressed 
via the zevA promoter (zevA Reporter strain) This study 
R5X R5 xylA∆4-804::zevAB; Strain R5 complemented with zevAB 
expressed via the zevA promoter replacing xylA This study 
R5fnr R5 fnr’::nptII; fnr mutant of strain R5 with Km
R
 transposon 
insertion in fnr This study 
R5fnrX R5fnr xylA∆4-804::fnr; fnr mutant of strain R5 complemented 
with fnr expressed via the fnr promoter in place of xylA This study 
RdlacZ Rd xylA∆4-804::lacZ; lacZ coding sequence expressed via the 
trc promoter replacing xylA (302) 
Plasmids   
pXT10 
Delivery vector for chromosomal expression at the xylose 
locus of H. influenzae containing xylF, xylB, xylA∆4-804, and 
the tetAR tetracycline resistance cassette 
(301) 
P1249J pXT10 carrying zevA from NT127 expressed from the zevA promoter This study 
p1248J1 pXT10 carrying zevAB from NT127 expressed from the zevA promoter This study 
pX1248R pXT10 carrying zevAB from Rd expressed from the zevA promoter This study 
pXELacZ2 pXT10 carrying lacZ expressed from the xylA promoter This study 
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for the zevA mutant (NTzevAV; c.i. 0.364) and ~22 fold lower for the zevB mutant, 
(NTzevBV; c.i. 0.064), when compared to the parent strain (NTV; c.i. 1.22) (Figure 3.3). 
Complementation restored the ability of the mutants to survive in the lung, verifying that 
defects are specific to mutation of zevA and zevB. The complemented strains, NTzevAX 
and NTzevBX, exhibited competitive indices that were slightly higher than the parent 
strain likely due to increased expression of the complementing genes due to the presence 
of both the zevA and xylA promoters in the constructs. To examine the possibility that 
mixed infection influences relative survival of the mutants, the zevA mutant was 
evaluated in the lung model in single strain infections. Consistent with results obtained 
with mixed infections, average CFU recovery at 40 hrs post infection was significantly 
reduced (p=0.027) by 3.5 fold for the zevA mutant compared to the parent strain (data not 
shown). In agreement with HITS analysis in Rd, these data indicate that the zevAB genes 
are required for colonization and survival of pathogenic NTHi in the mouse lung but, are 
not required for normal growth in rich media. 
Bioinformatic analysis of zevA and zevB. Blast (4) reveals that zevA and zevB of H. 
influenzae are conserved in other bacterial species within the Pastuerellaceae and 
Enterobacteriaceae including several human pathogens such as Klebsiella pnemoniae, 
Yersinia pestis, Proteus mirablilis, and Salmonella typhimurium (Table 3.4). In the 
Conserved Domains Database (CDD) (170) ZevA and ZevB are annotated by structural 
domain classification as the periplasmic substrate-binding protein (PBP) and permease 
subunit of an ATP-binding cassette (ABC) transporter, respectively. ZevB is also 
annotated as member of the NiCoT superfamily of potential nickel/cobalt importers and  
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Figure 3.3. Effect of zevA and zevB mutations on survival of NTHi in the mouse lung 
infection model. Mice were coinfected with reference strain NTlacZ and either the 
parent strain carrying the “empty vector” (NTV), zevA mutant (NTzevAV), 
complemented zevA mutant (NTzevAX), zevB mutant (NTzevBV), or complemented 
zevB mutant (NTzevBX). Bacteria were recovered from lung homogenates after 40 hours. 
Competitive indices (c.i.) are calculated as the ratio of recovered CFU of the LacZ– 
experimental strain to recovered CFU of the LacZ+ reference strain. The symbols indicate 
data for individual animals, and the dashed lines indicate the averages. The lower limit of 
detection (LLD) was c.i. = 0.001. Relevant statistical comparisons were indicated by 
brackets and p-values were determined using ANOVA with Tukey’s multiple comparison 
test. For NTV n=8, NTzevAV n=7, NTzevAX, n=8, NTzevBV n=7, and NTzevBX n=6. 
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TABLE 3.4. H. influenzae Rd ZevA and ZevB homologs in other pathogens 
  
Organism  Blast Results  
 ZevA (HI1249, Length 206)  ZevB (HI1248, Length 322) 
 Locus ID Identity (%) Length Expect  Locus ID 
Identity 
(%) Length Expect 
H.influenzae 
NT127 
HIAG_01
363 97 206 2e-117  
HIAG_01
364 96 322 5e-165 
K. pnemoniae 
342 Kpk_1251 42 199 7e-42  Kpk_1252 36 326 2e-40 
Y. pestis KIM 10 y1329 43 224 3e-41  y1330 38 340 7e-52 
P. mirabilis 
HI4320 PMI1519 37 221 2e-32  PMI1518 38 333 8e-47 
S. typhimurium 
LT2 STM2552 37 212 1e-33  STM2551 38 328 1e-50 
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exporters (4). This superfamily is comprised of a diverse group of eight transmembrane 
segmented secondary transporters, with a characteristic HX4DH sequence in their second 
transmembrane span (66). ZevB does not show these characteristics. Moreover, modeling 
of ZevB using the consensus prediction of membrane protein topology server 
(TOPCONS) (21) indicates that it contains only the typical six transmembrane spans 
present in each of the two transmembrane subunits observed in ABC ATPases (54). This 
evidence suggests that ZevA and ZevB are partnering components of an ABC ATPase 
transport system probably involved in substrate influx. 
ZevA and ZevB are important for growth of H. influenzae during zinc limitation. 
Metal restricted growth conditions can be generated by titration of the media with 
increasing concentrations of EDTA (5, 32, 223). To determine if zevAB is involved in 
metal acquisition in H. influenzae, strains were grown in media containing 0.25, 0.5, or 
0.75 mM EDTA. Mutants of zevA and zevB were able to acquire essential nutrients for 
optimal growth in rich media as evidenced by the lack of apparent growth defects in vitro 
(Figure 3.4A). However, media containing 0.5 mM EDTA inhibited growth of the zevA 
and zevB mutants, in which growth yields at 10 hrs were reduced by 81% and 87% 
respectively, compared to the parent or complemented strains that grew normally (Figure 
3.4B). Supplementation with 0.25 mM EDTA had no effect on growth of any strains 
whereas 0.75 mM significantly reduced growth of the parent and complemented strains in 
addition to the mutants (data not shown). 
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Figure 3.4. Growth phenotypes of zevA and zevB mutants in liquid media. Parent 
strain (NTV), zevA mutant (NTzevAV), complemented zevA mutant (NTzevAX), zevB 
mutant (NTzevBV), complemented zevB mutant (NTzevBX), grown in (A) sBHI, (B) 
sBHI containing 0.5 mM EDTA, or (C) sBHI containing 0.5 mM EDTA supplemented 
with 60 µM ZnS04. Symbols represent average absorbance (Abs) readings of three 
cultures. Error bars indicate the SD.
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In preliminary studies, specific metals were added to media chelated with EDTA 
in attempt to promote growth of the mutants. At concentrations of 30 or 60 µM, the 
addition of MgCl2, CaCl2, MnCl2, FeCl3, CoCl2, NiCl2, CuSO4, or Na2MoO4 at either 
concentration had no significant effect on growth of the zevB mutant in the presence of 
0.5 mM EDTA (data not shown). In contrast, addition of 30 µM ZnSO4, partially restored 
growth of the zevB mutant and addition of 60 µM ZnSO4 completely restored growth to 
the level of the parent strain. Figure 3.4C shows that in the presence of 0.5 mM EDTA, 
addition of 60 µM zinc restores both the zevA and zevB mutants to levels of the parent 
and complemented strains. These data suggest that zevAB is important for growth of H. 
influenzae during conditions when free zinc is limiting. 
ZevA protein binds zinc with high affinity. Metal binding assays were performed to 
determine whether ZevA binds Zn2+ and therefore can participate in metal uptake. 
Recombinant ZevA was cloned, expressed in Escherichia coli, affinity purified, and the 
metal binding tag was removed. After incubation in the presence of Zn2+, the metal bound 
to ZevA was determined by atomic absorption spectroscopy (AAS). Results indicate that 
ZevA binds 1.9±0.3 Zn2+ ions per mol of ZevA. The affinity of ZevA for Zn2+ was 
determined in metal competition assays including ZevA and mag-fura-2. The fluorescent 
metal chelator mag-fura-2 binds Zn2+ with a Ka of 5 x 107 M-1 and this is associated with 
a shift from 366 nm to 325 nm in the chelator’s spectrum maximum. Thus, the decrease 
in OD366 was used to calculate the concentration of the various species in the assay. 
Figure 3.5 shows the results of these assays. Cooperativity in binding to the two Zn2+ 
binding sites was not observed. Fitting the data to a Langmuir equation yielded an  
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Figure 3.5. Zn2+ binding to purified recombinant ZevA. The association constant (Ka) 
and the number of metal binding sites (n) of ZevA, were calculated by fitting the data to v 
= nKa[Metal]f/(1 + Ka[Metal]f), where v is the ratio of moles of metal bound to total 
protein and n is the number of binding sites. Symbols represent the average of three 
independent measurements and error bars indicate S.E. 
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association constant of ZevA for Zn2+ of 1.9 ± 0.3 x 107 M-1. This affinity is similar to 
those observed in other known Zn2+ binding proteins (60, 90, 163).  
Relative contributions of zevAB and znuABC in zinc utilization. Aside from the 
ZevAB system presented here, only one other system has been implicated in zinc 
utilization of H. influenzae, the high affinity zinc transporter ZnuABC. An H. influenzae 
znuA (originally called pzp1) mutant was shown to exhibit growth defects in normal 
media that could be rescued by addition of zinc, and recombinant ZnuA bound up to 5 
molecules of zinc per protein (166). The znuBC genes have also been demonstrated to 
participate in zinc utilization in other organisms (32, 221) including Pasteurella 
multocida (83), a close relative of H. influenzae, and are thought to encode the ATPase 
(znuC) and membrane permease (znuB) components of the transporter (220, 221). To 
evaluate conditions in which ZevAB and ZnuABC are needed, their relative contributions 
to growth of H. influenzae were examined through single and double mutant analysis. 
First, a znuA mutant was generated by replacement of its coding region with an antibiotic 
resistance marker and compared to growth of the zevA and zevB mutants. The znuA 
mutant (NTznuA) exhibited an ~16% increase in generation time in sBHI broth relative 
to the parent strain (NTV), zevA mutant (NTzevAV) and zevB mutant (NTzevBV) 
(Figure 3.6A). Addition of 60 µM zinc restored growth of the znuA mutant in rich media 
to wild-type levels (data not shown), similar to results previously reported for znuA 
mutants of other H. influenzae strains (166). When grown in 0.1 mM EDTA, the znuA 
mutant exhibited both a 21-fold reduction in growth yield at 10-hrs and a 2.3-fold 
increase in generation time compared with growth of this strain in sBHI media, whereas  
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Figure 3.6. Growth phenotypes of zevA, zevB, and znuA mutnats in liquid media. 
Parent strain (NTV), zevA mutant (NTzevAV), zevB mutant (NTzevBV), and znuA 
mutant (NTznuA), grown in (A) sBHI, (B) sBHI containing 0.1 mM EDTA, or (C) sBHI 
containing 0.5 mM EDTA. Symbols represent average absorbance (Abs) readings of 
three cultures. Error bars indicate the SD. 
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the parent strain, zevA mutant, and zevB mutant grew normally in this condition (Figure 
3.6B). In the presence of 0.5 mM EDTA, growth yield of the znuA mutant was also 
reduced by 21-fold compared to the parent (Figure 3.6C). Additionally, growth yields of 
the zevA and zevB mutants were reduced by 67% compared with the parent strain, similar 
to data reported for these strains in Figure 3.4B (Figure 3.6C). A znuBC deletion, which 
was also constructed by gene replacement, exhibited defects similar to the znuA mutant 
for growth in rich media or media containing 0.5 mM EDTA (data not shown) providing 
evidence that ZnuBC functions together with ZnuA in NTHi as components of the zinc 
transport system described previously in other organisms (32, 83, 221) . 
Next, to examine the role of zevAB in zinc uptake in the absence of the znuABC 
pathway, double mutants were generated by deletion of znuA or znuBC in either the zevA 
or zevB mutant backgrounds. Growth phenotypes of double mutants were equal in 
severity to znuA or znuBC mutants in sBHI media, sBHI with various concentrations of 
EDTA (0.0025 mM, 0.005 mM, or 0.01 mM), or sBHI supplemented with various 
concentrations of zinc (0.001 mM, 0.003 mM, or 0.05 mM). The lack of an additive 
effect of zevA or zevB mutation in combination with znuA or znuBC mutations indicates 
that ZevAB does not substitute for ZnuABC for zinc uptake, at these zinc concentrations. 
Taken together, these data suggest that ZevAB functions in a specialized pathway needed 
only when the concentration of free zinc is low in contrast to ZnuABC, which is essential 
for growth over a wide range of free zinc concentrations. 
FNR participates in the regulation of ZevAB operon. In many species that have been 
examined, transcriptional regulation of bacterial genes involved in zinc uptake is 
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mediated by the zinc responsive metalloregulatory protein, Zur (109). When zinc is 
abundant in the cell, dimerized Zur binds to a specific palindromic sequence in promoters 
to repress transcription of zinc uptake genes such as znuABC of E. coli (221) and zinT of 
S. typhimurium (223). However, previous studies, as well as our own Blast searches, 
indicate that the Pasturellaceae do not contain a zur homolog (83). In these organisms, 
zinc uptake is likely regulated by other mechanisms. For example, in Pasteurella 
multocida, znuABC is regulated by the iron response regulator Fur (83). 
To investigate the potential regulation of zevAB, the 330 bp region directly 
upstream of the zevA translational start site from the start codon of HI1250 (negative 
strand relative to the zevA coding sequence) to the start codon of zevA (positive strand) 
was analyzed for potential transcriptional regulator binding sites. A palindromic sequence 
between 235 and 248 bp upstream of the HI1250 start that was conserved in both Rd and 
NT127 strains was identified (Figure 3.7A). This sequence matches the known consensus 
binding site for the oxygen responsive transcriptional regulator, FNR (65, 177). FNR 
directly senses a range of low oxygen conditions and binds to DNA to either repress 
genes required for aerobic growth or activate those needed for growth in low oxygen 
(110, 156). 
 To determine the expression profile of zevA and zevB, we first examined 
transcription of these genes in the Rd strain. Cultures were grown in liquid media and 
transcript levels were determined by quantitative PCR, revealing that zevA and zevB are 
expressed similarly relative to transcript levels of the reference gene rpoA which encodes  
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Figure 3.7. FNR-mediated regulation of the zevA promoter. (A) Schematic of zevA 
promoter-lacZ fusion construct inserted into the Rd genome at the zevAB locus. The 330 
bp intergenic region, from the start codon of HI1250 to the start codon of lacZ is 
displayed above. A potential FNR binding site is indicated by a box and bold letters 
indicate the palindromic sequence. The predicted -10 and -35 promoter elements are 
underlined. (B) β-galactosidase activity. Parent strain (Rd), reporter strain (R5), 
complemented reporter strain (R5X), reporter strain carrying an fnr mutation (R5fnr), 
complemented fnr mutant (R5fnrX), and positive control strain (RdlacZ), were plated at a 
density of 5 x 108 CFU, grown in aerobic and anerobic environments and assayed for 
production of β-galactosidase. Values are displayed in Miller Units. Relevant statistical 
comparisons are indicated by brackets and p-values were determined using ANOVA with 
Tukey’s multiple comparison test. Bars represent the average measurements of three 
technical replicates. Error bars indicate the SD.
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RNA polymerase. Together with their genomic organization, these data suggest that zevA 
and zevB may be expressed via the same promoter.  
Next, to determine if the zevAB genes are regulated in response to oxygen, 
reporter strain R5 was constructed as a zevA promoter lacZ fusion with deletion of zevAB 
in the Rd background (Figure 3.7A). A complemented reporter strain, R5X, was also 
generated in which the zevAB genes are expressed via their native promoter at the xyl 
locus in trans to the zevA promoter-lacZ fusion. When grown aerobically (sBHI agar 
plate), β-gal activities were similar between the reporter strain R5 and complemented 
reporter strain R5X (Figure 3.7B). When bacteria were grown anaerobically, β-gal 
activity was reduced for both strains by ~50% compared with aerobic levels. A strain 
carrying an fnr disruption mutation in the R5 background, R5fnr, exhibited ~80% greater 
β-gal activity compared to the parent-reporter strain or complemented-reporter strain in 
the anaerobic condition, effectively restoring activity to levels observed for the parent 
strain in the aerobic condition. The fnr mutant also exhibited an ~25% increase in β-gal 
activity compared with the parent strain in the aerobic condition, likely due to oxygen 
availability decreasing as culture density increases on the plate. Complementation 
restored levels of fusion expression in the fnr mutant to that of wild-type. Additionally, 
RdlacZ, a strain expressing lacZ via a constitutive promoter produced equivalent β-
galactosidase (β-gal) levels in both the aerobic and anaerobic environments, suggesting 
that β-gal activity itself is not affected by the growth condition (Figure 3.7B). 
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 To examine whether free zinc concentrations affect zevA reporter expression, the 
complemented reporter strain, R5X, was grown in liquid media in the presence or 
absence of 0.5 mM EDTA in the aerobic condition. In this assay, β-gal levels of R5X 
were indistinguishable between conditions (data not shown). When R5X was grown in 
either an aerobic or anaerobic condition in media supplemented with 100 mM zinc (a 
concentration non-toxic to H. influenzae), β-gal levels were similar to those observed for 
this strain in normal sBHI media (data not shown). Taken together, these data indicate 
that expression from the zevA promoter is unaffected by the presence or absence of zevAB 
or changes in free zinc concentrations and is repressed by FNR under oxygen limiting 
conditions. Furthermore, a higher level of zevA promoter activity in the aerobic 
environment is consistent with the requirement for zevAB for lung infection, in which H. 
influenzae is likely to encounter high oxygen concentrations. 
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DISCUSSION 
Secreted bacterial proteins mediate critical aspects of pathogenesis and often 
require disulfide bond formation in the periplasm to stabilize their mature structures. Due 
to their extracytoplasmic location and accessibility, identification of these factors may aid 
in design of novel therapeutics or vaccines for combatting NTHi infections. Here, we 
generated a list of potential substrates of the periplasmic disulfide oxidoreductase protein, 
DsbA (Table 3.2), and integrated our findings with results of a previous study in which 
HITS technology was used to identify genes required for lung infection (84). Using this 
strategy, we identified three genes that were potentially important for lung infection 
including two, znuA and nlpD, that have been previously implicated in virulence of 
several organisms (5, 32, 53, 55, 83, 161, 244, 267, 309), and a third gene, zevA, whose 
function had not been determined. Therefore, zevA and its neighboring gene, zevB, were 
investigated for their roles in pathogenesis of a clinical NTHi isolate. NTHi mutants of 
zevA and zevB were not defective for growth in vitro on rich medium compared with 
parent or complemented strains but exhibited significant survival defects in a mouse lung 
infection model (Figure 3.3). These data confirmed that zevA and zevB are indispensable 
for virulence of H. influenzae strains in the murine lung. Interestingly, several potential 
DsbA-dependent proteins that were not required in the lung model as determined by 
HITS are important for H. influenzae pathogenesis in other sites of infection. For 
example, the hemopexin utilization protein, HxuA, has been shown to be required for 
wild-type bacteremic levels in an infant rat model of H. influenzae type-B infection (191) 
and the outer membrane protein P5 (OmpA) is required for virulence of NTHi in a 
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chinchilla model of otitis media (256). This suggests that examination of the requirement 
for DsbA-substrates in other H. influenzae infection models is likely to reveal additional 
mechanisms involved in pathogenesis.  
Informatics-based analysis of ZevAB suggested potential roles in metal transport 
and this possibility was explored. Mutants of zevA and zevB were highly defective for 
growth in the presence of 0.5 mM EDTA (Figure 3.4B), suggesting that these genes are 
important during metal restricted growth. Supplementation with 60 µM zinc, but not 
other metals, was able to rescue growth of the zevA and zevB mutants in the presence of 
0.5 mM EDTA to levels of the parent and complemented strains (Figure 3.4C). The 
concentration of zinc in sBHI media was determined to be 40 µM using AAS. Therefore, 
upon chelation with EDTA, addition of 60 µM likely restores free zinc concentrations to 
the normal range found in sBHI media. Together, these data indicate that zevAB is a 
novel zinc utilization pathway important for growth of H. influenzae when free zinc 
concentrations are limiting. Consistent with this observation, we also demonstrated that 
ZevA protein binds to two zinc ions with high affinity (Figure 3.5), similar to periplasmic 
binding proteins of other high affinity zinc transporters (60, 90). 
H. influenzae encodes at least two zinc utilization systems, the ZnuABC system 
and the ZevAB system described here. Mutants of individual genes in both pathways 
were compared for growth in rich or metal restricted media and growth defects of the 
znuA mutant were consistently more severe than defects exhibited by the parent strain, 
zevA, or zevB mutants in rich media or media containing EDTA (Figure 3.6A, B, and C). 
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These data are consistent with the role of ZnuABC as a primary zinc transport system of 
H. influenzae, required over a wide range of conditions, whereas contributions from 
ZevAB are important for supporting growth only when zinc concentrations are limiting. 
Because double mutant analysis revealed that strains lacking both Znu and Zev pathways 
are not completely inhibited for growth in rich media, it is likely that an additional 
pathway is involved in zinc acquisition of this organism. One possibility is the PitA-
dependent inorganic phosphate utilization pathway which was proposed to be a low 
affinity zinc transporter of E. coli (18). Whole-genome mutant fitness analysis via HITS 
suggested that PitA is required for optimal growth in vitro as well as for lung infection 
(84). Together, these observations suggest that H. influenzae contains several zinc 
utilization pathways whose functions are specialized to maintain zinc homeostasis in 
diverse environments. 
Consistent with our observation that these proteins participate in zinc utilization, 
bioinformatic analysis of ZevA and ZevB suggested that they constitute PBP and 
membrane permease components of an ABC-type transporter, respectively. However, the 
zevAB locus does not encode a protein containing the Walker-A/B nucleotide binding 
sequences known to be required by ABC-transporters for activity (54). HITS analysis 
reveals seven genes required for lung infection that are predicted to encode ABC-type 
ATPases (84). Possibly ZevAB utilizes one of these ATPases for function, however 
further investigation will be needed to address this question. 
In many bacterial species, genes important for zinc acquisition and homeostasis 
are repressed in response to elevated intracellular zinc by the transcriptional regulator Zur 
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(109, 223). Because H. influenzae does not contain a homolog of this regulator and 
expression of zevAB was not influenced by exogenous zinc levels, we sought to 
determine if another regulator was involved. Expression analysis using zevA promoter-
lacZ fusion reporter strains revealed that zevAB is repressed in low oxygen conditions by 
the oxygen responsive transcriptional regulator, FNR (Figure 3.7B). Of note, FNR has 
been shown to positively regulate transcription of metal transporters such as nikABCDE 
nickel transport genes and feoABC iron uptake genes of E. coli (144, 305) and feoABC, 
sitABCD, and fhuA iron uptake genes of Shigella flexneri (28, 307). To our knowledge, 
FNR mediated regulation of genes involved in zinc acquisition or homeostasis has not 
been previously demonstrated. 
Potential explanations for repression of zevAB by FNR are that maximum 
expression of zevAB may be detrimental to survival of H. influenzae in the anaerobic 
environment due to excessive zinc uptake or zevAB may be dispensable during anaerobic 
growth and repressed to conserve resources. However, an fnr mutant and a wild-type 
strain were equally sensitive to a range of toxic zinc concentrations during anaerobic 
growth, and the defect in growth of a zevB mutant in zinc limiting medium was not 
significantly different between aerobic and anaerobic conditions (Rosadini, C.V. 
unpublished results). Ultimately, regulation of zevAB by FNR may serve as an important 
strategy for increasing this system’s expression exclusively in sites of infection where the 
bacterium encounters zinc limitation, as is likely to occur at airway mucosal surfaces, and 
is consistent with other reports indicating that oxygen is an important signal for 
modulation of virulence factor expression in H. influenzae (300, 302, 303). 
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Bacteria are thought to contain high affinity zinc transporters as a strategy to 
overcome zinc limitation during infection in which the acute phase response has been 
shown to result in reduced plasma zinc concentrations (82, 164) with upregulation and 
release of the zinc binding complex calprotectin in the blood and lungs (111, 134, 234). 
In accord with this hypothesis, we demonstrated here that H. influenzae requires a 
specialized high affinity zinc utilization pathway for virulence. The result that zevAB is 
needed exclusively during growth under low zinc conditions and is required for lung 
infection, suggests that bacteria growing in the lung experience zinc limitation that may 
represent an immune defense for controlling pulmonary infection. 
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CHAPTER IV 
The role of outer membrane protein P5 in serum resitance of  
Haemophilus influenzae 
ABSTRACT 
 Defense against serum complement is an important mechanism for survival of 
Haemophilus influenzae during infection. Previously, we demonstrated that the 
periplasmic disulfide oxidoreductase, DsbA, was important for serum resistance of H. 
influenzae, however the DsbA-dependent factors required defense against serum 
bactericidal activity are not known. In the present study, we determine that the outer 
membrane protein P5 is important for resistance of pathogenic nontypeable H. influenzae 
(NTHi) to normal human serum. Mutants of P5 were found to bind increased levels of 
complement components C3 and C4, as well as increased levels of IgM. Together these 
data suggest that P5 decreases serum bactericidal activity by inhibiting binding of IgM to 
the surface of H. influenzae. Additionally, an Rd P5 mutant complemented with an NTHi 
P5 allele was more serum resistant than wild-type Rd, suggesting that variation in P5 
between H. influenzae isolates is a contributor to strain specific serum resistance. 
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INTRODUCTION 
The complement system is an important first line of defense for mammalian hosts 
against invading pathogens. This system consists of over 30 proteins which can mediate 
lysis of pathogens, serve as opsonins, and stimulate the inflammatory response (286). 
Complement resistance is an important feature for H. influenzae survival during 
infection. This is supported by the fact that patients deficient in complement component 3 
(C3) are more susceptible to H. influenzae type-B (Hib) infection (299). Additionally, 
when infected with Hib, C3-depleted infant rats develop elevated levels of bacteremia 
and increased mortality rates compared with control animals (46). The importance of 
complement in clearance of H. influenzae was also extended to capsule deficient strains, 
where C3-depleted infant rats were found to be more susceptible to infection than 
controls rats (43). 
Hib has been shown to encounter complement during bloodstream infection (46, 
214) and is highly resistant to serum complement by virtue of its outer surface 
polysaccharide capsule (43, 212, 265). Conversely, nontypeable strains (NTHi), which 
are typically less resistant to complement than encapsulated strains, are thought to be 
exposed to complement at mucosal surfaces during infections of the inner ear (208, 209) 
and respiratory tract (9, 94, 278). However, several examples of invasive NTHi strains 
have been recently documented (31, 34, 47, 110, 211, 215) and complement resistance is 
likely important for their survival in the bloodstream. NTHi strains have been found to 
utilize their outer surface lipooligosaccharide (LOS) (117, 303), and sialic acid (75, 123) 
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for protection against complement. Several outer membrane proteins have also been 
implicated in this process and are thought to participate in recruitment of complement 
regulatory factors (102, 106), dissociate complement components, and prevent binding of 
protective antibody and subsequent complement mediated killing (105).  
Previously, DsbA was shown to contribute to serum resistance of H. influenzae 
(241), however, the DsbA-dependent factors important for defense against serum 
bactericidal activity have not been identified. To determine what they might be, a list of 
potential DsbA substrates (Rosadini et al. 2011, submitted to Infection and Immunity) 
was examined for proteins that have been implicated in serum resistance of other 
organisms. The outer membrane protein P5 was identified because it is ~50% identical to 
E. coli outer membrane protein A (OmpA) (199), a factor previously shown to be 
important for serum resistance (292). E. coli OmpA has also been implicated in binding 
of complement regulatory factor, C4b-binding protein (C4BP) (227) allowing E. coli to 
survival more efficiently in serum (304). NTHi P5, a β-barrel protein with eight 
transmembrane spans and four outer surface loops (288), was shown to be required for 
virulence in a chinchilla ear infection model (256) and has also been implicated in 
adhesion of H. influenzae to various mucosal surface structures (26, 115, 132, 186, 236). 
However, its role in serum resistance has not been previously examined.  
Here we demonstrate that P5 is a critical factor involved in defense against serum 
complement. Results suggest that P5 is important for inhibiting binding of natural serum 
antibody to surface structures of H. influenzae. Additionally, heterogeneity within P5 
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alleles may be a determining factor in varying levels of serum resistance between 
different H. influenzae strains. 
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MATERIALS AND METHODS 
Strains and culture conditions. H. influenzae RdAW (NZ_ACSM00000000), a capsule-
deficient serotype d derivative (301), and nontypable H. influenzae clinical isolate NT127 
(NZ_ACSL01000014.1) (110) were grown in brain heart infusion broth (BHI) 
supplemented with 10 µg/ml hemin and 10 µg/ml NAD (sBHI), or on sBHI agar plates at 
35°C. Development of competence for transformation of H. influenzae was accomplished 
as previously described (15). For selection of Rd- and NTHi-derived strains, antibiotics 
were used at the following concentrations: 8 µg/ml tetracycline (Tc), 20 µg/ml kanamycin 
(Km), and 10 µg/ml gentamicin (Gm). For strain generation, plasmids and PCR products 
were constructed using standard molecular biology techniques (12). For complementation 
of mutants, DNA fragments were amplified by PCR and cloned between adjacent SapI 
restriction sites of the chromosomal delivery vector pXT10, linearized and used to 
transform H. influenzae strains as previously described (301).  
P5 mutant strain construction. Rd P5 mutant strain, RP5G, was constructed by 
replacement of the coding sequence of P5 with the gentamicin resistance gene from the 
aacC1 Gm resistance cassette via PCR “stitching”. First, three overlapping fragments 
were generated representing the 1,008 bp region immediately 5’ of the P5 translational 
start codon (primers 5omp1 5’-TGCTACTCTCACTTAATTCAAGCGCAT-3’ and 
3omp1 5’-TGCTGCTGCGTAACAtTTTGATGTCCTCTATTTAGTGATCGAATAGT-
3’), the 537-bp coding region of the gentamicin resistance gene (primers 5gent2 5’-
ATGTTACGCAGCAGCAACGATGTT-3’ and 3gent2 5’-
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TTAGGTGGCGGTACTTGGGTCGAT-3’), and a 1,477-bp region immediately 3’ of the 
P5 translational termination codon (primers 5omp2 5’-
AAGTACCGCCACCTAaTTTTAGTATTTGTTTAACGAAAGATTAAATACAGCA-
3’ and 3omp2 5’-TTAGATAAACTAACTCGTTATCCAGATGCGA-3’). Subsequently, 
these fragments were assembled using overlap extension PCR with primers 5omp1 and 
3omp2. The resulting 2,990-bp exchange fragment was transformed into competent cells 
of strain RdAW or strain NTV (a version or NT127 carrying a modified xylose locus for 
efficient recombination with plasmid pXT10 and its derivatives (110)) and selected on 
media containing Gm to create strains RP5G and NTP5V, respectively. 
To complement the P5 mutation in RP5G, a 1,503-bp fragment containing the 
coding region of Rd P5 and 441-bp of sequence immediately upstream of the P5 
translational start site, was generated using primers 5pOmpAHA (5’-
aaagctcttcaATGAAAAAAACTGCAATCGCATTAGTAGT-3’) and 3OmpAS (5’-
tttgctcttctttaTTTAGTACCGTTTACCGCGATTTCTACA-3’) which introduce SapI sites 
in the termini of the fragment. The resulting 1,458-bp fragment was digested with SapI 
and ligated between SapI restriction sites of the chromosomal delivery vector pXT10, 
which does not replicate in H. influenzae (301). Ligated products were used to transform 
RP5G and Tc resistant colonies were isolated creating strain RP58. Strain RP58 contains 
a co-integrate structure in which the entire pXT10 vector is integrated via single 
crossover into xylF. Next, a 1,373-bp fragment including 932-bp of 5’ xylA-flanking 
sequence fused to the 441-bp putative promoter region of P5 generated from strain RP58 
(primers pXT10thyAF 5’-AGGGCTTGAATCGCACCTCCA-3’ and 3P51 5’-
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TTTGATGTCCTCTATTTAGTGATCGAATAGT-3’), a 1,063-bp fragment containing 
the P5 coding sequence amplified from Rd (primers p5switch 5’-
actattcgatcactaaatagaggacatcaaaATGAAAAAAACTGCAATCGCATTAGTAGT-3’ and 
3ompkan1 5’-
CATCAGAGATTTTGAGACACGGGCCTCTTATTTAGTACCGTTTACCGCGATTT
CTACA-3’), and a 2,716-bp PCR product containing the Km resistance (KmR) gene and 
homology to xylB amplified from a kanamycin-marked derivative of pXT10 (primers 
5pkan1 5’-GAGGCCCGTGTCTCAAAATCTCTGATG-3’ and 3revRfaD1 5’-
AACAGGCTACGATAAACCATTCAAAACAGT-3’) were joined by PCR stitching 
(primers pXT10thyAFand 3revRfaD1). The resulting 5,072-bp fragment was introduced 
into strain RP5G and transformants were selected on Km generating strain RP5X.  
To complement the mutation in NTP5V and generate an RdP5 mutant expressing 
NT127 P5, the 1,373-bp P5 promoter fragment, a 1,063-bp fragment containing the P5 
coding sequence from NT127 amplified with primers p5stitch and 3ompAkan, and the 
2,716-bp KmR-xylB fragment were joined by PCR stitching (primers pXT10thyAFand 
3revRfaD1). The resulting 5,072-bp fragment was introduced into strains NTP5V and 
RP5G and transformants were selected on Km generating strains NTP5X and RP5XNT, 
respectively. 
Serum bactericidal assay. The sensitivity of P5 mutants to serum was determined as 
previously described (233). Briefly, strains were inoculated in triplicate from overnight 
cultures into 25 ml of sBHI in 50-ml Erlenmeyer flasks to obtain an optical density at 600 
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nm (OD600) of 0.01 and incubated at 35°C with shaking at 250 rpm. At log phase, 2,000 
CFU from each culture were diluted in Hank's Balanced Salt Solution (HBSS) and 
incubated at 37°C for 30 min with or without 1, 2, or 3% (final concentration) pooled 
normal human serum (NHS) or rat serum (RS) (Innovative research, Novi, Michigan) in a 
150-µl reaction mixture. The reaction was also performed with or without 10 mM Mg2+ 
EGTA (final concentration). To determine the number of CFU, 15 µl was plated on sBHI 
agar. Bacteria were also incubated in parallel with serum that had been previously 
inactivated by incubation at 56°C for 30 min. Results of the serum bactericidal assay are 
reported as percent survival, which is calculated by dividing the CFU recovered from 
serum treated samples by the CFU recovered from the untreated sample. Statistical 
analyses were performed using one-way ANOVA with Tukey’s multiple-comparison test 
(Prism 5.03; GraphPad Software, La Jolla, CA). 
Polymyxin B assay. For evaluating sensitivity to polymyxin B, strains were inoculated in 
triplicate from overnight cultures into 25 ml of sBHI in a 50-ml Erlenmeyer flask at an 
OD600 of 0.01 and incubated at 35°C with shaking at 250 RPM. When cultures reached 
log-phase, they were diluted in sBHI to an OD600 of 0.02 and 100 µl was transferred to a 
96-well flat bottom dish. Each well in the dish was then treated with 100 µl of sBHI 
containing polymyxin B to final concentrations of 100, 200, 300, 400, 500, and 600 nM, 
or with sBHI alone in control wells. The plate was then incubated at 35°C for 16 hours in 
a Versamax microplate reader (Molecular Devices, Sunnyvale, CA) set to read absorbance 
at 600 nm every 10 min. Sensitivity was scored as a relative growth yield as assessed by 
OD600 at the end of the incubation period. 
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Complement binding. Western blotting for assessment of binding of iC3b was 
performed as previously described (75, 231). Briefly, cultures of strains were grown as 
described above for serum bactericidal assays, washed and suspended in HBSS 
containing 0.15 mM CaCl2 and 1 mM MgCl2 (final reaction mixture volume, 0.5 ml). 
NHS was added to a final concentration of 10% and incubated for 30 min at 37°C.  
Bacteria were lysed in 1x SDS-PAGE sample buffer and lysates were separated on 4-12% 
SDS-PAGE gels and analyzed by immunoblotting using primary antibodies to human 
iC3b (Sigma-Aldrich, St. Louis, MO) and alkaline phosphatase-conjugated secondary 
anti-human antibodies as described previously (231). Band densities were calculated by 
densitometry using ImageJ (National Institutes of Health, Bethesda, MD). 
Flow cytometry. Measurement of complement component C4, IgG, or IgM binding was 
performed as described previously (232). Briefly, strains were cultured as described 
above for serum bactericidal assays. Log-phase bacteria were washed and suspended in 
HBSS containing 0.15mM CaCl2 and 1mM MgCl2at a concentration of 108 CFU/ml. 
They were then incubated with 5% NHS for 30 min at 37°C. Detection was performed 
using anti-C416, IgM (Abcam), and IgG (Sigma) FITC-conjugated polyclonal antibodies 
(Sigma). 
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RESULTS 
P5 is important for serum resistance of H. influenzae. P5 mutants were constructed by 
replacement of coding regions with a drug resistance marker to generate non-polar 
deletions in Rd and NT127, a clinical NTHI strain isolated from the cerebrospinal fluid of 
a patient with meningitis (110) that was observed to be more serum resistant than Rd 
(data not shown). Complementation was conducted using PCR-based exchange vectors 
described in Materials and Methods for delivery and expression at the xylose locus. The 
complete strain set consisted of parent strain (Rd), Rd P5 mutant (RP5G), complemented 
Rd P5 mutant (RP5X), NT127parent strain carrying the “empty vector” (NTV), NT127 
P5 mutant carrying the empty vector (NTP5V), and complemented NT127 P5 mutant 
(NTP5X) (Table 4.1). First, strains were evaluated for in vitro growth in rich media. The 
Rd P5 mutant, RP5G, exhibited similar generation times (~ 32 min) and growth yields 
(0.6 OD600) to the parent strain, Rd, or complemented strain, RP5X. However, the NT127 
P5 mutant NTP5V exhibited an ~46% increase in generation time (~62 min) and a ~20% 
decrease in growth yield (0.4 OD600) compared with parent strain, NTV (~40 min, 0.5 
OD600) or complemented strain, NTP5X (~40 min, 0.5 OD600). This data suggests that P5 
is important for optimal growth of NTHi strains, but is not required for growth of Rd. 
To determine if P5 is important for serum resistance of H. influenzae, strains were 
assayed for survival in the presence of normal human serum (NHS). To control for 
variable growth rates between strains, experiments were performed in growth 
independent conditions described in Materials and Methods. When incubated in 1% 
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Table 4.1. Strains used in this chapter 
  
Strains Genotypes, description, and/or relevant features Reference 
or source 
NT127 Nontypeable H. influenzae clinical isolate (110) 
NTV NT127 xylA∆4-804::tetAR; tetAR sequence from pXT10 
replaces xylA 
(110) 
NTP5V NT127 ∆P5::aacCI, xylA∆4-804::tetAR; P5 deletion mutant 
with tetAR tetR cassette replacing xylA 
This study 
NTP5X NT127 ∆P5::aacCI; xylA∆4-804::P5; P5 deletion mutant 
complemented with P5 expressed via the P5 promoter in 
place of xylA 
This study 
Rd Rd AW, wild type; H. influenzae capsule-deficient type d (300) 
RP5G Rd ∆P5::aacCI; P5 deletion mutant This study 
RP5X Rd ∆P5::aacCI; xylA∆4-804::P5; P5 deletion mutant 
complemented with Rd P5 expressed via the Rd P5 promoter 
in place of xylA 
This study 
RP5XNT Rd ∆P5::aacCI; xylA∆4-804::P5; P5 deletion mutant 
complemented with NT127 P5 expressed via the Rd P5 
promoter in place of xylA 
This study 
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NHS, survival of the Rd P5 mutant, RP5V, was reduced to levels below the lower limit of 
detection (LLD) of our assay of 1.5%, whereas survival of the parent strain, RDV, and 
complemented strain, RP5X was unaffected (Figure. 4.1A). For comparison, viability of a 
strain carrying a disruption mutation in the coding region of galU, which encodes UDP-
glucose pyrophosphorylase an essential enzyme for synthesis of the LOS outer core and 
complement resistance (229), was significantly reduced in this assay (survival 3.45%). 
Heat inactivation abrogated the effect of serum on the P5 and galU mutants, consistent 
with the essential role for serum complement in this assay (data not shown).  
When NTHi strains were evaluated for resistance to 1% NHS, survival of the 
NT127 P5 mutant strain, NTP5V, was reduced by ~70%, compared with the parent 
strain, NTV, or complemented P5 mutant, NTP5X, which were unaffected (Figure 4.1B). 
Additionally, treatment with 2% NHS reduced survival of NTP5V by ~99% compared 
with survival of the parent and complemented strains which were both reduced by ~40%. 
Moreover, treatment with 3% NHS reduced the survival of the P5 mutant to less than the 
LLD of 0.25%, which was 584-fold lower than the parent strain and 272-fold lower than 
the complemented strain at this concentration. Heat treatment of NHS eliminated killing 
of NTHi strains at all concentrations (data not shown). Together, these results indicate 
that P5 is required for resistance of both Rd and an NTHi clinical isolate to the 
bactericidal activity of NHS. Furthermore, the effect of NHS on the P5 mutants is heat 
labile suggesting serum complement is important in killing of these strains. 
Membrane integrity of a P5 mutant. Mutation of P5 may result in disruption of the 
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Figure 4.1. Effect of P5 mutation of resistance of H. influenzae to human serum. 
Strains were treated with NHS for 30 min at 37°C and plated for survivors. (A) Parent 
stain (Rd), Rd P5 mutant (RP5G), complemented Rd P5 mutant (RP5X), and galU 
mutant (∆galU), were treated with 1% NHS. The lower limit of detection (LLD) was 5%. 
(B) NTHi parent strain (NTV), P5 mutant (NTP5V), and complemented P5 mutant 
(NTP5X), treated with 1, 2, or 3% NHS. The LLD was 0.05%. Bars represent the mean 
% Survival (CFU treated /CFU untreated) of 3 replicates and error bars indicate the S.E. 
Statistical comparisons between parent strains and mutants are indicated by asterisks 
(single: p<0.01, double: p<0.001) and were determined using ANOVA with Tukey’s 
multiple comparison test. 
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outer membrane resulting in increased serum sensitivity compared to the parent strain. 
This mechanism has been proposed for increased serum sensitivity of mutants of the 
peptidoglycan-associated outer membrane protein of H. influenzae, P6 (204). To examine 
whether mutation of P5 alters membrane structure, the parent strain, RDV, mutant strain, 
RP5V, and complemented P5 mutant, RP5X, were treated with 100, 200, 300, 400, 500, 
or 600 nM of the positively charged polypeptide antibiotic, polymyxin B, and assayed for 
growth in liquid media. The minimum concentration of polymyxin B needed for 
complete growth inhibition of all strains was 400 nM and no differences in survival were 
observed between the wild-type, mutant, and complemented strains (data not shown). 
These data suggest that mutation of P5 does not result in significant membrane alterations 
compared with parent or complemented strains.  
C3 binding to P5 mutants. To determine if P5 mutants are more susceptible to killing by 
complement, strains were evaluated for binding of complement component C3, a central 
component of the pathway. Binding of C3 was assessed by incubating strains in 5 % NHS 
and performing Western blots with anti-iC3b mAb, which detects iC3b, a cleavage 
product of C3b. Differences in binding were calculated using densitometry. First, when 
analyzed for iC3b binding, non-opsonized bacteria produced minimal signal on Western 
blots (Figure 4.2; lane 6 ). Next, the P5 mutant strain, RP5V, was evaluated for C3 
binding and was found to bind ~45% more iC3b than the parent strain, RdV, or 
complemented P5 mutant, RP5X. This was assessed by densitometric analysis of the ~67 
kDa band which is likely to represent the iC3b-LOS complex (303)(Grey arrow; Figure 
4.2; Lanes 1, 2 and 3). Binding of iC3b to the mutant was also increased on structures  
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Figure 4.2. Effect of P5 mutation on binding of complement component C3. Parent 
strain (Rd) (lane 1), Rd P5 mutant (RP5G) (lane 2), and complemented P5 mutant 
(RP5CX) (lane 3) or NTHi parent strain (NTV) (lane 4) and NTHi P5 mutant (NTP5V) 
(lane 5) were incubated with 2% NHS for 30 min at 37°C. C3 binding was analyzed by 
Western blot with primary anti-human iC3b antibody and secondary anti-human alkaline 
phosphatase conjugated antibody. Lane 6 is purified iC3b and lane 7 is non-opsonized 
Rd. The bottom portion of the gel was stained with Coomassie blue to serve as a loading 
control. Black arrows indicate structures with increased C3 binding on P5 mutants 
compared to parent strains. Grey arrows indicate LOS + iC3b complex. 
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that were not detected with the parent or complemented strain (Black arrows; Figure 4.2; 
Lanes 1, 2, and 3). These data suggest that mutation of P5 “unmasks” additional binding 
sites for linkage of iC3b to the surface of Rd, but also increases overall C3 binding to 
normal surface exposed structures. 
Because outer surface structures vary in composition between H. influenzae 
isolates, C3 binding sites exposed by mutation of P5 in the Rd strain may not be present 
in an NTHi isolate. Therefore, NTV and NTP5V were also examined for binding of iC3b. 
Results of densitometric analysis of the LOS-iC3b band indicated that the NTP5V bound 
~40% more iC3b than the parent strain (Grey arrow; Figure 4.2; Lanes 4 and 5). 
However, iC3b binding sites were common to both the parent and mutant strains (Black 
arrows; Figure 4.2; Lanes 4 and 5). This suggests that increased sensitivity of NTHi P5 
mutants to NHS is not dependent on “unmasking” of new binding sites as a result of 
deletion of P5 as observed with Rd, but is due to an overall increase in C3 deposition on 
normal surface structures of H. influenzae. Together, these data demonstrate that 
increased sensitivity of the P5 mutant to serum correlates with increased binding of 
complement components. 
Complement activation by P5 mutants. Previous reports indicate C3 deposition on the 
H. influenzae cell surface is largely mediated by classical complement pathway activation 
(298). To determine if the classical/MBL- pathways are required for killing of P5 
mutants, Rd strains were treated with NHS in buffer with or without 10 mM Mg2+ EGTA. 
Incubation with Mg2+ EGTA alone had no effect on viability of the strains, indicating that 
129 
 
EGTA does not interfere with their survival at this concentration (Figure 4.3). When 
incubated in 1% or 2% NHS, survival of the P5 mutant was decreased significantly 
compared with parent and complemented strains (Figure 4.3). Addition of Mg2+ EGTA 
eliminated the lethal effects of both concentrations of serum on all strains (Figure 4.3). 
Taken together, these data suggest that the classical/MBL pathway is required for killing 
of P5 mutants.  
C4 binding to P5 mutants. C4 is an essential component of the classical C3 convertase 
and increases in C4 binding or activation can lead to greater bactericidal activity (117). 
To determine if mutation of P5 affects C4 binding to H. influenzae, strains were 
incubated in ~5 % NHS and evaluated for total C4 binding using flow cytometry. 
Binding of C4 to the P5 mutant was ~10-fold greater than to the parent strain or 
complemented strain as determined by fluorescence intensity (Figure 4.4). These data 
suggest that P5 plays a role in inhibition of the initial steps of the complement cascade. 
Furthermore, increased C4 binding to the P5 mutant is consistent with increased C3 
binding observed in Figure 4.2A. 
Complement regulatory component C4BP. NTHi strains have been previously shown 
to bind the complement regulatory factor C4b-binding protein (C4BP) (103). Binding of 
C4BP to C4b prevents formation and promotes dissociation of the classical C3 convertase 
C4b2a (85). C4BP also participates in degradation of C4b by functioning as a co-factor 
for the serine proteinase factor I (80, 81). Because P5 mutants bound elevated levels of 
C4 compared to parent strains and, a putative P5homolog of E.coli, OmpA, binds C4BP 
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Figure 4.3. Effect of P5 mutation of resistance of H. influenzae to human serum in 
the presence or absence of Mg2+-EGTA. Parent stain (Rd), Rd P5 mutant (RP5G), and 
complemented Rd P5 mutant (RP5X) were treated with or without NHS in the presence 
of absence of 10 mM Mg2+-EGTA for 30 min at 37°C and plated for survivors. The LLD 
was 0.15%. Bars represent the mean % Survival (CFU treated /CFU untreated) of 3 
replicates and error bars indicate the S.E. Statistical comparison between parent strain 
and mutant is indicated by a double asterisk (p<0.001) and was determined using 
ANOVA with Tukey’s multiple comparison test.
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Figure 4.4. Effect of P5 mutation on binding of complement component C4. Parent 
stain (Rd), P5 mutant (RP5G), and complemented P5 mutant (RP5X) were incubated 
with 5% NHS for 30 min at 37°C and assayed for binding of complement component C4 
using flow cytometry. Log10 fluorescence is represented on the x-axis. Dashed line 
represents the background fluorescence and the solid line represents fluorescence of 
strains indicated. Values on each graph represent the mean fluorescence for strains 
indicated (bold number) and background (number within dashed box).
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(227), the possibility that P5 may participate in interaction with C4BP was examined. To 
test this hypothesis, Rd strains were incubated in C4BP-depleted NHS (immuno-depleted 
to <2% of normal C4BP levels) or C4BP-depleted serum, supplemented with purified 
C4BP. The parent strain, RdV, exhibited equivalent survival of ~35% in both the 
presence and absence of C4BP (data not shown). Similar to data observed in Figure 4.1A, 
the P5 mutant, RP5V, exhibited ~230-fold lower survival compared to the parent strain in 
both C4BP-replete and C4BP-depleted serum (data not shown). Together, these data 
suggest that P5 does not play a role in binding of regulatory factor C4BP. Additionally, 
C4BP binding contributes minimally to protection of Rd strains from bactericidal activity 
of NHS. 
Immunoglobulin binding to P5 mutants. Antibody binding to the surface of a pathogen 
is an important step in complement activation via the classical pathway. To determine if 
P5 effects antibody binding to the surface of H. influenzae, Rd strains were incubated 
with NHS and antibody levels were examined using flow cytometry. Levels of IgG 
binding were found to be similar between the parent, P5 mutant, and complemented 
strain (Figure 4.5A). However, IgM binding to the P5 mutant was increased by ~100% 
over the parent and ~120% over the complemented strain (Figure 4.5B). Similar results 
were obtained for these strains in separate experiments (data not shown). Increased IgM 
binding is consistent with the observation that P5 mutants are more sensitive to classical 
complement pathway activation. 
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Figure 4.5. Effect of P5 mutation on binding of serum antibodies. Parent stain (Rd), 
P5 mutant (RP5G), and complemented P5 mutant (RP5X), were incubated with 5% NHS 
for 30 min at 37°C and assayed for binding of (A) IgG or (B) IgM using flow cytometry. 
Log10 fluorescence is represented on the x-axis. Dashed line represents the background 
fluorescence and the solid line represents fluorescence of strains indicated. Values on 
each graph represent the mean fluorescence for strains indicated (bold number) and 
background (number within dashed box). 
134 
 
Sensitivity of a P5 mutant to rat serum. Because humans are repeatedly colonized by 
H. influenzae, NHS may contain specific antibodies to this organism. To determine if the 
effect of mutation of P5 on serum resistance was exclusive to human sera, Rd strains 
were exposed to 1 or 2% pooled rat sera (RS) which is unlikely to contain specific H. 
influenzae antibody. In 1% RS, survival of the P5 mutant, RP5V, was ~74 to ~75-fold 
lower than the parent strain, RdV or complemented strain, RP5X, respectively (Figure 
4.6A). Next, NTHi strains were tested for survival in 1, 2, or 3% RS. Survival of the P5 
mutant strain, NTP5V, was below the LLD for the assay at all concentrations, whereas 
the parent strain NTV and complemented strain, NTP5X survived to ~100%, ~30%, and 
~15% in 1, 2, and 3 % RS, respectively (Figure 4.6B). These data indicate that P5 is 
required for resistance of H. influenzae to RS and suggest that specific H. influenzae 
antibody is not required for complement mediated killing of P5 mutants. 
Heterogeneity of P5 alleles effects serum resistance. Surface exposed residues on P5 
have been previously shown to be variable between NTHi clinical isolates, likely due to 
antigenic pressure (62, 288). In accordance with this, alignments of Rd and NT127 P5 
alleles show variability in predicted outer surface loops, whereas other portions of the 
proteins were largely identical in sequence (Figure 4.7A). To determine if variability in 
P5 alleles contributes to differences in serum resistance between Rd and NT127, Rd P5 
mutants were complemented with either the P5 allele from Rd, (strain RP5X) or the P5 
allele from NT127 (strain RP5XNT). To exclude possible differences in gene expression, 
complementing alleles were expressed via the Rd P5 promoter. When assayed for 
survival in 1% NHS, complementation of the P5 mutant with Rd P5 (strain RP5X)  
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Figure 4.6. Effect of P5 mutation of resistance of H. influenzae to rat serum. Strains 
were treated with RS for 30 min at 37°C and plated for survivors. (A) Parent stain (Rd), 
Rd P5 mutant (RP5G), and complemented Rd P5 mutant (RP5X), were treated with 1% 
RS. The lower limit of detection (LLD) was 0.15%. (B) NTHi parent strain (NTV), P5 
mutant (NTP5V), and complemented P5 mutant (NTP5X), treated with 1, 2, or 3% RS. 
The LLD was 0.15%. Bars represent the mean % Survival (CFU treated /CFU untreated) 
of 3 replicates and error bars indicate the S.E. Statistical comparisons between parent 
strains and mutants are indicated by asterisks (single: p<0.01, double: p<0.001) and were 
determined using ANOVA with Tukey’s multiple comparison test. 
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restored the survival defect of the Rd P5 mutant to near parent levels (Fig. 4.7B). 
However, survival of the Rd P5 mutant complemented with NT127 P5, RP5XNT, was 
significantly increased by 3-fold over RP5X (Figure 4.7B). When strains were treated 
with 2% NHS, survival of RP5XNT was increased by ~13-fold over Rd or RP5X (Figure 
4.7B). In 3% NHS, survival of stains Rd, RP5G, and RP5X was below the LLD, whereas 
strain RP5XNT exhibited a percent survival of 0.06. Together, these data demonstrate that 
P5 is not only necessary for resistance to NHS, but also a determinant of strain specific 
serum resistance.  
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Figure 4.7. Effect of P5 allele heterogeneity on serum resistance. (A) Comparison of 
Rd and NT127 P5 amino-acid sequences. Alignments were performed using BLAST. 
Putative surface exposed regions were described previously (283) and are indicated by 
boxes. (B) Parent stain (Rd), Rd P5 mutant (RP5G), Rd P5 mutant complemented with 
Rd P5 (RP5X), and Rd P5 mutant complemented with NT127 P5 (RP5XNT) were treated 
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with 1, 2, or 3% NHS for 30 min at 37°C and plated for survivors. The LLD was 0.015%. 
Bars represent the mean % Survival (CFU treated /CFU untreated) of 3 replicates and 
error bars indicate the S.E. Relevant statistical comparisons are indicated on the graph 
and were determined using ANOVA with Tukey’s multiple comparison test. 
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DISCUSSION 
NTHi strains utilize several outer surface structures including LOS and sialic acid 
for defense against serum complement. Outer surface proteins are also thought to 
participate in serum resistance; however their role in this process is not well understood. 
In this study, we demonstrated that P5 is required for serum resistance of both a lab 
passaged strain, Rd, and a clinical NTHi isolate, strain NT127. The effects of NHS on our 
strains were abolished by addition of EGTA and heat treatment, consistent with the 
essential role for complement in the assay. These data also suggested antibody 
agglutination is not a significant mechanism responsible for killing in our assays. 
Additionally, polymyxin B assays suggest that P5 mutants do not exhibit membrane 
disruptions which have been shown to result in increased sensitivity to serum (204). 
Together, these data implicate P5 in resistance of H. influenzae to complement. 
The mechanism by which P5 participates in serum resistance was investigated. An 
increase in C3-binding was observed for Rd and NTHi P5 mutants versus wild-type 
strains. Results from this analysis suggested that increased sensitivity of P5 mutants to 
complement is not a result of unmasking of additional C3 binding sites on the surface, but 
due to an overall increase in C3 deposition on normal surface structures of H. influenzae. 
Mg-EGTA eliminated the effect of NHS on all of the strains in our assays, suggesting 
that the majority of the complement activation in the assay is mediated through the 
classical or MBL pathway. In accordance with this hypothesis, P5 mutants exhibited 
increased binding of C4 compared with parent or complemented strains. Together, these 
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results suggested that P5 mediates serum resistance through inhibition of the initial stages 
of complement activation. 
Increased binding of C4 to P5 mutants suggested that P5 may participate in 
binding of the classical pathway inhibitor, C4BP. This possibility was also suggested by 
previous reports showing that the putitive P5 homolog, E. coli OmpA, binds C4BP (227) 
and that this mechanism is important for survival of E. coli in NHS (304). However, data 
presented here does not support a role for C4BP in P5 mediated serum resistance of H. 
influenzae. 
Due to the apparent role of classical pathway activation in killing of P5 mutants, 
we examined immunoglobulin binding to our strains. P5 mutants were found to bind 
increased levels of IgM compared to parent and complemented strains. These results 
were consistent with previous reports suggesting that increases in IgM, a potent activator 
of complement, results in serum sensitivity of H. influenzae. For example, serum 
sensitivity of mutants of vacJ and yrb, which encode factors important for control of 
phospholipid turnover in the outer leaflet of NTHi, correlated with increased IgM binding 
(207). Furthermore, deletion of dsrA of Haemophilus dureyi, which encodes an outer 
membrane protein required for infection of humans (25), resulted in IgM dependent 
serum sensitivity (1, 67). Therefore, it is likely that increased IgM binding is responsible 
for serum sensitivity of P5 mutants.  
Because, colonization of the human respiratory tract by NTHi has been shown to 
stimulate humoral immunity against other NTHi strains, human serum may contain 
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specific antibody against H. influenzae surface epitopes (149). To determine whether 
serum sensitivity was due to specific or natural antibody, P5 mutants were assayed for 
survival in rat serum, which does not likely contain specific anti-H. influenzae antibody. 
P5 mutants were found to be more sensitive to rat serum than parent or complemented 
strains, suggesting that the bactericidal effect of serum on P5 mutants is not dependent on 
pre-exposure of the serum donor to H. influenzae. We cannot rule out the potential for 
cross-reactive responses to resident bacterial flora, however, rats were housed in SPF 
conditions and therefore are not expected to have encountered a wide range of pathogens 
to elicit strong cross-reactive antibody responses. Hence, complement activation on P5 
mutants is likely mediated by natural IgM present in serum, consistent with previous 
studies which found that natural antibody in NHS that is bactericidal for H. influenzae is 
predominantly IgM (70, 87, 207).  
Multiple reports have concluded that strain specific serum resistance is mediated 
by variation in the outer surface structures of H. influenzae including heterogeneity in 
oligosaccharide components (70, 75, 117, 123, 295, 303), phospholipid trafficking (207), 
and membrane protein heterogeneity (105). We observed that predicted surface exposed 
regions of P5 were also heterogeneous between our strains. Modifications to P5 may be 
influenced by selective pressure imposed by host antibody and complement (62). 
Therefore, we postulated that heterogeneity in P5 alleles may contribute to varied levels 
of serum resistance between strains. Accordingly, a P5 allele from the more serum 
resistant NTHi strain, NT127, was found to enhance resistance of the low serum resistant 
strain, Rd, to NHS. These results suggest that variation in P5 contributes to strain specific 
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serum resistance. Greater resistance of RP5XNT to NHS compared with RP5X may 
involve inhibition of IgM-binding, however, when examined by flow cytometry, IgM 
binding was indistinguishable between these strains (Rosadini C.V. unpublished data). 
Perhaps this assay was not sensitive enough to detect minute changes in IgM binding 
between strains. One other possibility is that expression of P5 may participate in 
inhibition of C4b deposition on H. influenzae, similar to the mechanism reported for 
participation of LOS biosynthesis gene, lgtC (117). Further analysis will have to be 
performed to address these possibilities.  
A P5 mutant has been shown to be impaired for colonization of the chinchilla 
nasopharynx and middle ear (256). Subsequently, a role for P5 in adherence to the 
mucosal epithelium via CEACAM1 receptors or mucin was suggested to be responsible 
for in vivo defects (26, 115, 132, 186, 236). The role of complement in clearance of 
NTHi P5 mutants from the chinchilla middle ear was not addressed. However, other 
reports have shown that complement is important for clearance of NTHi from this site 
(75). Possibly, P5 mediates several functions in vivo including complement resistance 
and adherence allowing for efficient colonization. Taken together, our understanding of 
the role of P5 in colonization and virulence of NTHi is not complete, and future analysis 
will need to be performed to examine requirements for P5 at various sites of infection. 
In summary, the complement pathway is an important immune defense for 
mammalian hosts against invading pathogens. To defend themselves, bacteria utilize 
diverse strategies to subvert complement activation. The data presented here suggests that 
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the outer membrane protein P5 inhibits binding of natural IgM present in NHS to the 
surface of H. influenzae. By doing so, P5 inhibits activation of the classical complement 
pathway and subsequent killing of the cell. Furthermore, variation in P5 is a contributor 
to strain specific serum resistance. Thus, P5 is a critical factor for H. influenzae resistance 
to serum complement. 
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CHAPTER V 
Conclusions and future directions 
Various aspects of H. influenzae pathogenesis including proteins and nutrients 
required for infection of specific anatomical locations, such as the bloodstream and lung, 
are not well understood. The goal of this thesis was to identify and characterize some of 
these virulence proteins and by doing so, develop an understanding of specific nutrients 
that this organism requires to survive during disease. In many Gram-negative organisms, 
proteins important for virulence are often secreted and require periplasmic disulfide bond 
formation for function and stability. Consistent with this, data described in this thesis 
demonstrates that mutation of dsbA, which encodes the major disulfide oxidoreductase in 
the periplasm, results in reduced colonization and virulence of H. influenzae. DsbA was 
not required for in vitro growth, but was indispensable for blood stream infection in both 
Rd and Hib in the mouse and infant rat infection models, respectively. Additionally, 
preliminary data indicates that DsbA is required for H. influenzae colonization of the 
mouse nasopharynx (Rosadini, C.V. unpublished results) and lung (84). Using in vitro 
assays, dsbA mutants were shown to be defective for resistance of H. influenzae to serum 
complement. Together these data suggested that some of the targets of the disulfide 
pathway must be necessary for this organism’s pathogenesis and at least one of them is 
involved in serum resistance.  
The set of disulfide-dependent proteins of H. influenzae was not previously 
known. Therefore, to address the hypothesis that DsbA-dependent factors are important 
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for virulence, informatics-based approaches were utilized to produce a database of 
potential DsbA-substrates. Using literature based analyses and data from a genome-wide 
screen to identify genes required during murine lung infection, the list of substrates was 
examined for factors that were potentially important for pathogenesis of H. influenzae. 
Results of these analyses led to identification of a factor required for bloodstream 
infection, HbpA, as well as novel virulence mechanisms including zinc utilization via 
ZevAB and serum resistance via P5 (Figure 5.1). HbpA was shown to contain a DsbA-
dependent disulfide and preliminary data suggests that ZevA also contains a disulfide 
bond (Rosadini C.V. unpublished results). Additionally, sequence comparisons revealed 
that cysteine pairs within ZevA and HbpA, as well as other virulence factors including 
ZnuA and P5, are highly conserved in their homologs in the Pasteurellaceae and 
Enterobacteriaceae (4). Moreover, many of the 81 potential DsbA-dependent proteins of 
H. influenzae described in this thesis are conserved in other species, including members 
of the above families (4). Taken together, results of this thesis demonstrate that 
evaluating DsbA substrates for virulence properties is a viable way to determine 
pathogenic mechanisms of H. influenzae and suggest that searching for these substrates in 
other Gram-negative organisms is likely to be a productive area for future research. 
Several potential DsbA-dependent proteins were not required in the lung model, 
but are important for H. influenzae pathogenesis in other sites of infection. For example, 
the hemopexin utilization protein, HxuA, has been shown to be required for wild-type 
bacteremic levels in an infant rat model of H. influenzae type-B infection (191) and the 
outer membrane protein P5 (OmpA) is required for virulence of NTHi in a chinchilla  
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Figure 5.1. Summary of H. influenzae virulence factors presented in this thesis. 
Proteins highlighted in red were examined for their participation in various pathogenesis 
related phenotypes of H. influenzae. Items in grey were not characterized by this work. 
The disulfide bond oxidoreductase DsbA was found to be required for bloodstream 
infection by Hib and Rd. HbpA, although characterized previously by other groups as 
important for heme binding and utilization of H. influenzae, was first found to be 
important for bloodstream infection by work described in this thesis. The ZevAB system 
was characterized as a zinc binding system necessary for zinc utilization during 
conditions when zinc is limiting and is required for survival in the mammalian lung. 
Lastly, the outer membrane protein P5 was found to prevent complement mediated 
killing likely through inhibition of natural IgM binding. OM is outer membrane and IgM 
is displayed in the “staple” confirmation. 
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model of otitis media (256). Therefore, we can conclude that DsbA-dependent virulence 
factors are differentially required at diverse sites of infection. Examination of the 
requirement for DsbA-substrates in sites such as the bloodstream, nasopharynx, or middle 
ear may reveal additional mechanisms involved in pathogenesis. Understanding of 
processes needed for H. influenzae to survive within specific host environments might aid 
in developing strategies for preventing its transition from asymptomatic colonization to 
invasive infection. 
Heme utilization 
Although there are many known systems in H. influenzae for binding heme at the 
outer surface, little is understood about how heme is transported to the cytoplasm. 
Previously, several reports had demonstrated that HbpA was important for heme binding 
and utilization by H. influenzae and concluded that HbpA is a periplasmic binding protein 
for a heme specific ABC transporter (108) composed of the putative dipeptide transport 
system DppBCDF (192). However, the role of HbpA during infection was not known. 
The result that HbpA is required for H. influenzae bloodstream infection was first 
demonstrated by the work discussed in Chapter II. Consistent with our results, recent 
studies indicated that HbpA was required for Hib infection of 30 day old rats (190). 
However, unpublished data from our lab as well as other reports indicated that HbpA is 
not required for Rd or NTHi colonization of the mouse and chinchilla nasopharynx, 
respectively (190) (Rosadini C.V. unpublished results). Moreover, HbpA was not 
required by NTHi for infection of the chinchilla ear or by Hib for infection of the 
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bloodsteam in 5-day old rats (190). The fact that HbpA is not always required during 
infection suggests that it is not the only pathway available for H. influenzae to transport 
heme sources across the inner membrane. Interestingly, the periplasmic antimicrobial 
peptide resistance protein, SapA, has been recently shown to bind heme and is required 
for optimal growth of H. influenzae in vitro (171, 174). The Sap system has been shown 
to be upregulated in the chinchilla middle ear and is required for H. influenzae 
colonization of the chinchilla middle ear and nasopharynx (172). Potentially, SapA 
represents a second pathway for heme transport across the inner membrane (174). 
Therefore, the result, presented in this thesis, that HbpA is required for bloodstream 
infection, combined with results from others, have provided necessary insight into 
mechanisms for H. influenzae to import heme, a key molecule which is required for its 
success in vivo. 
Zinc utilization 
One of the highlights in this thesis is the discovery of the ZevAB zinc utilization 
pathway. Our results suggest that ZevAB functions as a high-affinity zinc importer that 
likely transports zinc across the inner membrane. This pathway was found to be essential 
for NTHi survival in the mouse lung infection model; however, it is not necessary for in 
vitro growth on rich media. ZevAB is required for zinc utilization exclusively during 
conditions when zinc is limiting. This is in contrast to the H. influenzae ZnuABC zinc 
transporter which was shown to be required over a wide range of zinc concentrations in 
this work and by others (166). Therefore, these results suggest that ZnuABC is the 
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primary zinc uptake pathway of H. influenzae and ZevAB is an alternate transporter 
system needed to sustain growth during severe zinc limitation. 
ZnuABC is required for virulence of several Gram-negative pathogens at different 
sites of infection, including the gut, tissues, and blood, suggesting that zinc is not readily 
available to pathogens in vivo (5, 32, 55, 83, 161, 244, 309). However, the requirement 
for ZevAB for H. influenzae survival in the lung suggests that this infection site also 
represents a condition where pathogens encounter severe zinc limitation. Potentially these 
results could reflect host immune processes which are thought to promote sequestration 
of zinc to inhibit growth of invading pathogens during disease (145). For instance, 
initiation of the acute phase response during infection has been shown to result in up-
regulation of the host intracellular metal binding protein metallothionein in hepatocytes 
and increased expression of cellular zinc import systems, such as the hepatic ZIP14 
transporter, resulting in reduced plasma zinc concentrations (82, 164). Possibility, the 
metallothionein-null (MT -/-) mouse model (180) might be employed to address the role 
of this pathway in zinc limitation during H. influenzae infection. Previous studies have 
indicated that even at extremely high plasma zinc concentrations, MT -/- mice fail to 
store zinc in their livers (44). This suggests that during activation of the inflammatory 
response due to challenge with pathogens such as H. influenzae, MT -/- mice will be 
unable to reduce the level of zinc available. Potentially, mutants of znuABC or zevAB 
described in this thesis will exhibit enhanced survival during infection of the MT -/- 
mouse.  
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In addition to increased zinc storage in the liver, the acute phase response also 
stimulates up-regulation and release of the antimicrobial zinc binding complex 
calprotectin in the blood and lungs (36, 111, 134, 234, 257, 262). Several reports indicate 
that calprotectin is antimicrobial when applied to microbes in vitro (257, 262). Perhaps 
the effect of calprotectin on zevAB mutants could be examined to explore the role of these 
genes in H. influenzae defense against host immune functions. In vivo studies could also 
be performed using calprotectin-null mice which are not able to produce this highly 
expressed antimicrobial complex (118).  
The role of zinc limitation in growth inhibition of H. influenzae during lung 
infection might also be explored by supplementation of mice with zinc during challenge 
with wild-type NTHi compared with zevAB mutants. Previous studies indicate that 
alteration of dietary zinc intake can affect the levels of zinc in the lungs of mammals 
(14). Possibly, zinc supplementation will overcome the requirement for zevAB in vivo. 
This result would suggest that attenuation of zevAB mutants during infection is zinc 
specific. Interestingly, zinc is an essential element for proper immune function in 
mammals and severe zinc deficiency has been liked to failure of the host to defend 
against bacterial infection and sepsis (14). However, restoration of host tissue and serum 
zinc levels through dietary zinc supplementation or administration of zinc directly into 
the serum or tissues before or during infection results in increased immune response and 
improved host survival (14, 269). Therefore, zinc supplementation in humans might help 
boost immunity against organisms like H. influenzae which contain mechanisms to 
overcome the hosts attempt at halting their growth through zinc limitation. Overall, an 
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important area for future investigation would be to examine the role of host zinc 
sequestration mechanisms in defense against H. influenzae during infection. 
The discovery of ZevAB and its role is zinc uptake has potential implications for 
other pathogens. For example, with the hypothesis that zinc limitation likely occurs 
during infection, Desrosiers and co-workers recently examined pathways important for Y. 
pestis to acquire zinc in vivo (59). Similar to reports on other organisms, they determined 
that ZnuABC is required for in vitro growth on low zinc. However, they found that this 
pathway is not required for Y. pestis pathogenesis in mouse bubonic and pneumonic 
plague models (59). These researchers concluded that a yet undiscovered high-affinity 
zinc uptake pathway is likely to support growth and survival of Y. pestis during infection 
(59). Blast searches performed in Chapter III indicate that Y. pestis contains putative zevA 
and zevB homologs. Possibly, the ZevAB system could be the critical transporter required 
for Y. pestis pathogenesis. 
In addition to discovery of the role of ZevAB in infection, the work presented 
here describes biochemical characteristics of the transporter. Specifically, the putative 
periplasmic binding protein ZevA was shown to bind two Zn2+ ions with high-affinity. 
However, the residues important for substrate specificity have not been determined. 
Studies analyzing the functionally related “cluster 9” family of Zn2+ and Mn2+ 
transporters illustrate the critical amino acids involved in zinc binding. For example, the 
primary zinc binding site of E. coli consists of three His residues and a Glu that bind Zn2+ 
in a nearly tetrahedral geometry (162, 310). Additionally, periplasmic binding proteins 
152 
 
PsaA of Streptococcus pneumoniae and TroA of Treponema pallidum also contain at 
least two His residues in their primary metal binding sites (310). Although ZevA is not 
classified as a cluster 9 family periplasmic binding protein, analysis of its amino acid 
sequence reveals that this protein contains four His residues, three of which are highly 
conserved in ZevA homologs in other species. Potentially, these residues could 
participate in binding of Zn2+; however, further analysis will be needed to determine their 
role in this process.  
The predicted permease ZevB also contains interesting features that could 
participate in function of the transporter. Analysis of ZevB secondary structure revealed 
that this protein has six potential transmembrane spans with three large cytoplasmic 
loops. The second cytoplasmic loop in ZevB, as well as ZevB homologs of other bacterial 
pathogens including members of the Pastuerellaceae and Enterobacteriaceae, contains a 
highly conserved sequence with the consensus C(S/G)CGHXH (where X is Q, K, R or 
A). Due to its high conservation, this sequence is likely important for function of the 
transporter. Although a motif similar to this has not been previously described, pairs of 
Cys and His residues are common among zinc binding domains (153). Possibly the 
residues in this motif are important for mediating substrate specificity of the transporter. 
Alternatively, this motif may serve as part of a sensory domain for regulation of the 
transporter. Overall, investigation of the second cytoplasmic loop of ZevB may reveal 
novel mechanisms for transport by this system. 
Serum resistance 
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The outer membrane protein P5 was found to be important for serum resistance of 
H. influenzae. Results suggest that P5 inhibits binding of natural IgM to the surface of H. 
influenzae, thus preventing activation of the classical complement pathway and 
subsequent killing of the cell. In the P5 mutant, the absence of this outer membrane 
protein may reveal epitopes for binding of IgM or alternatively generate a more favorable 
binding site for IgM to conform to the staple conformation, its most potent complement 
activating state (88). However, further analysis will be needed to fully address the role of 
P5 in inhibition of IgM binding to H.influenzae. For example, depletion of IgM from 
normal human serum has been reported for addressing the role of IgM in killing of 
bacterial mutants (1). Additionally, purified IgM from NHS has also been used in 
conjunction with a complement source such as baby rabbit serum to reconstitute IgM 
specific bactericidal activity against bacterial mutants (87, 207). Potentially these 
strategies could be employed to examine the role of IgM in P5 mediated serum 
sensitivity. Alternatively, P5 might participate in preventing binding of C4 and/or C3 to 
the surface of H. influenzae. This could be addressed by identification of the surface 
targets of C4 and C3 using immunoblotting and mass spectrometry techniques on P5 
mutants versus WT as has been described previously (117). Identification of the C4 and 
C3 binding sites might indicate a novel role for P5 in blocking complement component 
binding to specific surface structures on H. influenzae. Overall, the results presented here 
suggest that P5 is a critical factor for H. influenzae to avoid detection by host antibody or 
complement and prevent complement mediated clearance. 
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When examining the possibility that P5 plays a role in strain specific serum 
resistance, an Rd strain expressing a P5 allele from the more serum resistant NTHi strain, 
NT127, was found to be more resistant to serum than Rd expressing its own P5 allele. 
Although both alleles were expressed via the Rd promoter to control for differences in 
expression between strains, we acknowledge that we did not address possible membrane 
protein concentration differences between these strains which could account for 
differences in serum resistance between them. Potentially, future analysis using 
Coomassie Brilliant Blue stained gels or Western blots using an anti-P5 antibody might 
be used to address this possibility. In either case, the majority of the amino acid sequence 
heterogeneity between NT127 P5 and Rd P5 is contained within their predicted outer 
surface loops. Therefore, differences in serum resistance conferred by each allele might 
be attributed to variability within these loops. Heterogeneity between outer loops of P5 is 
likely due to adaptations in response to immune pressure encountered during infection 
and is thought to be a critical feature for preventing host recognition (62). However, the 
loops of P5 are also important for mediating specific processes. For example, outer 
surface loops 3 and 4 were shown to be important for binding to CEACAM1 (26). Taken 
together, variation of outer surface loops of P5 may reflect both functional adaptations for 
adherence as well as defensive adaptations for avoiding host recognition. Perhaps 
evolution of outer surface loops requires a delicate balance between functional and 
defensive roles; however, future research will be necessary to investigate this possibility.  
Concluding remarks 
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The work presented in this thesis identifies four secreted virulence factors of H. 
influenzae including those involved in disulfide formation, heme and zinc acquisition, as 
well as resistance to complement (Figure 5.1). Potentially, due to their extracytoplasmic 
location, these factors may be useful targets for development of vaccines or therapeutics 
against NTHi strains. Additionally, this work provides insight into nutrient requirements 
for H. influenzae to survive within the bloodstream and lung. This knowledge could 
prove valuable in development of strategies for preventing dissemination of H. influenzae 
from the nasopharynx to other sites within the body. Lastly, the results of this thesis 
indicate that future research into the secreted factors within other Gram-negative 
pathogens is likely to result in discovery of additional mechanisms allowing for bacteria 
to cause disease. 
 
 
  
156 
 
References 
 
1. Abdullah, M., I. Nepluev, G. Afonina, S. Ram, P. Rice, W. Cade, and C. 
Elkins. 2005. Killing of dsrA mutants of Haemophilus ducreyi by normal human 
serum occurs via the classical complement pathway and is initiated by 
immunoglobulin M binding. Infect Immun 73:3431-3439. 
2. Ahrén, I. L., H. Janson, A. Forsgren, and K. Riesbeck. 2001. Protein D 
expression promotes the adherence and internalization of non-typeable 
Haemophilus influenzae into human monocytic cells* 1. Microbial pathogenesis 
31:151-158. 
3. Akerley, B. J., and D. J. Lampe. 2002. Analysis of gene function in bacterial 
pathogens by GAMBIT. Methods Enzymol 358:100-108. 
4. Altschul, S. F., W. Gish, W. Miller, E. W. Myers, and D. J. Lipman. 1990. 
Basic local alignment search tool. J Mol Biol 215:403-410. 
5. Ammendola, S., P. Pasquali, C. Pistoia, P. Petrucci, P. Petrarca, G. Rotilio, 
and A. Battistoni. 2007. High-affinity Zn2+ uptake system ZnuABC is required 
for bacterial zinc homeostasis in intracellular environments and contributes to the 
virulence of Salmonella enterica. Infect Immun 75:5867-5876. 
6. Andersen, C. L., A. Matthey-Dupraz, D. Missiakas, and S. Raina. 1997. A 
new Escherichia coli gene, dsbG, encodes a periplasmic protein involved in 
disulphide bond formation, required for recycling DsbA/DsbB and DsbC redox 
proteins. Mol Microbiol 26:121-132. 
7. Anderson, M. E., and A. Meister. 1980. Dynamic state of glutathione in blood 
plasma. Journal of Biological Chemistry 255:9530. 
8. Anderson, P., R. B. Johnston, Jr., and D. H. Smith. 1972. Human serum 
activities against Hemophilus influenzae, type b. The Journal of clinical 
investigation 51:31-38. 
9. Andersson, M., L. Michel, J. B. Llull, and U. Pipkorn. 1994. Complement 
activation on the nasal mucosal surface--a feature of the immediate allergic 
reaction in the nose. Allergy 49:242-245. 
10. Armstrong, D. S., K. Grimwood, J. B. Carlin, R. Carzino, J. P. Gutierrez, J. 
Hull, A. Olinsky, E. M. Phelan, C. F. Robertson, and P. D. Phelan. 1997. 
Lower airway inflammation in infants and young children with cystic fibrosis. 
American journal of respiratory and critical care medicine 156:1197-1204. 
11. Arredondo, S. A., T. F. Chen, A. F. Riggs, H. F. Gilbert, and G. Georgiou. 
2009. Role of dimerization in the catalytic properties of the Escherichia coli 
disulfide isomerase DsbC. Journal of Biological Chemistry 284:23972. 
12. Ausubel, F. M., R. Brent, R. E. Kingston, D. E. Moore, J. G. Seidman, J. A. 
Smith, and K. Struhl (ed.). 1995. Current protocols in molecular biology. John 
Wiley & Sons, Inc, New York, NY. 
157 
 
13. Bader, M., W. Muse, D. P. Ballou, C. Gassner, and J. C. Bardwell. 1999. 
Oxidative protein folding is driven by the electron transport system. Cell 98:217-
227. 
14. Bao, S., M. J. Liu, B. Lee, B. Besecker, J. P. Lai, D. C. Guttridge, and D. L. 
Knoell. 2010. Zinc modulates the innate immune response in vivo to 
polymicrobial sepsis through regulation of NF-kappaB. American Journal of 
Physiology-Lung Cellular and Molecular Physiology 298:L744. 
15. Barcak, G. J., M. S. Chandler, R. J. Redfield, and J. F. Tomb. 1991. Genetic 
systems in Haemophilus influenzae. Methods Enzymol 204:321-342. 
16. Bardwell, J. C., J. O. Lee, G. Jander, N. Martin, D. Belin, and J. Beckwith. 
1993. A pathway for disulfide bond formation in vivo. Proc Natl Acad Sci U S A 
90:1038-1042. 
17. Bardwell, J. C., K. McGovern, and J. Beckwith. 1991. Identification of a 
protein required for disulfide bond formation in vivo. Cell 67:581-589. 
18. Beard, S. J., R. Hashim, G. Wu, M. R. Binet, M. N. Hughes, and R. K. Poole. 
2000. Evidence for the transport of zinc(II) ions via the pit inorganic phosphate 
transport system in Escherichia coli. FEMS Microbiol Lett 184:231-235. 
19. Bendtsen, J. D., H. Nielsen, G. von Heijne, and S. Brunak. 2004. Improved 
prediction of signal peptides: SignalP 3.0. J Mol Biol 340:783-795. 
20. Berkmen, M., D. Boyd, and J. Beckwith. 2005. The nonconsecutive disulfide 
bond of Escherichia coli phytase (AppA) renders it dependent on the protein-
disulfide isomerase, DsbC. Journal of Biological Chemistry 280:11387. 
21. Bernsel, A., H. Viklund, A. Hennerdal, and A. Elofsson. 2009. TOPCONS: 
consensus prediction of membrane protein topology. Nucleic Acids Res 
37:W465-468. 
22. Berven, F. S., K. Flikka, H. B. Jensen, and I. Eidhammer. 2004. BOMP: a 
program to predict integral beta-barrel outer membrane proteins encoded within 
genomes of Gram-negative bacteria. Nucleic Acids Res 32:W394-399. 
23. Bessette, P. H., J. J. Cotto, H. F. Gilbert, and G. Georgiou. 1999. In Vivo and 
in Vitro Function of the Escherichia coli Periplasmic Cysteine Oxidoreductase 
DsbG. Journal of Biological Chemistry 274:7784. 
24. Bishai, W. R., N. S. Howard, J. A. Winkelstein, and H. O. Smith. 1994. 
Characterization and virulence analysis of catalase mutants of Haemophilus 
influenzae. Infection and immunity 62:4855-4860. 
25. Bong, C. T., R. E. Throm, K. R. Fortney, B. P. Katz, A. F. Hood, C. Elkins, 
and S. M. Spinola. 2001. DsrA-deficient mutant of Haemophilus ducreyi is 
impaired in its ability to infect human volunteers. Infect Immun 69:1488-1491. 
26. Bookwalter, J. E., J. A. Jurcisek, S. D. Gray-Owen, S. Fernandez, G. 
McGillivary, and L. O. Bakaletz. 2008. A carcinoembryonic antigen-related cell 
adhesion molecule 1 homologue plays a pivotal role in nontypeable Haemophilus 
influenzae colonization of the chinchilla nasopharynx via the outer membrane 
protein P5-homologous adhesin. Infect Immun 76:48-55. 
27. Bouchet, V., D. W. Hood, J. Li, J. R. Brisson, G. A. Randle, A. Martin, Z. Li, 
R. Goldstein, E. K. Schweda, S. I. Pelton, J. C. Richards, and E. R. Moxon. 
158 
 
2003. Host-derived sialic acid is incorporated into Haemophilus influenzae 
lipopolysaccharide and is a major virulence factor in experimental otitis media. 
Proceedings of the National Academy of Sciences of the United States of America 
100:8898-8903. 
28. Boulette, M. L., and S. M. Payne. 2007. Anaerobic regulation of Shigella 
flexneri virulence: ArcA regulates Fur and iron acquisition genes. Journal of 
bacteriology 189:6957-6967. 
29. Bringer, M. A., N. Rolhion, A. L. Glasser, and A. Darfeuille-Michaud. 2007. 
The oxidoreductase DsbA plays a key role in the ability of the Crohn's disease-
associated adherent-invasive Escherichia coli strain LF82 to resist macrophage 
killing. Journal of bacteriology 189:4860. 
30. Burall, L. S., J. M. Harro, X. Li, C. Lockatell, S. D. Himpsl, J. R. Hebel, D. E. 
Johnson, and H. L. T. Mobley. 2004. Proteus mirabilis genes that contribute to 
pathogenesis of urinary tract infection: identification of 25 signature-tagged 
mutants attenuated at least 100-fold. Infection and immunity 72:2922. 
31. Campos, J., M. Hernando, F. Roman, M. Perez-Vazquez, B. Aracil, J. Oteo, 
E. Lazaro, and F. de Abajo. 2004. Analysis of invasive Haemophilus influenzae 
infections after extensive vaccination against H. influenzae type b. J Clin 
Microbiol 42:524-529. 
32. Campoy, S., M. Jara, N. Busquets, A. M. Perez De Rozas, I. Badiola, and J. 
Barbe. 2002. Role of the high-affinity zinc uptake znuABC system in Salmonella 
enterica serovar typhimurium virulence. Infect Immun 70:4721-4725. 
33. CDC. 2002. From the Centers for Disease Control and Prevention. Progress 
toward elimination of Haemophilus influenzae type b invasive disease among 
infants and children-- United States, 1998-2000. JAMA 287:2206-2207. 
34. Cerquetti, M., M. L. Ciofi degli Atti, G. Renna, A. E. Tozzi, M. L. Garlaschi, 
and P. Mastrantonio. 2000. Characterization of non-type B Haemophilus 
influenzae strains isolated from patients with invasive disease. The HI Study 
Group. J Clin Microbiol 38:4649-4652. 
35. Chen, J., J. Song, S. Zhang, Y. Wang, D. Cui, and C. Wang. 1999. Chaperone 
activity of DsbC. Journal of Biological Chemistry 274:19601. 
36. Clohessy, P., and B. Golden. 1995. Calprotectin Mediated Zinc Chelation as a 
Biostatic Mechanism in Host Defence. Scandinavian journal of immunology 
42:551-556. 
37. Coleman, H. N., D. A. Daines, J. Jarisch, and A. L. Smith. 2003. Chemically 
defined media for growth of Haemophilus influenzae strains. Journal of clinical 
microbiology 41:4408-4410. 
38. Cope, L. D., Z. Hrkal, and E. J. Hansen. 2000. Detection of phase variation in 
expression of proteins involved in hemoglobin and hemoglobin-haptoglobin 
binding by nontypeable Haemophilus influenzae. Infection and immunity 
68:4092. 
39. Cope, L. D., R. P. Love, S. E. Guinn, A. Gilep, S. Usanov, R. W. Estabrook, 
Z. Hrkal, and E. J. Hansen. 2001. Involvement of HxuC outer membrane 
159 
 
protein in utilization of hemoglobin by Haemophilus influenzae. Infection and 
immunity 69:2353. 
40. Cope, L. D., S. E. Thomas, Z. Hrkal, and E. J. Hansen. 1998. Binding of 
heme-hemopexin complexes by soluble HxuA protein allows utilization of this 
complexed heme by Haemophilus influenzae. Infection and immunity 66:4511. 
41. Cope, L. D., S. E. Thomas, J. L. Latimer, C. A. Slaughter, U. Müller 
Eberhard, and E. J. Hansen. 1994. The 100 kDa haem: haemopexin binding 
protein of Haemophilus influenzae: structure and localization. Molecular 
microbiology 13:863-873. 
42. Cope, L. D., R. Yogev, U. Muller-Eberhard, and E. J. Hansen. 1995. A gene 
cluster involved in the utilization of both free heme and heme: hemopexin by 
Haemophilus influenzae type b. Journal of bacteriology 177:2644. 
43. Corrall, C. J., J. A. Winkelstein, and E. R. Moxon. 1982. Participation of 
complement in host defense against encapsulated Haemophilus influenzae types a, 
c, and d. Infect Immun 35:759-763. 
44. Coyle, P., J. Philcox, and A. Rofe. 1995. Hepatic zinc in metallothionein-null 
mice following zinc challenge: in vivo and in vitro studies. Biochemical Journal 
309:25. 
45. Crack, J., J. Green, and A. J. Thomson. 2004. Mechanism of oxygen sensing 
by the bacterial transcription factor fumarate-nitrate reduction (FNR). The Journal 
of biological chemistry 279:9278-9286. 
46. Crosson, F. J., Jr., J. A. Winkelstein, and E. R. Moxon. 1976. Participation of 
complement in the nonimmune host defense against experimental Haemophilus 
influenzae type b septicemia and meningitis. Infect Immun 14:882-887. 
47. Cuthill, S. L., M. M. Farley, and L. G. Donowitz. 1999. Nontypable 
Haemophilus influenzae meningitis. Pediatr Infect Dis J 18:660-662. 
48. D'mello, R. A., P. R. Langford, and J. S. Kroll. 1997. Role of bacterial Mn-
cofactored superoxide dismutase in oxidative stress responses, nasopharyngeal 
colonization, and sustained bacteremia caused by Haemophilus influenzae type b. 
Infection and immunity 65:2700. 
49. Dailey, F. E., and H. C. Berg. 1993. Mutants in disulfide bond formation that 
disrupt flagellar assembly in Escherichia coli. Proceedings of the National 
Academy of Sciences of the United States of America 90:1043. 
50. Daines, D. A., L. A. Cohn, H. N. Coleman, K. S. Kim, and A. L. Smith. 2003. 
Haemophilus influenzae Rd KW20 has virulence properties. Journal of medical 
microbiology 52:277. 
51. Dakin, C. J., A. H. Numa, H. Wang, J. R. Morton, C. C. Vertzyas, and R. L. 
Henry. 2002. Inflammation, infection, and pulmonary function in infants and 
young children with cystic fibrosis. American journal of respiratory and critical 
care medicine 165:904-910. 
52. Darby, N. J., and T. E. Creighton. 1995. Catalytic mechanism of DsbA and its 
comparison with that of protein disulfide isomerase. Biochemistry 34:3576-3587. 
160 
 
53. Darwin, A. J., and V. L. Miller. 1999. Identification of Yersinia enterocolitica 
genes affecting survival in an animal host using signature-tagged transposon 
mutagenesis. Mol Microbiol 32:51-62. 
54. Davidson, A. L., E. Dassa, C. Orelle, and J. Chen. 2008. Structure, function, 
and evolution of bacterial ATP-binding cassette systems. Microbiol Mol Biol Rev 
72:317-364, table of contents. 
55. Davis, L. M., T. Kakuda, and V. J. DiRita. 2009. A Campylobacter jejuni znuA 
orthologue is essential for growth in low-zinc environments and chick 
colonization. J Bacteriol 191:1631-1640. 
56. Dawid, S., S. J. Barenkamp, and J. W. St Geme. 1999. Variation in expression 
of the Haemophilus influenzae HMW adhesins: a prokaryotic system reminiscent 
of eukaryotes. Proceedings of the National Academy of Sciences of the United 
States of America 96:1077. 
57. De Souza-Hart, J. A., W. Blackstock, V. Di Modugno, I. B. Holland, and M. 
Kok. 2003. Two-component systems in Haemophilus influenzae: a regulatory role 
for ArcA in serum resistance. Infection and immunity 71:163-172. 
58. Depuydt, M., S. E. Leonard, D. Vertommen, K. Denoncin, P. Morsomme, K. 
Wahni, J. Messens, K. S. Carroll, and J. F. Collet. 2009. A periplasmic 
reducing system protects single cysteine residues from oxidation. Science 
326:1109. 
59. Desrosiers, D. C., S. W. Bearden, I. Mier, Jr., J. Abney, J. T. Paulley, J. D. 
Fetherston, J. C. Salazar, J. D. Radolf, and R. D. Perry. 2010. Znu is the 
predominant zinc importer in Yersinia pestis during in vitro growth but is not 
essential for virulence. Infect Immun 78:5163-5177. 
60. Desrosiers, D. C., Y. C. Sun, A. A. Zaidi, C. H. Eggers, D. L. Cox, and J. D. 
Radolf. 2007. The general transition metal (Tro) and Zn2+ (Znu) transporters in 
Treponema pallidum: analysis of metal specificities and expression profiles. Mol 
Microbiol 65:137-152. 
61. Dibden, D. P., and J. Green. 2005. In vivo cycling of the Escherichia coli 
transcription factor FNR between active and inactive states. Microbiology 
151:4063-4070. 
62. Duim, B., L. D. Bowler, P. P. Eijk, H. M. Jansen, J. Dankert, and L. van 
Alphen. 1997. Molecular variation in the major outer membrane protein P5 gene 
of nonencapsulated Haemophilus influenzae during chronic infections. Infect 
Immun 65:1351-1356. 
63. Duim, B., L. Vogel, W. Puijk, H. M. Jansen, R. H. Meloen, J. Dankert, and L. 
van Alphen. 1996. Fine mapping of outer membrane protein P2 antigenic sites 
which vary during persistent infection by Haemophilus influenzae. Infection and 
immunity 64:4673-4679. 
64. Dutton, R. J., D. Boyd, M. Berkmen, and J. Beckwith. 2008. Bacterial species 
exhibit diversity in their mechanisms and capacity for protein disulfide bond 
formation. Proceedings of the National Academy of Sciences 105:11933. 
65. Eiglmeier, K., N. Honore, S. Iuchi, E. C. Lin, and S. T. Cole. 1989. Molecular 
genetic analysis of FNR-dependent promoters. Mol Microbiol 3:869-878. 
161 
 
66. Eitinger, T., J. Suhr, L. Moore, and J. A. Smith. 2005. Secondary transporters 
for nickel and cobalt ions: theme and variations. Biometals 18:399-405. 
67. Elkins, C., K. J. Morrow, Jr., and B. Olsen. 2000. Serum resistance in 
Haemophilus ducreyi requires outer membrane protein DsrA. Infect Immun 
68:1608-1619. 
68. Eren, E., D. C. Kennedy, M. J. Maroney, and J. M. Arguello. 2006. A novel 
regulatory metal binding domain is present in the C terminus of Arabidopsis 
Zn2+-ATPase HMA2. J Biol Chem 281:33881-33891. 
69. Erwin, A. L., P. J. Bonthuis, J. L. Geelhood, K. L. Nelson, K. W. McCrea, J. 
R. Gilsdorf, and A. L. Smith. 2006. Heterogeneity in tandem octanucleotides 
within Haemophilus influenzae lipopolysaccharide biosynthetic gene losA affects 
serum resistance. Infection and immunity 74:3408-3414. 
70. Erwin, A. L., Y. A. Brewah, D. A. Couchenour, P. R. Barren, S. J. Burke, G. 
H. Choi, R. Lathigra, M. S. Hanson, and J. N. Weiser. 2000. Role of 
lipopolysaccharide phase variation in susceptibility of Haemophilus influenzae to 
bactericidal immunoglobulin M antibodies in rabbit sera. Infect Immun 68:2804-
2807. 
71. Erwin, A. L., K. L. Nelson, T. Mhlanga-Mutangadura, P. J. Bonthuis, J. L. 
Geelhood, G. Morlin, W. C. Unrath, J. Campos, D. W. Crook, M. M. Farley, 
F. W. Henderson, R. F. Jacobs, K. Muhlemann, S. W. Satola, L. van Alphen, 
M. Golomb, and A. L. Smith. 2005. Characterization of genetic and phenotypic 
diversity of invasive nontypeable Haemophilus influenzae. Infection and 
immunity 73:5853-5863. 
72. Evans, N. M., D. D. Smith, and A. J. Wicken. 1974. Haemin and nicotinamide 
adenine dinucleotide requirements of Haemophilus influenzae and Haemophilus 
parainfluenzae. Journal of medical microbiology 7:359-365. 
73. Fan, X., H. Goldfine, E. Lysenko, and J. N. Weiser. 2001. The transfer of 
choline from the host to the bacterial cell surface requires glpQ in Haemophilus 
influenzae. Molecular microbiology 41:1029-1036. 
74. Farley, M. M., D. S. Stephens, S. L. Kaplan, and E. O. Mason. 1990. Pilus-and 
Non-Pilus-Mediated Interactions of Haemophilus influenzae Type b with Human 
Erythrocytes and Human Nasopharyngeal Mucosa. Journal of Infectious Diseases 
161:274. 
75. Figueira, M. A., S. Ram, R. Goldstein, D. W. Hood, E. R. Moxon, and S. I. 
Pelton. 2007. Role of complement in defense of the middle ear revealed by 
restoring the virulence of nontypeable Haemophilus influenzae siaB mutants. 
Infect Immun 75:325-333. 
76. Fink, D. L., and B. A. Green. 2002. The Haemophilus influenzae Hap 
autotransporter binds to fibronectin, laminin, and collagen IV. Infection and 
immunity 70:4902. 
77. Fleischmann, R. D., M. D. Adams, O. White, R. A. Clayton, E. F. Kirkness, 
A. R. Kerlavage, C. J. Bult, J. F. Tomb, B. A. Dougherty, and J. M. Merrick. 
1995. Whole-genome random sequencing and assembly of Haemophilus 
influenzae Rd. Science 269:496. 
162 
 
78. Fox, K. L., J. Li, E. K. Schweda, V. Vitiazeva, K. Makepeace, M. P. Jennings, 
E. R. Moxon, and D. W. Hood. 2008. Duplicate copies of lic1 direct the addition 
of multiple phosphocholine residues in the lipopolysaccharide of Haemophilus 
influenzae. Infect Immun 76:588-600. 
79. Frech, C., M. Wunderlich, R. Glockshuber, and F. X. Schmid. 1996. 
Preferential binding of an unfolded protein to DsbA. EMBO J 15:392-398. 
80. Fujita, T., I. Gigli, and V. Nussenzweig. 1978. Human C4-binding protein. II. 
Role in proteolysis of C4b by C3b-inactivator. J Exp Med 148:1044-1051. 
81. Fujita, T., and V. Nussenzweig. 1979. The role of C4-binding protein and beta 
1H in proteolysis of C4b and C3b. J Exp Med 150:267-276. 
82. Gabay, C., and I. Kushner. 1999. Acute-phase proteins and other systemic 
responses to inflammation. N Engl J Med 340:448-454. 
83. Garrido, M. E., M. Bosch, R. Medina, M. Llagostera, A. M. Perez de Rozas, 
I. Badiola, and J. Barbe. 2003. The high-affinity zinc-uptake system znuACB is 
under control of the iron-uptake regulator (fur) gene in the animal pathogen 
Pasteurella multocida. FEMS Microbiol Lett 221:31-37. 
84. Gawronski, J. D., S. M. Wong, G. Giannoukos, D. V. Ward, and B. J. 
Akerley. 2009. Tracking insertion mutants within libraries by deep sequencing 
and a genome-wide screen for Haemophilus genes required in the lung. Proc Natl 
Acad Sci U S A 106:16422-16427. 
85. Gigli, I., T. Fujita, and V. Nussenzweig. 1979. Modulation of the classical 
pathway C3 convertase by plasma proteins C4 binding protein and C3b 
inactivator. Proc Natl Acad Sci U S A 76:6596-6600. 
86. Gilligan, P. H. 1991. Microbiology of airway disease in patients with cystic 
fibrosis. Clin Microbiol Rev 4:35-51. 
87. Gnehm, H. E., S. I. Pelton, S. Gulati, and P. A. Rice. 1985. Characterization of 
antigens from nontypable Haemophilus influenzae recognized by human 
bactericidal antibodies. Role of Haemophilus outer membrane proteins. J Clin 
Invest 75:1645-1658. 
88. Goldsby, R. A. 2003. Immunology, 5th ed. W.H. Freeman, New York. 
89. Gonzalez, M. D., C. A. Lichtensteiger, and E. R. Vimr. 2001. Adaptation of 
signature tagged mutagenesis to Escherichia coli K1 and the infant rat model of 
invasive disease. FEMS microbiology letters 198:125-128. 
90. Graham, A. I., S. Hunt, S. L. Stokes, N. Bramall, J. Bunch, A. G. Cox, C. W. 
McLeod, and R. K. Poole. 2009. Severe zinc depletion of Escherichia coli: roles 
for high affinity zinc binding by ZinT, zinc transport and zinc-independent 
proteins. J Biol Chem 284:18377-18389. 
91. Granick, S., and H. Gilder. 1946. The Porphyrin Requirements of Haemophilus 
influenzae and Some Functions of the Vinyl and Propionic Acid Side Chains of 
Heme. J Gen Physiol 30:1-13. 
92. Grauschopf, U., A. Fritz, and R. Glockshuber. 2003. Mechanism of the 
electron transfer catalyst DsbB from Escherichia coli. The EMBO journal 
22:3503-3513. 
163 
 
93. Grauschopf, U., J. R. Winther, P. Korber, T. Zander, P. Dallinger, and J. C. 
Bardwell. 1995. Why is DsbA such an oxidizing disulfide catalyst? Cell 83:947-
955. 
94. Greiff, L., M. Andersson, J. S. Erjefalt, C. G. Persson, and P. Wollmer. 2003. 
Airway microvascular extravasation and luminal entry of plasma. Clin Physiol 
Funct Imaging 23:301-306. 
95. Griffin, R., C. D. Bayliss, M. A. Herbert, A. D. Cox, K. Makepeace, J. C. 
Richards, D. W. Hood, and E. R. Moxon. 2005. Digalactoside expression in the 
lipopolysaccharide of Haemophilus influenzae and its role in intravascular 
survival. Infection and immunity 73:7022. 
96. Griffin, R., A. D. Cox, K. Makepeace, J. C. Richards, E. R. Moxon, and D. 
W. Hood. 2005. Elucidation of the monoclonal antibody 5G8-reactive, virulence-
associated lipopolysaccharide epitope of Haemophilus influenzae and its role in 
bacterial resistance to complement-mediated killing. Infection and immunity 
73:2213-2221. 
97. Groeneveld, K., L. van Alphen, C. Voorter, P. P. Eijk, H. M. Jansen, and H. 
C. Zanen. 1989. Antigenic drift of Haemophilus influenzae in patients with 
chronic obstructive pulmonary disease. Infection and immunity 57:3038-3044. 
98. Guest, J. 1992. Oxygen-regulated gene expression in Escherichia coli. The 1992 
Marjory Stephenson Prize Lecture. Microbiology 138:2253-2263. 
99. Guilhot, C., G. Jander, N. L. Martin, and J. Beckwith. 1995. Evidence that the 
pathway of disulfide bond formation in Escherichia coli involves interactions 
between the cysteines of DsbB and DsbA. Proceedings of the National Academy 
of Sciences of the United States of America 92:9895-9899. 
100. Guo, J., and D. P. Giedroc. 1997. Zinc site redesign in T4 gene 32 protein: 
structure and stability of cobalt(II) complexes formed by wild-type and metal 
ligand substitution mutants. Biochemistry 36:730-742. 
101. Ha, U. H., Y. Wang, and S. Jin. 2003. DsbA of Pseudomonas aeruginosa is 
essential for multiple virulence factors. Infect Immun 71:1590-1595. 
102. Hallstrom, T., A. M. Blom, P. F. Zipfel, and K. Riesbeck. 2009. Nontypeable 
Haemophilus influenzae protein E binds vitronectin and is important for serum 
resistance. J Immunol 183:2593-2601. 
103. Hallstrom, T., H. Jarva, K. Riesbeck, and A. M. Blom. 2007. Interaction with 
C4b-binding protein contributes to nontypeable Haemophilus influenzae serum 
resistance. J Immunol 178:6359-6366. 
104. Hallstrom, T., F. Resman, M. Ristovski, and K. Riesbeck. 2010. Binding of 
complement regulators to invasive nontypeable Haemophilus influenzae isolates 
is not increased compared to nasopharyngeal isolates, but serum resistance is 
linked to disease severity. J Clin Microbiol 48:921-927. 
105. Hallstrom, T., and K. Riesbeck. 2010. Haemophilus influenzae and the 
complement system. Trends Microbiol 18:258-265. 
106. Hallstrom, T., E. Trajkovska, A. Forsgren, and K. Riesbeck. 2006. 
Haemophilus influenzae surface fibrils contribute to serum resistance by 
interacting with vitronectin. J Immunol 177:430-436. 
164 
 
107. Hallstrom, T., P. F. Zipfel, A. M. Blom, N. Lauer, A. Forsgren, and K. 
Riesbeck. 2008. Haemophilus influenzae interacts with the human complement 
inhibitor factor H. J Immunol 181:537-545. 
108. Hanson, M. S., C. Slaughter, and E. J. Hansen. 1992. The hbpA gene of 
Haemophilus influenzae type b encodes a heme-binding lipoprotein conserved 
among heme-dependent Haemophilus species. Infect Immun 60:2257-2266. 
109. Hantke, K. 2005. Bacterial zinc uptake and regulators. Curr Opin Microbiol 
8:196-202. 
110. Harrington, J. C., S. M. Wong, C. V. Rosadini, O. Garifulin, V. Boyartchuk, 
and B. J. Akerley. 2009. Resistance of Haemophilus influenzae to reactive 
nitrogen donors and gamma interferon-stimulated macrophages requires the 
formate-dependent nitrite reductase regulator-activated ytfE gene. Infect Immun 
77:1945-1958. 
111. Henke, M. O., A. Renner, B. K. Rubin, J. I. Gyves, E. Lorenz, and J. S. Koo. 
2006. Up-regulation of S100A8 and S100A9 protein in bronchial epithelial cells 
by lipopolysaccharide. Exp Lung Res 32:331-347. 
112. Heras, B., M. A. Edeling, H. J. Schirra, S. Raina, and J. L. Martin. 2004. 
Crystal structures of the DsbG disulfide isomerase reveal an unstable disulfide. 
Proceedings of the National Academy of Sciences of the United States of America 
101:8876. 
113. Heras, B., S. R. Shouldice, M. Totsika, M. J. Scanlon, M. A. Schembri, and J. 
L. Martin. 2009. DSB proteins and bacterial pathogenicity. Nat Rev Microbiol 
7:215-225. 
114. Herbert, M., S. Hayes, M. Deadman, C. Tang, D. Hood, and E. Moxon. 2002. 
Signature tagged mutagenesis of Haemophilus influenzae identifies genes 
required for in vivo survival. Microbial pathogenesis 33:211-223. 
115. Hill, D. J., M. A. Toleman, D. J. Evans, S. Villullas, L. Van Alphen, and M. 
Virji. 2001. The variable P5 proteins of typeable and non-typeable Haemophilus 
influenzae target human CEACAM1. Mol Microbiol 39:850-862. 
116. Hiniker, A., and J. C. Bardwell. 2004. In vivo substrate specificity of 
periplasmic disulfide oxidoreductases. J Biol Chem 279:12967-12973. 
117. Ho, D. K., S. Ram, K. L. Nelson, P. J. Bonthuis, and A. L. Smith. 2007. lgtC 
expression modulates resistance to C4b deposition on an invasive nontypeable 
Haemophilus influenzae. J Immunol 178:1002-1012. 
118. Hobbs, J. A. R., R. May, K. Tanousis, E. McNeill, M. Mathies, C. Gebhardt, 
R. Henderson, M. J. Robinson, and N. Hogg. 2003. Myeloid cell function in 
MRP-14 (S100A9) null mice. Molecular and cellular biology 23:2564. 
119. Hong, W., K. Mason, J. Jurcisek, L. Novotny, L. O. Bakaletz, and W. E. 
Swords. 2007. Phosphorylcholine decreases early inflammation and promotes the 
establishment of stable biofilm communities of nontypeable Haemophilus 
influenzae strain 86-028NP in a chinchilla model of otitis media. Infection and 
immunity 75:958-965. 
120. Hood, D. W., A. D. Cox, M. Gilbert, K. Makepeace, S. Walsh, M. E. 
Deadman, A. Cody, A. Martin, M. Mansson, E. K. Schweda, J. R. Brisson, J. 
165 
 
C. Richards, E. R. Moxon, and W. W. Wakarchuk. 2001. Identification of a 
lipopolysaccharide alpha-2,3-sialyltransferase from Haemophilus influenzae. 
Molecular microbiology 39:341-350. 
121. Hood, D. W., M. E. Deadman, A. D. Cox, K. Makepeace, A. Martin, J. C. 
Richards, and E. R. Moxon. 2004. Three genes, lgtF, lic2C and lpsA, have a 
primary role in determining the pattern of oligosaccharide extension from the 
inner core of Haemophilus influenzae LPS. Microbiology 150:2089. 
122. Hood, D. W., M. E. Deadman, M. P. Jennings, M. Bisercic, R. D. 
Fleischmann, J. C. Venter, and E. R. Moxon. 1996. DNA repeats identify novel 
virulence genes in Haemophilus influenzae. Proceedings of the National Academy 
of Sciences of the United States of America 93:11121. 
123. Hood, D. W., K. Makepeace, M. E. Deadman, R. F. Rest, P. Thibault, A. 
Martin, J. C. Richards, and E. R. Moxon. 1999. Sialic acid in the 
lipopolysaccharide of Haemophilus influenzae: strain distribution, influence on 
serum resistance and structural characterization. Mol Microbiol 33:679-692. 
124. Huber-Wunderlich, M., and R. Glockshuber. 1998. A single dipeptide 
sequence modulates the redox properties of a whole enzyme family. Fold Des 
3:161-171. 
125. Humphries, H. E., and N. J. High. 2002. The role of licA phase variation in the 
pathogenesis of invasive disease by Haemophilus influenzae type b. FEMS 
Immunology & Medical Microbiology 34:221-230. 
126. Inaba, K., and K. Ito. 2008. Structure and mechanisms of the DsbB-DsbA 
disulfide bond generation machine. Biochimica et Biophysica Acta (BBA)-
Molecular Cell Research 1783:520-529. 
127. Inaba, K., S. Murakami, M. Suzuki, A. Nakagawa, E. Yamashita, K. Okada, 
and K. Ito. 2006. Crystal structure of the DsbB-DsbA complex reveals a 
mechanism of disulfide bond generation. Cell 127:789-801. 
128. Inaba, K., Y. H. Takahashi, and K. Ito. 2005. Reactivities of quinone-free 
DsbB from Escherichia coli. The Journal of biological chemistry 280:33035-
33044. 
129. Ito, T., H. Shibata, M. Nakazawa, M. Myokai, K. Ikegaya, K. Tsuchiya, and 
T. Kamimaki. 2011. Meningitis and septicemia caused by nontypeable 
Haemophilus influenzae in a previously healthy 2-year-old girl. J Infect 
Chemother. 
130. Jackson, M. W., and G. V. Plano. 1999. DsbA is required for stable expression 
of outer membrane protein YscC and for efficient Yop secretion in Yersinia 
pestis. J Bacteriol 181:5126-5130. 
131. Jacob-Dubuisson, F., J. Pinkner, Z. Xu, R. Striker, A. Padmanhaban, and S. 
J. Hultgren. 1994. PapD chaperone function in pilus biogenesis depends on 
oxidant and chaperone-like activities of DsbA. Proc Natl Acad Sci U S A 
91:11552-11556. 
132. Jiang, Z., N. Nagata, E. Molina, L. O. Bakaletz, H. Hawkins, and J. A. Patel. 
1999. Fimbria-mediated enhanced attachment of nontypeable Haemophilus 
166 
 
influenzae to respiratory syncytial virus-infected respiratory epithelial cells. Infect 
Immun 67:187-192. 
133. Jin, H., Z. Ren, P. W. Whitby, D. J. Morton, and T. L. Stull. 1999. 
Characterization of hgpA, a gene encoding a haemoglobin/haemoglobin-
haptoglobin-binding protein of Haemophilus influenzae. Microbiology 145:905. 
134. Johne, B., M. K. Fagerhol, T. Lyberg, H. Prydz, P. Brandtzaeg, C. F. Naess-
Andresen, and I. Dale. 1997. Functional and clinical aspects of the 
myelomonocyte protein calprotectin. Mol Pathol 50:113-123. 
135. Juncker, A. S., H. Willenbrock, G. Von Heijne, S. Brunak, H. Nielsen, and A. 
Krogh. 2003. Prediction of lipoprotein signal peptides in Gram-negative bacteria. 
Protein Sci 12:1652-1662. 
136. Jurcisek, J., L. Greiner, H. Watanabe, A. Zaleski, M. A. Apicella, and L. O. 
Bakaletz. 2005. Role of sialic acid and complex carbohydrate biosynthesis in 
biofilm formation by nontypeable Haemophilus influenzae in the chinchilla 
middle ear. Infection and immunity 73:3210-3218. 
137. Jurcisek, J. A., J. E. Bookwalter, B. D. Baker, S. Fernandez, L. A. Novotny, 
R. S. Munson Jr, and L. O. Bakaletz. 2007. The PilA protein of non typeable 
Haemophilus influenzae plays a role in biofilm formation, adherence to epithelial 
cells and colonization of the mammalian upper respiratory tract. Molecular 
microbiology 65:1288-1299. 
138. Kadokura, H., and J. Beckwith. 2002. Four cysteines of the membrane protein 
DsbB act in concert to oxidize its substrate DsbA. The EMBO journal 21:2354-
2363. 
139. Kadokura, H., and J. Beckwith. 2010. Mechanisms of oxidative protein folding 
in the bacterial cell envelope. Antioxid Redox Signal 13:1231-1246. 
140. Kadokura, H., F. Katzen, and J. Beckwith. 2003. Protein disulfide bond 
formation in prokaryotes. Annu Rev Biochem 72:111-135. 
141. Kadokura, H., H. Tian, T. Zander, J. C. Bardwell, and J. Beckwith. 2004. 
Snapshots of DsbA in action: detection of proteins in the process of oxidative 
folding. Science 303:534-537. 
142. Kall, L., A. Krogh, and E. L. Sonnhammer. 2007. Advantages of combined 
transmembrane topology and signal peptide prediction--the Phobius web server. 
Nucleic Acids Res 35:W429-432. 
143. Kamitani, S., Y. Akiyama, and K. Ito. 1992. Identification and characterization 
of an Escherichia coli gene required for the formation of correctly folded alkaline 
phosphatase, a periplasmic enzyme. The EMBO journal 11:57-62. 
144. Kammler, M., C. Schon, and K. Hantke. 1993. Characterization of the ferrous 
iron uptake system of Escherichia coli. Journal of bacteriology 175:6212-6219. 
145. Kehl-Fie, T. E., and E. P. Skaar. 2010. Nutritional immunity beyond iron: a role 
for manganese and zinc. Curr Opin Chem Biol 14:218-224. 
146. Ketterer, M. R., J. Q. Shao, D. B. Hornick, B. Buscher, V. K. Bandi, and M. 
A. Apicella. 1999. Infection of primary human bronchial epithelial cells by 
Haemophilus influenzae: macropinocytosis as a mechanism of airway epithelial 
cell entry. Infection and immunity 67:4161. 
167 
 
147. Kilian, M., J. Mestecky, and R. E. Schrohenloher. 1979. Pathogenic species of 
the genus Haemophilus and Streptococcus pneumoniae produce immunoglobulin 
A1 protease. Infection and immunity 26:143. 
148. Kim, S., K. Watanabe, T. Shirahata, and M. Watarai. 2004. Zinc uptake 
system (znuA locus) of Brucella abortus is essential for intracellular survival and 
virulence in mice. J Vet Med Sci 66:1059-1063. 
149. King, P. T., J. Ngui, D. Gunawardena, P. W. Holmes, M. W. Farmer, and S. 
R. Holdsworth. 2008. Systemic humoral immunity to non-typeable Haemophilus 
influenzae. Clin Exp Immunol 153:376-384. 
150. Kishigami, S., and K. Ito. 1996. Roles of cysteine residues of DsbB in its 
activity to reoxidize DsbA, the protein disulphide bond catalyst of Escherichia 
coli. Genes to Cells 1:201-208. 
151. Kishigami, S., E. Kanaya, M. Kikuchi, and K. Ito. 1995. DsbA-DsbB 
interaction through their active site cysteines. Evidence from an odd cysteine 
mutant of DsbA. The Journal of biological chemistry 270:17072-17074. 
152. Klein, J. O. 1997. Role of nontypeable Haemophilus influenzae in pediatric 
respiratory tract infections. Pediatr Infect Dis J 16:S5-8. 
153. Klug, A., and J. Schwabe. 1995. Protein motifs 5. Zinc fingers. The FASEB 
journal 9:597. 
154. Kobayashi, T., S. Kishigami, M. Sone, H. Inokuchi, T. Mogi, and K. Ito. 
1997. Respiratory chain is required to maintain oxidized states of the DsbA-DsbB 
disulfide bond formation system in aerobically growing Escherichia coli cells. 
Proceedings of the National Academy of Sciences of the United States of America 
94:11857-11862. 
155. Krupp, R., C. Chan, and D. Missiakas. 2001. DsbD-catalyzed transport of 
electrons across the membrane of Escherichia coli. J Biol Chem 276:3696-3701. 
156. Lazazzera, B. A., H. Beinert, N. Khoroshilova, M. C. Kennedy, and P. J. 
Kiley. 1996. DNA binding and dimerization of the Fe-S-containing FNR protein 
from Escherichia coli are regulated by oxygen. J Biol Chem 271:2762-2768. 
157. Lee, B. C. 1995. Quelling the red menace: haem capture by bacteria. Molecular 
microbiology 18:383-390. 
158. Leichert, L. I., and U. Jakob. 2004. Protein thiol modifications visualized in 
vivo. PLoS Biol 2:e333. 
159. Leroy, M., H. Cabral, M. Figueira, V. Bouchet, H. Huot, S. Ram, S. I. Pelton, 
and R. Goldstein. 2007. Multiple consecutive lavage samplings reveal greater 
burden of disease and provide direct access to the nontypeable Haemophilus 
influenzae biofilm in experimental otitis media. Infect Immun 75:4158-4172. 
160. Levinson, G., and G. A. Gutman. 1987. Slipped-strand mispairing: a major 
mechanism for DNA sequence evolution. Molecular biology and evolution 4:203. 
161. Lewis, D. A., J. Klesney-Tait, S. R. Lumbley, C. K. Ward, J. L. Latimer, C. 
A. Ison, and E. J. Hansen. 1999. Identification of the znuA-encoded periplasmic 
zinc transport protein of Haemophilus ducreyi. Infect Immun 67:5060-5068. 
168 
 
162. Li, H., and G. Jogl. 2007. Crystal structure of the zinc-binding transport protein 
ZnuA from Escherichia coli reveals an unexpected variation in metal 
coordination. Journal of molecular biology 368:1358-1366. 
163. Liu, J., A. J. Stemmler, J. Fatima, and B. Mitra. 2005. Metal-binding 
characteristics of the amino-terminal domain of ZntA: binding of lead is different 
compared to cadmium and zinc. Biochemistry 44:5159-5167. 
164. Liuzzi, J. P., L. A. Lichten, S. Rivera, R. K. Blanchard, T. B. Aydemir, M. D. 
Knutson, T. Ganz, and R. J. Cousins. 2005. Interleukin-6 regulates the zinc 
transporter Zip14 in liver and contributes to the hypozincemia of the acute-phase 
response. Proc Natl Acad Sci U S A 102:6843-6848. 
165. Loeb, M., E. Connor, and D. Penney. 1988. A comparison of the adherence of 
fimbriated and nonfimbriated Haemophilus influenzae type b to human adenoids 
in organ culture. Infection and immunity 56:484. 
166. Lu, D., B. Boyd, and C. A. Lingwood. 1997. Identification of the key protein for 
zinc uptake in Hemophilus influenzae. J Biol Chem 272:29033-29038. 
167. Magnet, S., S. Bellais, L. Dubost, M. Fourgeaud, J. L. Mainardi, S. Petit-
Frère, A. Marie, D. Mengin-Lecreulx, M. Arthur, and L. Gutmann. 2007. 
Identification of the L, D-transpeptidases responsible for attachment of the Braun 
lipoprotein to Escherichia coli peptidoglycan. Journal of bacteriology 189:3927. 
168. Mannino, D. M., and V. A. Kiriz. 2006. Changing the burden of COPD 
mortality. Int J Chron Obstruct Pulmon Dis 1:219-233. 
169. Marc, M. M., P. Korosec, M. Kosnik, I. Kern, M. Flezar, S. Suskovic, and J. 
Sorli. 2004. Complement factors c3a, c4a, and c5a in chronic obstructive 
pulmonary disease and asthma. Am J Respir Cell Mol Biol 31:216-219. 
170. Marchler-Bauer, A., S. Lu, J. B. Anderson, F. Chitsaz, M. K. Derbyshire, C. 
DeWeese-Scott, J. H. Fong, L. Y. Geer, R. C. Geer, N. R. Gonzales, M. 
Gwadz, D. I. Hurwitz, J. D. Jackson, Z. Ke, C. J. Lanczycki, F. Lu, G. H. 
Marchler, M. Mullokandov, M. V. Omelchenko, C. L. Robertson, J. S. Song, 
N. Thanki, R. A. Yamashita, D. Zhang, N. Zhang, C. Zheng, and S. H. 
Bryant. 2011. CDD: a Conserved Domain Database for the functional annotation 
of proteins. Nucleic Acids Res 39:D225-229. 
171. Mason, K. M., M. E. Bruggeman, R. S. Munson, and L. O. Bakaletz. 2006. 
The non typeable Haemophilus influenzae Sap transporter provides a mechanism 
of antimicrobial peptide resistance and SapD dependent potassium acquisition. 
Molecular microbiology 62:1357-1372. 
172. Mason, K. M., R. S. Munson Jr, and L. O. Bakaletz. 2005. A mutation in the 
sap operon attenuates survival of nontypeable Haemophilus influenzae in a 
chinchilla model of otitis media. Infection and immunity 73:599. 
173. Mason, K. M., R. S. Munson Jr, and L. O. Bakaletz. 2003. Nontypeable 
Haemophilus influenzae gene expression induced in vivo in a chinchilla model of 
otitis media. Infection and immunity 71:3454. 
174. Mason, K. M., F. K. Raffel, W. C. Ray, and L. O. Bakaletz. 2011. Heme 
Utilization by Nontypeable Haemophilus influenzae is Essential and Dependent 
on Sap Transporter Function. Journal of bacteriology:JB. 01313-01310v01311. 
169 
 
175. Masoud, H., E. R. Moxon, A. Martin, D. Krajcarski, and J. C. Richards. 
1997. Structure of the variable and conserved lipopolysaccharide oligosaccharide 
epitopes expressed by Haemophilus influenzae serotype b strain Eagan. 
Biochemistry 36:2091-2103. 
176. McCarthy, A. A., P. W. Haebel, A. Törrönen, V. Rybin, E. N. Baker, and P. 
Metcalf. 2000. Crystal structure of the protein disulfide bond isomerase, DsbC, 
from Escherichia coli. Nat Struct Mol Biol 7:196-199. 
177. Melville, S. B., and R. P. Gunsalus. 1996. Isolation of an oxygen-sensitive FNR 
protein of Escherichia coli: interaction at activator and repressor sites of FNR-
controlled genes. Proc Natl Acad Sci U S A 93:1226-1231. 
178. Messens, J., J. F. Collet, K. Van Belle, E. Brosens, R. Loris, and L. Wyns. 
2007. The oxidase DsbA folds a protein with a nonconsecutive disulfide. Journal 
of Biological Chemistry 282:31302. 
179. Metheringham, R., L. Griffiths, H. Crooke, S. Forsythe, and J. Cole. 1995. 
An essential role for DsbA in cytochromec synthesis and formate-dependent 
nitrite reduction byEscherichia coli K-12. Archives of microbiology 164:301-307. 
180. Michalska, A. E., and K. Choo. 1993. Targeting and germ-line transmission of a 
null mutation at the metallothionein I and II loci in mouse. Proceedings of the 
National Academy of Sciences of the United States of America 90:8088. 
181. Miki, T., N. Okada, and H. Danbara. 2004. Two periplasmic disulfide 
oxidoreductases, DsbA and SrgA, target outer membrane protein SpiA, a 
component of the Salmonella pathogenicity island 2 type III secretion system. J 
Biol Chem 279:34631-34642. 
182. Miki, T., N. Okada, Y. Kim, A. Abe, and H. Danbara. 2008. DsbA directs 
efficient expression of outer membrane secretin EscC of the enteropathogenic 
Escherichia coli type III secretion apparatus. Microbial pathogenesis 44:151-158. 
183. Miller, J. H. 1972. Experiments in molecular genetics. Cold Spring Harbor 
Laboratory, Cold Spring Harbor, N.Y. 
184. Missiakas, D., C. Georgopoulos, and S. Raina. 1993. Identification and 
characterization of the Escherichia coli gene dsbB, whose product is involved in 
the formation of disulfide bonds in vivo. Proceedings of the National Academy of 
Sciences of the United States of America 90:7084. 
185. Missiakas, D., F. Schwager, and S. Raina. 1995. Identification and 
characterization of a new disulfide isomerase-like protein (DsbD) in Escherichia 
coli. The EMBO journal 14:3415. 
186. Miyamoto, N., and L. O. Bakaletz. 1996. Selective adherence of non-typeable 
Haemophilus influenzae (NTHi) to mucus or epithelial cells in the chinchilla 
eustachian tube and middle ear. Microb Pathog 21:343-356. 
187. Moller, L. V., A. G. Regelink, H. Grasselier, J. E. Dankert-Roelse, J. 
Dankert, and L. van Alphen. 1995. Multiple Haemophilus influenzae strains and 
strain variants coexist in the respiratory tract of patients with cystic fibrosis. J 
Infect Dis 172:1388-1392. 
188. Morton, D. J., L. O. Bakaletz, J. A. Jurcisek, T. M. VanWagoner, T. W. 
Seale, P. W. Whitby, and T. L. Stull. 2004. Reduced severity of middle ear 
170 
 
infection caused by nontypeable Haemophilus influenzae lacking the 
hemoglobin/hemoglobin-haptoglobin binding proteins (Hgp) in a chinchilla 
model of otitis media. Microbial pathogenesis 36:25-33. 
189. Morton, D. J., L. L. Madore, A. Smith, T. M. Vanwagoner, T. W. Seale, P. 
W. Whitby, and T. L. Stull. 2005. The heme-binding lipoprotein (HbpA) of 
Haemophilus influenzae: role in heme utilization. FEMS Microbiol Lett 253:193-
199. 
190. Morton, D. J., T. W. Seale, L. O. Bakaletz, J. A. Jurcisek, A. Smith, T. M. 
VanWagoner, P. W. Whitby, and T. L. Stull. 2009. The heme-binding protein 
(HbpA) of Haemophilus influenzae as a virulence determinant. International 
journal of medical microbiology : IJMM 299:479-488. 
191. Morton, D. J., T. W. Seale, L. L. Madore, T. M. VanWagoner, P. W. Whitby, 
and T. L. Stull. 2007. The haem-haemopexin utilization gene cluster (hxuCBA) 
as a virulence factor of Haemophilus influenzae. Microbiology 153:215-224. 
192. Morton, D. J., T. W. Seale, T. M. VanWagoner, P. W. Whitby, and T. L. 
Stull. 2009. The dppBCDF gene cluster of Haemophilus influenzae: Role in heme 
utilization. BMC research notes 2:166. 
193. Morton, D. J., A. Smith, Z. Ren, L. L. Madore, T. M. VanWagoner, T. W. 
Seale, P. W. Whitby, and T. L. Stull. 2004. Identification of a haem-utilization 
protein (Hup) in Haemophilus influenzae. Microbiology 150:3923-3933. 
194. Morton, D. J., A. Smith, T. M. VanWagoner, T. W. Seale, P. W. Whitby, and 
T. L. Stull. 2007. Lipoprotein e (P4) of Haemophilus influenzae: role in heme 
utilization and pathogenesis. Microbes and infection 9:932-939. 
195. Moxon, E. R. 2009. Bacterial variation, virulence and vaccines. Microbiology 
155:997. 
196. Moxon, E. R. 1992. Molecular basis of invasive Haemophilus influenzae type b 
disease. Journal of Infectious Diseases 165:S77. 
197. Moxon, E. R., and T. F. Murphy 2000. Haemophilus influenzae, p. 2369-2378. 
In G. L. Mandell, J. R. Bennett, and R.Dolin (ed.), Mandell, Douglas, and 
Bennett's principles and practices of infectious diseases, 5th ed, vol. 2. Churchill 
Livingstone, New York, NY. 
198. Munson Jr, R., and K. Sasaki. 1993. Protein D, a putative immunoglobulin D-
binding protein produced by Haemophilus influenzae, is glycerophosphodiester 
phosphodiesterase. Journal of bacteriology 175:4569. 
199. Munson, R. S., Jr., S. Grass, and R. West. 1993. Molecular cloning and 
sequence of the gene for outer membrane protein P5 of Haemophilus influenzae. 
Infect Immun 61:4017-4020. 
200. Murphy, G. L., T. D. Connell, D. S. Barritt, M. Koomey, and J. G. Cannon. 
1989. Phase variation of gonococcal protein II: regulation of gene expression by 
slipped-strand mispairing of a repetitive DNA sequence. Cell 56:539-547. 
201. Murphy, T. F. 2003. Respiratory infections caused by non-typeable Haemophilus 
influenzae. Curr Opin Infect Dis 16:129-134. 
171 
 
202. Murphy, T. F., A. L. Brauer, A. T. Schiffmacher, and S. Sethi. 2004. 
Persistent colonization by Haemophilus influenzae in chronic obstructive 
pulmonary disease. Am J Respir Crit Care Med 170:266-272. 
203. Murphy, T. F., H. Faden, L. O. Bakaletz, J. M. Kyd, A. Forsgren, J. Campos, 
M. Virji, and S. I. Pelton. 2009. Nontypeable Haemophilus influenzae as a 
pathogen in children. The Pediatric infectious disease journal 28:43-48. 
204. Murphy, T. F., C. Kirkham, and A. J. Lesse. 2006. Construction of a mutant 
and characterization of the role of the vaccine antigen P6 in outer membrane 
integrity of nontypeable Haemophilus influenzae. Infect Immun 74:5169-5176. 
205. Murphy, T. F., and S. Sethi. 2002. Chronic obstructive pulmonary disease: role 
of bacteria and guide to antibacterial selection in the older patient. Drugs Aging 
19:761-775. 
206. Nakamoto, H., and J. C. Bardwell. 2004. Catalysis of disulfide bond formation 
and isomerization in the Escherichia coli periplasm. Biochim Biophys Acta 
1694:111-119. 
207. Nakamura, S., M. Shchepetov, A. B. Dalia, S. E. Clark, T. F. Murphy, S. 
Sethi, J. R. Gilsdorf, A. L. Smith, and J. N. Weiser. 2011. Molecular basis of 
increased serum resistance among pulmonary isolates of non-typeable 
Haemophilus influenzae. PLoS Pathog 7:e1001247. 
208. Narkio-Makela, M., J. Hellwage, O. Tahkokallio, and S. Meri. 2001. 
Complement-regulator factor H and related proteins in otitis media with effusion. 
Clin Immunol 100:118-126. 
209. Narkio-Makela, M., A. M. Teppo, and S. Meri. 2000. Complement C3 cleavage 
and cytokines interleukin-1beta and tumor necrosis factor-alpha in otitis media 
with effusion. Laryngoscope 110:1745-1749. 
210. Nickitenko, A. V., S. Trakhanov, and F. A. Quiocho. 1995. 2. ANG. 
Resolution Structure of DppA, a Periplasmic Dipeptide Transport/Chemosensory 
Receptor. Biochemistry 34:16585-16595. 
211. Nizet, V., K. F. Colina, J. R. Almquist, C. E. Rubens, and A. L. Smith. 1996. 
A virulent nonencapsulated Haemophilus influenzae. J Infect Dis 173:180-186. 
212. Noel, G. J., A. Brittingham, A. A. Granato, and D. M. Mosser. 1996. Effect of 
amplification of the Cap b locus on complement-mediated bacteriolysis and 
opsonization of type b Haemophilus influenzae. Infect Immun 64:4769-4775. 
213. Noel, G. J., S. K. Hoiseth, and P. J. Edelson. 1992. Type b capsule inhibits 
ingestion of Haemophilus influenzae by murine macrophages: studies with 
isogenic encapsulated and unencapsulated strains. The Journal of infectious 
diseases 166:178-182. 
214. Noel, G. J., S. Katz, and P. J. Edelson. 1988. Complement-mediated early 
clearance of Haemophilus influenzae type b from blood is independent of serum 
lytic activity. J Infect Dis 157:85-90. 
215. O'Neill, J. M., J. W. St Geme, 3rd, D. Cutter, E. E. Adderson, J. Anyanwu, 
R. F. Jacobs, and G. E. Schutze. 2003. Invasive disease due to nontypeable 
Haemophilus influenzae among children in Arkansas. J Clin Microbiol 41:3064-
3069. 
172 
 
216. Okamoto, K., T. Baba, H. Yamanaka, N. Akashi, and Y. Fujii. 1995. Disulfide 
bond formation and secretion of Escherichia coli heat-stable enterotoxin II. 
Journal of bacteriology 177:4579. 
217. Ostberg, K. L., M. W. Russell, and T. F. Murphy. 2009. Mucosal 
immunization of mice with recombinant OMP P2 induces antibodies that bind to 
surface epitopes of multiple strains of nontypeable Haemophilus influenzae. 
Mucosal Immunol 2:63-73. 
218. Panek, H., and M. R. O'Brian. 2002. A whole genome view of prokaryotic 
haem biosynthesis. Microbiology 148:2273-2282. 
219. Pang, B., D. Winn, R. Johnson, W. Hong, S. West-Barnette, N. Kock, and W. 
E. Swords. 2008. Lipooligosaccharides containing phosphorylcholine delay 
pulmonary clearance of nontypeable Haemophilus influenzae. Infect Immun 
76:2037-2043. 
220. Patzer, S. I., and K. Hantke. 2000. The zinc-responsive regulator Zur and its 
control of the znu gene cluster encoding the ZnuABC zinc uptake system in 
Escherichia coli. J Biol Chem 275:24321-24332. 
221. Patzer, S. I., and K. Hantke. 1998. The ZnuABC high-affinity zinc uptake 
system and its regulator Zur in Escherichia coli. Mol Microbiol 28:1199-1210. 
222. Peek, J. A., and R. K. Taylor. 1992. Characterization of a periplasmic 
thiol:disulfide interchange protein required for the functional maturation of 
secreted virulence factors of Vibrio cholerae. Proc Natl Acad Sci U S A 89:6210-
6214. 
223. Petrarca, P., S. Ammendola, P. Pasquali, and A. Battistoni. 2010. The Zur-
regulated ZinT protein is an auxiliary component of the high-affinity ZnuABC 
zinc transporter that facilitates metal recruitment during severe zinc shortage. J 
Bacteriol 192:1553-1564. 
224. Phillips, N. J., M. A. Apicella, J. M. Griffiss, and B. W. Gibson. 1993. 
Structural studies of the lipooligosaccharides from Haemophilus influenzae type b 
strain A2. Biochemistry 32:2003-2012. 
225. Pittman, M. 1931. Variation and Type Specificity in the Bacterial Species 
Hemophilus Influenzae. The Journal of experimental medicine 53:471-492. 
226. Poolman, J., L. Bakaletz, A. Cripps, P. Denoel, A. Forsgren, and J. Kyd. 
2000. Developing a nontypeable Haemophilus influenzae (NTHi) vaccine. 
Vaccine 19:S108-S115. 
227. Prasadarao, N. V., A. M. Blom, B. O. Villoutreix, and L. C. Linsangan. 2002. 
A novel interaction of outer membrane protein A with C4b binding protein 
mediates serum resistance of Escherichia coli K1. J Immunol 169:6352-6360. 
228. Prasadarao, N. V., E. Lysenko, C. A. Wass, K. S. Kim, and J. N. Weiser. 
1999. Opacity-associated protein A contributes to the binding of Haemophilus 
influenzae to Chang epithelial cells. Infection and immunity 67:4153. 
229. Priebe, G. P., C. R. Dean, T. Zaidi, G. J. Meluleni, F. T. Coleman, Y. S. 
Coutinho, M. J. Noto, T. A. Urban, G. B. Pier, and J. B. Goldberg. 2004. The 
galU Gene of Pseudomonas aeruginosa is required for corneal infection and 
173 
 
efficient systemic spread following pneumonia but not for infection confined to 
the lung. Infect Immun 72:4224-4232. 
230. Prinz, W. A., F. Åslund, A. Holmgren, and J. Beckwith. 1997. The role of the 
thioredoxin and glutaredoxin pathways in reducing protein disulfide bonds in the 
Escherichia colicytoplasm. Journal of Biological Chemistry 272:15661. 
231. Ram, S., A. D. Cox, J. C. Wright, U. Vogel, S. Getzlaff, R. Boden, J. Li, J. S. 
Plested, S. Meri, S. Gulati, D. C. Stein, J. C. Richards, E. R. Moxon, and P. 
A. Rice. 2003. Neisserial lipooligosaccharide is a target for complement 
component C4b. Inner core phosphoethanolamine residues define C4b linkage 
specificity. J Biol Chem 278:50853-50862. 
232. Ram, S., M. Cullinane, A. M. Blom, S. Gulati, D. P. McQuillen, B. G. Monks, 
C. O'Connell, R. Boden, C. Elkins, and M. K. Pangburn. 2001. Binding of 
C4b-Binding Protein to Porin. The Journal of experimental medicine 193:281. 
233. Ram, S., J. Ngampasutadol, A. D. Cox, A. M. Blom, L. A. Lewis, F. St 
Michael, J. Stupak, S. Gulati, and P. A. Rice. 2007. Heptose I glycan 
substitutions on Neisseria gonorrhoeae lipooligosaccharide influence C4b-
binding protein binding and serum resistance. Infect Immun 75:4071-4081. 
234. Raquil, M. A., N. Anceriz, P. Rouleau, and P. A. Tessier. 2008. Blockade of 
antimicrobial proteins S100A8 and S100A9 inhibits phagocyte migration to the 
alveoli in streptococcal pneumonia. J Immunol 180:3366-3374. 
235. Read, R. C., R. Wilson, A. Rutman, V. Lund, H. C. Todd, A. P. R. Brain, P. 
K. Jeffery, and P. J. Cole. 1991. Interaction of nontypable Haemophilus 
influenzae with human respiratory mucosa in vitro. Journal of Infectious Diseases 
163:549. 
236. Reddy, M. S., J. M. Bernstein, T. F. Murphy, and H. S. Faden. 1996. Binding 
between outer membrane proteins of nontypeable Haemophilus influenzae and 
human nasopharyngeal mucin. Infect Immun 64:1477-1479. 
237. Reidl, J., and J. J. Mekalanos. 1996. Lipoprotein e (P4) is essential for hemin 
uptake by Haemophilus influenzae. The Journal of experimental medicine 
183:621. 
238. Ren, Z., H. Jin, D. J. Morton, and T. L. Stull. 1998. hgpB, a gene encoding a 
second Haemophilus influenzae hemoglobin-and hemoglobin-haptoglobin-
binding protein. Infection and immunity 66:4733. 
239. Rietsch, A., P. Bessette, G. Georgiou, and J. Beckwith. 1997. Reduction of the 
periplasmic disulfide bond isomerase, DsbC, occurs by passage of electrons from 
cytoplasmic thioredoxin. Journal of bacteriology 179:6602. 
240. Ristow, P., P. Bourhy, F. W. da Cruz McBride, C. P. Figueira, M. Huerre, P. 
Ave, I. S. Girons, A. I. Ko, and M. Picardeau. 2007. The OmpA-like protein 
Loa22 is essential for leptospiral virulence. PLoS Pathog 3:e97. 
241. Rosadini, C. V., S. M. Wong, and B. J. Akerley. 2008. The periplasmic 
disulfide oxidoreductase DsbA contributes to Haemophilus influenzae 
pathogenesis. Infect Immun 76:1498-1508. 
242. Rosenfeld, M., R. L. Gibson, S. McNamara, J. Emerson, J. L. Burns, R. 
Castile, P. Hiatt, K. McCoy, C. B. Wilson, A. Inglis, A. Smith, T. R. Martin, 
174 
 
and B. W. Ramsey. 2001. Early pulmonary infection, inflammation, and clinical 
outcomes in infants with cystic fibrosis. Pediatr Pulmonol 32:356-366. 
243. Rubin, L. G., and J. St Geme 3rd. 1993. Role of lipooligosaccharide in 
virulence of the Brazilian purpuric fever clone of Haemophilus influenzae 
biogroup aegyptius for infant rats. Infection and immunity 61:650. 
244. Sabri, M., S. Houle, and C. M. Dozois. 2009. Roles of the extraintestinal 
pathogenic Escherichia coli ZnuACB and ZupT zinc transporters during urinary 
tract infection. Infect Immun 77:1155-1164. 
245. Saiman, L. 2004. Microbiology of early CF lung disease. Paediatr Respir Rev 5 
Suppl A:S367-369. 
246. Schaffer, H. E., and R. R. Sederoff. 1981. Improved estimation of DNA 
fragment lengths from Agarose gels. Anal Biochem 115:113-122. 
247. Schlör, S., M. Herbert, M. Rodenburg, J. Blass, and J. Reidl. 2000. 
Characterization of ferrochelatase (hemH) mutations in Haemophilus influenzae. 
Infection and immunity 68:3007. 
248. Schweda, E. K., J. C. Richards, D. W. Hood, and E. R. Moxon. 2007. 
Expression and structural diversity of the lipopolysaccharide of Haemophilus 
influenzae: implication in virulence. International journal of medical 
microbiology : IJMM 297:297-306. 
249. Seale, T. W., D. J. Morton, P. W. Whitby, R. Wolf, S. D. Kosanke, T. M. 
VanWagoner, and T. L. Stull. 2006. Complex role of hemoglobin and 
hemoglobin-haptoglobin binding proteins in Haemophilus influenzae virulence in 
the infant rat model of invasive infection. Infection and immunity 74:6213. 
250. Serino, L., B. Nesta, R. Leuzzi, M. R. Fontana, E. Monaci, B. T. Mocca, E. 
Cartocci, V. Masignani, A. E. Jerse, R. Rappuoli, and M. Pizza. 2007. 
Identification of a new OmpA-like protein in Neisseria gonorrhoeae involved in 
the binding to human epithelial cells and in vivo colonization. Mol Microbiol 
64:1391-1403. 
251. Sethi, S., and T. F. Murphy. 2001. Bacterial infection in chronic obstructive 
pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev 14:336-
363. 
252. Sevier, C. S., and C. A. Kaiser. 2002. Formation and transfer of disulphide 
bonds in living cells. Nat Rev Mol Cell Biol 3:836-847. 
253. Shao, F., M. W. Bader, U. Jakob, and J. C. A. Bardwell. 2000. DsbG, a protein 
disulfide isomerase with chaperone activity. Journal of Biological Chemistry 
275:13349. 
254. Shevchik, V. E., G. Condemine, and J. Robert-Baudouy. 1994. 
Characterization of DsbC, a periplasmic protein of Erwinia chrysanthemi and 
Escherichia coli with disulfide isomerase activity. The EMBO journal 13:2007. 
255. Singh, I. R., R. A. Crowley, and P. O. Brown. 1997. High-resolution functional 
mapping of a cloned gene by genetic footprinting. Proc Natl Acad Sci U S A 
94:1304-1309. 
256. Sirakova, T., P. E. Kolattukudy, D. Murwin, J. Billy, E. Leake, D. Lim, T. 
DeMaria, and L. Bakaletz. 1994. Role of fimbriae expressed by nontypeable 
175 
 
Haemophilus influenzae in pathogenesis of and protection against otitis media and 
relatedness of the fimbrin subunit to outer membrane protein A. Infect Immun 
62:2002-2020. 
257. Sohnle, P. G., M. J. Hunter, B. Hahn, and W. J. Chazin. 2000. Zinc-
Reversible Antimicrobial Activity of Recombinant Calprotectin (Migration 
Inhibitory Factor—Related Proteins 8 and 14). Journal of Infectious Diseases 
182:1272. 
258. Sonnhammer, E. L., G. von Heijne, and A. Krogh. 1998. A hidden Markov 
model for predicting transmembrane helices in protein sequences. Proc Int Conf 
Intell Syst Mol Biol 6:175-182. 
259. St Geme 3rd, J. 1994. The HMW1 adhesin of nontypeable Haemophilus 
influenzae recognizes sialylated glycoprotein receptors on cultured human 
epithelial cells. Infection and immunity 62:3881. 
260. St Geme 3rd, J., M. De La Morena, and S. Falkow. 1994. A Haemophilus 
influenzae IgA protease-like protein promotes intimate interaction with human 
epithelial cells. Molecular microbiology 14:217. 
261. St Geme, J. W., 3rd. 2002. Molecular and cellular determinants of non-typeable 
Haemophilus influenzae adherence and invasion. Cell Microbiol 4:191-200. 
262. Steinbakk, M., C. Naess-Andresen, M. Fagerhol, E. Lingaas, I. Dale, and P. 
Brandtzaeg. 1990. Antimicrobial actions of calcium binding leucocyte L1 
protein, calprotectin. The Lancet 336:763-765. 
263. Stenson, T. H., and A. A. Weiss. 2002. DsbA and DsbC are required for 
secretion of pertussis toxin by Bordetella pertussis. Infect Immun 70:2297-2303. 
264. Sutton, A., R. Schneerson, S. Kendall-Morris, and J. B. Robbins. 1982. 
Differential complement resistance mediates virulence of Haemophilus influenzae 
type b. Infection and immunity 35:95-104. 
265. Swift, A. J., E. R. Moxon, A. Zwahlen, and J. A. Winkelstein. 1991. 
Complement-mediated serum activities against genetically defined capsular 
transformants of Haemophilus influenzae. Microb Pathog 10:261-269. 
266. Swords, W. E., B. A. Buscher, K. Ver Steeg Ii, A. Preston, W. A. Nichols, J. 
N. Weiser, B. W. Gibson, and M. A. Apicella. 2000. Non typeable Haemophilus 
influenzae adhere to and invade human bronchial epithelial cells via an interaction 
of lipooligosaccharide with the PAF receptor. Molecular microbiology 37:13-27. 
267. Tidhar, A., Y. Flashner, S. Cohen, Y. Levi, A. Zauberman, D. Gur, M. 
Aftalion, E. Elhanany, A. Zvi, A. Shafferman, and E. Mamroud. 2009. The 
NlpD lipoprotein is a novel Yersinia pestis virulence factor essential for the 
development of plague. PLoS One 4:e7023. 
268. Tinsley, C. R., R. Voulhoux, J. L. Beretti, J. Tommassen, and X. Nassif. 2004. 
Three homologues, including two membrane-bound proteins, of the disulfide 
oxidoreductase DsbA in Neisseria meningitidis: effects on bacterial growth and 
biogenesis of functional type IV pili. J Biol Chem 279:27078-27087. 
269. Tocco-Bradley, R., and M. J. Kluger. 1984. Zinc concentration and survival in 
rats infected with Salmonella typhimurium. Infection and immunity 45:332. 
176 
 
270. Tomb, J. F. 1992. A periplasmic protein disulfide oxidoreductase is required for 
transformation of Haemophilus influenzae Rd. Proc Natl Acad Sci U S A 
89:10252-10256. 
271. Turk, D. C. 1984. The pathogenicity of Haemophilus influenzae. Journal of 
medical microbiology 18:1-16. 
272. Uehara, T., K. R. Parzych, T. Dinh, and T. G. Bernhardt. 2010. Daughter cell 
separation is controlled by cytokinetic ring-activated cell wall hydrolysis. EMBO 
J 29:1412-1422. 
273. Van Alphen, L., P. Eijk, L. Geelen-van Den Broek, and J. Dankert. 1991. 
Immunochemical characterization of variable epitopes of outer membrane protein 
P2 of nontypeable Haemophilus influenzae. Infection and immunity 59:247. 
274. van Alphen, L., J. Poole, and M. Overbeeke. 1986. The Anton blood group 
antigen is the erythrocyte receptor for Haemophilus influenzae. FEMS 
microbiology letters 37:69-71. 
275. van den Berg, S., P. A. Lofdahl, T. Hard, and H. Berglund. 2006. Improved 
solubility of TEV protease by directed evolution. J Biotechnol 121:291-298. 
276. van Ham, S. M., L. van Alphen, F. R. Mooi, and J. P. M. van Putten. 1993. 
Phase variation of H. influenzae fimbriae: transcriptional control of two divergent 
genes through a variable combined promoter region. Cell 73:1187-1196. 
277. van Schilfgaarde, M., L. van Alphen, P. Eijk, V. Everts, and J. Dankert. 
1995. Paracytosis of Haemophilus influenzae through cell layers of NCI-H292 
lung epithelial cells. Infection and immunity 63:4729. 
278. Van Zele, T., F. Coppieters, P. Gevaert, G. Holtappels, P. Van Cauwenberge, 
and C. Bachert. 2009. Local complement activation in nasal polyposis. 
Laryngoscope 119:1753-1758. 
279. VanZile, M. L., N. J. Cosper, R. A. Scott, and D. P. Giedroc. 2000. The zinc 
metalloregulatory protein Synechococcus PCC7942 SmtB binds a single zinc ion 
per monomer with high affinity in a tetrahedral coordination geometry. 
Biochemistry 39:11818-11829. 
280. Vertommen, D., M. Depuydt, J. Pan, P. Leverrier, L. Knoops, J. P. Szikora, 
J. Messens, J. C. A. Bardwell, and J. F. Collet. 2008. The disulphide isomerase 
DsbC cooperates with the oxidase DsbA in a DsbD independent manner. 
Molecular microbiology 67:336-349. 
281. Vimr, E., and C. Lichtensteiger. 2002. To sialylate, or not to sialylate: that is the 
question. Trends in microbiology 10:254-257. 
282. Vitovski, S., K. T. Dunkin, A. J. Howard, and J. R. Sayers. 2002. Nontypeable 
Haemophilus influenzae in carriage and disease. JAMA: The Journal of the 
American Medical Association 287:1699. 
283. VITOVSKI, S., R. C. READ, and J. O. N. R. SAYERS. 1999. Invasive isolates 
of Neisseria meningitidis possess enhanced immunoglobulin A1 protease activity 
compared to colonizing strains. The FASEB journal 13:331. 
284. Vogel, L., B. Duim, F. Geluk, P. Eijk, H. Jansen, J. Dankert, and L. 
vanAlphen. 1996. Immune selection for antigenic drift of major outer membrane 
177 
 
protein P2 of Haemophilus influenzae during persistence in subcutaneous tissue 
cages in rabbits. Infection and immunity 64:980. 
285. Walkup, G. K. 1997. Fluorescent Chemosensors for Divalent Zinc Based on Zinc 
Finger Domains. Enhanced Oxidative Stability, Metal Binding Affinity, and 
Structural and Functional Characterization. J. Am. Chem. Soc 119:3443-3450. 
286. Walport, M. J. 2001. Complement. First of two parts. N Engl J Med 344:1058-
1066. 
287. Watarai, M., T. Tobe, M. Yoshikawa, and C. Sasakawa. 1995. Disulfide 
oxidoreductase activity of Shigella flexneri is required for release of Ipa proteins 
and invasion of epithelial cells. Proc Natl Acad Sci U S A 92:4927-4931. 
288. Webb, D. C., and A. Cripps. 1998. Secondary structure and molecular analysis 
of interstrain variability in the P5 outer-membrane protein of non-typable 
Haemophilus influenzae isolated from diverse anatomical sites. Journal of medical 
microbiology 47:1059. 
289. Weiser, J., D. Maskell, P. Butler, A. Lindberg, and E. Moxon. 1990. 
Characterization of repetitive sequences controlling phase variation of 
Haemophilus influenzae lipopolysaccharide. Journal of bacteriology 172:3304. 
290. Weiser, J. N., S. T. H. Chong, D. Greenberg, and W. Fong. 1995. 
Identification and characterization of a cell envelope protein of Haemophilus 
influenzae contributing to phase variation in colony opacity and nasopharyngeal 
colonization. Molecular microbiology 17:555-564. 
291. Weiser, J. N., J. B. Goldberg, N. Pan, L. Wilson, and M. Virji. 1998. The 
phosphorylcholine epitope undergoes phase variation on a 43-kilodalton protein 
in Pseudomonas aeruginosa and on pili of Neisseria meningitidis and Neisseria 
gonorrhoeae. Infect Immun 66:4263-4267. 
292. Weiser, J. N., and E. C. Gotschlich. 1991. Outer membrane protein A (OmpA) 
contributes to serum resistance and pathogenicity of Escherichia coli K-1. Infect 
Immun 59:2252-2258. 
293. Weiser, J. N., A. Lindberg, E. Manning, E. Hansen, and E. Moxon. 1989. 
Identification of a chromosomal locus for expression of lipopolysaccharide 
epitopes in Haemophilus influenzae. Infection and immunity 57:3045. 
294. Weiser, J. N., J. M. Love, and E. R. Moxon. 1989. The molecular mechanism of 
phase variation of H. influenzae lipopolysaccharide. Cell 59:657-665. 
295. Weiser, J. N., N. Pan, K. L. McGowan, D. Musher, A. Martin, and J. 
Richards. 1998. Phosphorylcholine on the lipopolysaccharide of Haemophilus 
influenzae contributes to persistence in the respiratory tract and sensitivity to 
serum killing mediated by C-reactive protein. J Exp Med 187:631-640. 
296. Whitby, P. W., T. W. Seale, D. J. Morton, T. M. VanWagoner, and T. L. 
Stull. 2010. Characterization of the Haemophilus influenzae tehB gene and its 
role in virulence. Microbiology 156:1188. 
297. White, D. C., and S. Granick. 1963. Hemin Biosynthesis in Haemophilus. 
Journal of bacteriology 85:842-850. 
178 
 
298. Williams, B. J., G. Morlin, N. Valentine, and A. L. Smith. 2001. Serum 
resistance in an invasive, nontypeable Haemophilus influenzae strain. Infect 
Immun 69:695-705. 
299. Winkelstein, J. A., and E. R. Moxon. 1992. The role of complement in the host's 
defense against Haemophilus influenzae. J Infect Dis 165 Suppl 1:S62-65. 
300. Wong, S. M., and B. J. Akerley. 2005. Environmental and genetic regulation of 
the phosphorylcholine epitope of Haemophilus influenzae lipooligosaccharide. 
Mol Microbiol 55:724-738. 
301. Wong, S. M., and B. J. Akerley. 2003. Inducible expression system and marker-
linked mutagenesis approach for functional genomics of Haemophilus influenzae. 
Gene 316:177-186. 
302. Wong, S. M., K. R. Alugupalli, S. Ram, and B. J. Akerley. 2007. The ArcA 
regulon and oxidative stress resistance in Haemophilus influenzae. Mol Microbiol 
64:1375-1390. 
303. Wong, S. M., F. St Michael, A. Cox, S. Ram, and B. J. Akerley. 2011. ArcA-
regulated glycosyltransferase Lic2B promotes complement evasion and 
pathogenesis of nontypeable Haemophilus influenzae. Infect Immun. 
304. Wooster, D. G., R. Maruvada, A. M. Blom, and N. V. Prasadarao. 2006. 
Logarithmic phase Escherichia coli K1 efficiently avoids serum killing by 
promoting C4bp-mediated C3b and C4b degradation. Immunology 117:482-493. 
305. Wu, L. F., M. A. Mandrand-Berthelot, R. Waugh, C. J. Edmonds, S. E. Holt, 
and D. H. Boxer. 1989. Nickel deficiency gives rise to the defective hydrogenase 
phenotype of hydC and fnr mutants in Escherichia coli. Mol Microbiol 3:1709-
1718. 
306. Wunderlich, M., and R. Glockshuber. 1993. Redox properties of protein 
disulfide isomerase (DsbA) from Escherichia coli. Protein science : a publication 
of the Protein Society 2:717-726. 
307. Wyckoff, E. E., M. L. Boulette, and S. M. Payne. 2009. Genetics and 
environmental regulation of Shigella iron transport systems. Biometals : an 
international journal on the role of metal ions in biology, biochemistry, and 
medicine 22:43-51. 
308. Yamanaka, H., M. Kameyama, T. Baba, Y. Fujii, and K. Okamoto. 1994. 
Maturation pathway of Escherichia coli heat-stable enterotoxin I: requirement of 
DsbA for disulfide bond formation. Journal of bacteriology 176:2906. 
309. Yang, X., T. Becker, N. Walters, and D. W. Pascual. 2006. Deletion of znuA 
virulence factor attenuates Brucella abortus and confers protection against wild-
type challenge. Infect Immun 74:3874-3879. 
310. Yatsunyk, L. A., J. A. Easton, L. R. Kim, S. A. Sugarbaker, B. Bennett, R. M. 
Breece, Vorontsov, II, D. L. Tierney, M. W. Crowder, and A. C. Rosenzweig. 
2008. Structure and metal binding properties of ZnuA, a periplasmic zinc 
transporter from Escherichia coli. J Biol Inorg Chem 13:271-288. 
311. Yu, J., H. Webb, and T. R. Hirst. 1992. A homologue of the Escherichia coli 
DsbA protein involved in disulphide bond formation is required for enterotoxin 
biogenesis in Vibrio cholerae. Mol Microbiol 6:1949-1958. 
179 
 
312. Zapun, A., J. C. Bardwell, and T. E. Creighton. 1993. The reactive and 
destabilizing disulfide bond of DsbA, a protein required for protein disulfide bond 
formation in vivo. Biochemistry 32:5083-5092. 
313. Zapun, A., and T. E. Creighton. 1994. Effects of DsbA on the disulfide folding 
of bovine pancreatic trypsin inhibitor and alpha-lactalbumin. Biochemistry 
33:5202-5211. 
314. Zapun, A., D. Missiakas, S. Raina, and T. E. Creighton. 1995. Structural and 
functional characterization of DsbC, a protein involved in disulfide bond 
formation in Escherichia coli. Biochemistry 34:5075-5089. 
315. Zhang, H. Z., and M. S. Donnenberg. 1996. DsbA is required for stability of the 
type IV pilin of enteropathogenic Escherichia coli. Mol Microbiol 21:787-797. 
 
 
